MITOCHONDRIAL DNA PROSTATE CANCER MARKER AND RELATED SYSTEMS AND METHODS

Abstract

There is described herein a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of said patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.

Description

SEQUENCE LISTING

The application contains a Sequence Listing prepared in compliance with ST.26 format and is hereby incorporated by reference in its entirety. Said Sequence Listing, created on Oct. 3, 2022 is named UCLAP0101USC1_SL and is 54,363 bytes in size.

FIELD OF INVENTION

The present disclosure relates generally to a prostate cancer biomarker signature. More particularly, the present disclosure relates to a mitochondrial DNA for the prognosis of prostate cancer outcomes, which can inform treatment decisions and guide therapy.

BACKGROUND

Prostate cancer remains the most prevalent non-skin cancer in men¹ and exhibits a remarkably quiet mutational profile². Exome sequencing studies of localized tumours have revealed few recurrent somatic single nucleotide variants (SNVs)^3,4, while whole-genome sequencing studies have not identified highly recurrent driver non-coding SNVs or genomic rearrangements (GRs)^5-8. Although strong mutagenic field effects have been observed^9,10, their underlying mechanisms and to what extent they drive tumour initiation or progression are unknown. Nevertheless, promising molecular diagnostics predictive of aggressive disease have been created using supervised machine-learning techniques, both from RNA abundance data^11,12 and from DNA copy number data¹³, showing strong linkage between molecular features of prostate tumour cells and patient outcome.

Most studies of the prostate cancer genome have focused on mutations occurring in the nuclear genome, and have ignored the other genome of the cell: the mitochondrial genome. Mitochondria are maternally inherited and play critical roles in pathways dysregulated in cancer cells, including energy production, metabolism and apoptosis¹⁴. While mitochondrial mutations have been observed in several tumour types^15-17, including prostate cancer^18-22 their global frequency and clinical impact have not yet been comprehensively characterized. Previous studies have found that mitochondrial mutations are associated with increased serum prostate-specific antigen (PSA) levels²¹, have suggested that mtDNA mutations increase cancer cell tumourigenicity²⁰, and indicate that overall mitochondrial mutation burden is correlated with higher Gleason Scores²².

SUMMARY OF INVENTION

In an aspect, there is provided a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of said patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.

In an aspect, there is provided a computer-implemented method of prognosing or predicting disease progression in a patient with prostate cancer, the method comprising: a) receiving, at at least one processor, sequencing data of mitochondrial genetic material from prostate cancer cells of the patient, the sequencing data reflecting at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); b) comparing, at the at least one processor, said sequencing data to corresponding control or reference sequences to determine mitochondrial single nucleotide variations (mtSNVs); d) determining, at the at least one processor, a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.

In an aspect, there is provided a computer program product for use in conjunction with a general-purpose computer having a processor and a memory connected to the processor, the computer program product comprising a computer readable storage medium having a computer mechanism encoded thereon, wherein the computer program mechanism may be loaded into the memory of the computer and cause the computer to carry out the method described herein.

In an aspect, there is provided a computer readable medium having stored thereon a data structure for storing the computer program product described herein.

In an aspect, there is provided a device for prognosing or predicting disease progression in a patient with prostate cancer, the device comprising: at least one processor; and electronic memory in communication with the at one processor, the electronic memory storing processor-executable code that, when executed at the at least one processor, causes the at least one processor to: a) receive sequencing data of mitochondrial genetic material from prostate cancer cells of the patient, the sequencing data reflecting at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); b) compare said sequencing data to corresponding control or reference sequences to determine mitochondrial single nucleotide variations (mtSNVs); and c) determining, at the at least one processor, a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1. In some embodiments, the processor further displays the prostate cancer prognosis on a user display.

In an aspect, there is provided a kit for prognosing or predicting disease progression in a patient with prostate cancer, the kit comprising primer sequences that permit the sequencing of a mitochondrial genome to determine mtSNVs in ATP8, OHR, ND4L and CSB1.

Other aspects and features of the present disclosure will become apparent to those ordinarily skilled in the art upon review of the following description of specific embodiments in conjunction with the accompanying figures.

BRIEF DESCRIPTION OF FIGURES

Embodiments of the present disclosure will now be described, by way of example only, with reference to the attached Figures and Tables.

FIG. 1 shows panorama of mitochondrial mutations in prostate cancer. (a) The top panel displays the number of mtSNVs per patient sorted first by T-Category and then by the number of mtSNVs; histogram bars are coloured by the average difference in the heteroplasmy fraction (ΔHF) between tumour and normal samples, light-blue 20-40%, medium-blue 40-60%, dark-blue ≥60%. A heatmap showing the location of each mtSNV on the mitochondrial genome (middle), where the colour of each dot represents ΔHF. The mitochondrial genome is represented on the left. The bottom panel shows the clinical covariates for all 384 patients: Age, Gleason Score, PSA and T-Category. Bottom right: Associations between the covariates and number of mtSNVs. (b) Frequency and distribution of single nucleotide variants (SNVs) within the mitochondrial genome. Mutation frequency normalized by dividing the number of mutations per locus of each patient by (length of the locus (kbp)×MCN). (c) Distribution of mtSNVs across the mitochondrial genome. mtSNVs were fairly evenly distributed across the genome (black bars) and recurrent mutation positions are indicated by the histogram.

FIG. 2 shows the difference in mitochondrial mutational frequency and copy number with age. (a) Association of nuclear (green) and mitochondrial (yellow) mutation SNV/Mbp rates with patient age. Mitochondrial mutation rate normalized by MCN. (b) Distribution of mtSNVs in EOPC (red) and LOPC (blue) patients. The histogram indicates presence and frequency of a mtSNV. The most recurrent mtSNV was at position 16093. (c) The fraction of patients by number of mtSNVs, EOPC (gray bars), LOPC (black bars). (d) Tumour mitochondrial copy number (MCN) for both patient age groups. EOPC: n=164; LOPC: n=220.

FIG. 3 shows associations between mitochondrial and nuclear genome mutations. (a) Correlations of mitochondrial features with nuclear genome features. The size and colour of the dot represents the Spearman correlation and the background shading represents the p-value. Nuclear features: SNVs, CTXs, INVs, kataegis data available for 172 patients; Chromothripsis: n=159; CNAs: MYC, NKX3-1 (n=203); CDH1, CDKN1B, CHD1, PTEN, RB1, TP53 (n=194); Methylation: n=104. Mitochondrial features: 216 patients. (b) Mutations in OHR are associated with CNAs in MYC. Heatmap showing those patients with CNA gains (red) in MYC and those with mtSNVs in OHR, CSB1, the control region and ATP6, mtSNV colour represents the ΔHF. Since CSB1 is a subregion within OHR, mutations in CSB1 are also considered as OHR mtSNVs, similarly, mtSNVs in OHR are also within the control region (n=203). The barplot on the right shows the fraction of patients with or without a MYC CNA that have a specific mtSNV. (c) Kaplan-Meier plot of 165 patients with OHR and MYC mutations. Patients were grouped according to whether they had neither MYC CNAs nor OHR SNVs (black line), a MYC CNA or an OHR mtSNV (blue) or had both (red line). The group that had a CNA gain in MYC and an mtSNV in the OHR region had significantly worse outcomes than those without the mutations. Biochemical RFR (Biochemical relapse-free rate).

FIG. 4 shows clinical impact of mitochondrial mutations in prostate cancer. (a) The associations of biochemical recurrence (BCR) and 21 mitochondrial features: 19 mitochondrial genes or regions, MCN (median-dichotomized), and mtSNV count (0 vs. 1+) were calculated using Cox models in 165 LOPC patients. Hazard ratios (HRs) are shown in the middle panel and p-values from the log-rank test in the right panel. The change in the 10 year survival for patients with mutations in each mitochondrial region is indicated (left panel). The colour of the bars indicate the average ΔHF for mtSNVs in that region; light-blue 20-40%, medium-blue 40-60%, dark-blue ≥60%. (b) Kaplan-Meier plots of mtSNVs occurring within HV1 and (c) OHR. (d) Kaplan-Meier plot of results of leave-one-out cross-validation predictions (p-value from log-rank test).

FIG. 5 shows the experimental design/experimental workflow for the project. Whole genome sequencing was performed on 333 CPC-GENE and EOPC samples. In addition, 51 publicly available samples with whole genome sequences were included in the dataset and realigned. Mitochondrial reads were extracted and the mitochondrial analysis tool MToolBox was run on the resulting BAM files. Heteroplasmic fractions (HF) were calculated for each nucleotide and only those positions that differed by 0.2 HF between the tumour and matched normal were included in the list of mtSNVs.

FIG. 6 shows MCN association with clinical variables. Tumour MCN categorized by age (a), T-category (b), and Gleason score (c). EOPC patients are indicated by red dots, LOPC by blue dots. (d) MCN of the matched normal samples show a significant difference between the two age groups.

FIG. 7 shows PCR validation confirms predicted mtSNVs. A comparison of chromatograms after PCR amplification and Sanger sequencing from (a) normal and (b) tumour samples from patient CPCG0196 for the mtDNA region: 187-208. Arrow indicates position 195 which has significant heteroplasmy in tumour.

FIG. 8 shows mtSNVs chosen for PCR validation. The 25 mtSNVs validated by PCR amplification and Sanger sequencing had varying levels in the difference in heteroplasmy (ΔHF) between tumour and normal samples. Light blue 20-40%, medium blue 40-60% and dark blue 60% ΔHF. mtDNA position on x-axis. Labels in red indicate those mtSNVs that failed PCR validation.

FIG. 9 shows frequency of mutations by patient and mitochondrial loci. Heatmap showing the distribution of mutations in the different mitochondrial regions (y-axis) by patients (x-axis). The difference in heteroplasmy fraction between tumour and normal sample (ΔHF) is indicated by colour, white: no mutation; light-blue: 20-40%; blue: 40-60% and dark blue ≥60%. Patients with more than one mtSNV in a particular mtDNA region are indicated by gray dots. Note: CSB1 and OHR are overlapping regions with the mtDNA Control region, mtSNVs in CSB1 are necessarily mtSNVs in OHR and both are mtSNVs within the Control region.

FIG. 10 shows distributions of mtSNV fractions by mitochondrial genome loci for EOPC and LOPC patients. The fraction of total mtSNVs per loci for EOPC and LOPC cohorts, those ≤50 years old (164 patients) and those >50 year old (220 patients) respectively.

FIG. 11 shows correlations between nuclear and mitochondrial features as a function of heteroplasmy fraction. Spearman's p (a) and p-values (b) were calculated using increasing ΔHF cutoffs for mtSNVs for several nuclear and mitochondrial features: MYC CNAs and OHR mtSNVs, the non-coding SNV chr4:39684557 and ND2 mtSNVs, TP53 SNVs and ND5 mtSNVs, and MYC CNAs and RNR2 mtSNVs. (c) The total number of mtSNVs for 384 patients at each ΔHF threshold (unadjusted).

FIG. 12 shows prognostic synergy between mitochondrial and nuclear mutations. Kaplan-Meier plots of patients with (a) methylation events in miR129-2 and mtSNVs in HV1 or (b) ND5; (c) NKX3-1 CNAs and OHR mtSNVs; (d) mtSNVs in HV1 and methylation events in TCERG1L-5′ or (e) TUBA3C; and (f) MYC CNAs and HV2 mtSNVs. Patients were grouped according to whether they had no mutations (black line), either a mtSNV or nuclear genomic mutation (blue) or had both (red line).

FIG. 13 shows signature flow chart and subset signature. (a) Flowchart showing details of the leave-one-out cross validation method. (b) Mitochondrial signature using three genes (HV1, OHR, CO3).

FIG. 14 shows mitochondrial signature in intermediate risk patients. Only patients classified as NCCN-intermediate risk were used with the mtSNV signature and were separated into three risk-prediction groups, ‘high’ (red line), ‘intermediate’ (black line), and ‘low’ (blue line).

FIG. 15 shows suitable configured computer device, and associated communications networks, devices, software and firmware to provide a platform for enabling one or more embodiments as described herein.

Table 1 shows results of PCR validation of 25 mtSNVs. The table includes the mtSNV position, which PCR primers were used to validate, the heteroplasmy fraction (adjusted by cellularity) of the major allele for both tumour and normal and the results of the PCR amplification and Sanger sequencing.

Table 2 shows results from univariate Cox proportional modeling. Hazard ratios were calculated for the different mitochondrial loci individually, the table includes the HR and 95% CI, p-values, the change in 10 year survival and the number of patients with a mtSNV in that loci.

Table 3 shows the sequence and mtDNA targeted region of 20 forward and reverse PCR primers.

Table 4 shows clinical and sequencing data per patient. The data includes patient age at treatment, Gleason Score, T-category, PSA (ng/mL) level, tumour cellularity, number of mtSNVs and the mean coverage depth, mitochondrial copy number for both normal and tumour sample and the aligner used for each wgs. The presence or absence of mutations in each of 20 mitochondrial regions and MYC and NKX3-1 copy number aberrations is indicated for each sample and the amount of DNA that was sent for sequencing for the CPC-GENE samples are included.

Table 5 shows 293 somatic mtSNVs. List of mtSNVs, including heteroplasmic fractions (HF), reference allele nucleotide, identity of tumour and normal major alleles and major allele heteroplasmy fractions (both adjusted and unadjusted by tumour cellularity), tumour and normal coverage at each position, the mtDNA gene or region and pathogenicity scores from MutPred and Polyphen2 obtained from MToolBox.

Table 6 shows mitochondrial mutation recurrence for 41 nuclear genomic features. The table includes the number of patients that had a specific nuclear genome CNA, GR, methylation event or SNV and of those patients the number that also harbours an mtSNV in any of 22 mtDNA features.

Table 7 shows mtSNVs with ΔHF values between 0.1 and 0.2. List of 265 mtSNVs, that had ΔHF values greater than 0.1, but less than 0.2. The table includes heteroplasmic frequencies, reference allele nucleotide, identity of tumour and normal major alleles and major allele heteroplasmy fractions, tumour and normal coverage at each position and the mtDNA gene or region.

DETAILED DESCRIPTION

Nuclear mutations are well-known to drive tumour incidence, aggression and response to therapy. By contrast, the frequency and roles of mutations in the maternally-inherited mitochondrial genome are poorly understood. To characterize the mitochondrial mutation landscape of prostate cancer, we analyzed the mitochondrial genomes of 384 adenocarcinomas of the prostate across all National Comprehensive Cancer Network (NCCN) defined risk categories, including 164 early-onset prostate cancers (EOPCs, age at diagnosis less than 50). We identified a median of one mitochondrial single nucleotide variant (mtSNV) per patient.

We identify recurrent mutational hotspots in the mitochondrial genome, which included recurrently mutated bases or recurrently mutated genes or regions. We also confirm increasing mutation burden with patient age^23-26, identify interactions between nuclear and mitochondrial mutation profiles and reveal specific mitochondrial mutations enriched in aggressive prostate tumours. For example certain control region mtSNVs co-occur with gain of the MYC oncogene, and these mutations are jointly associated with patient survival.

These data demonstrate frequent mitochondrial mutation in prostate cancer, and suggest interplay between nuclear and mitochondrial mutational profiles in prostate cancer.

The methods described herein are useful for prognosing the outcome of a subject that has, or has had, a cancer associated with the prostate. The cancer may be prostate cancer or a cancer that has metastasized from a cancer of the prostate.

In an aspect, there is provided a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of said patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.

The term “subject” as used herein refers to any member of the animal kingdom, preferably a human being and most preferably a human being that has, has had, or is suspected of having prostate cancer.

The term “sample” as used herein refers to any fluid (e.g. blood, urine, semen), cell, tumor or tissue sample from a subject which can be assayed for the biomarkers described herein.

The term “genetic material” used herein refers to materials found/originate in the nucleus, mitochondria and cytoplasm, which play a fundamental role in determining the structure and nature of cell substances, and capable of self-propagating and variation. In the context of the present methods, the genetic material is any material from which one can measure the biomakers described herein. The genetic material is preferably DNA.

The term “prognosis” as used herein refers to the prediction of a clinical outcome associated with a disease subtype which is reflected by a reference profile such as a biomarker reference profile. The prognosis provides an indication of disease progression and includes an indication of likelihood of death due to cancer. The prognosis may be a prediction of metastasis, or alternatively disease recurrence. In one embodiment the clinical outcome class includes a better survival group and a worse survival group. The term “prognosing or classifying” as used herein means predicting or identifying the clinical outcome of a subject according to the subject's similarity to a reference profile or biomarker associated with the prognosis. For example, prognosing or classifying comprises a method or process of determining whether an individual has a better or worse survival outcome, or grouping individuals into a better survival group or a worse survival group, or predicting whether or not an individual will respond to therapy.

The term “biomarker profile” as used herein refers to a dataset representing the state or expression level(s) of one or more biomarkers. A biomarker profile may represent one subject, or alternatively a consolidated dataset of a cohort of subjects, for example to establish a reference biomarker profile as a control.

As used herein, the term “control” refers to a specific value or dataset that can be used to prognose or classify the value e.g the measured biomarker or reference biomarker profile obtained from the test sample associated with an outcome. In one embodiment, a dataset may be obtained from samples from a group of subjects known to have cancer having different tumor states and/or healthy individuals. The state or expression data of the biomarkers in the dataset can be used to create a control value that is used in testing samples from new patients. In some embodiments, a cohort of subjects is used to obtain a control dataset. A control cohort patients may be a group of individuals with or without cancer. In a particularly embodiment, the control is a patient's own matched normal profile (e.g. from blood or normal tissue).

As used herein, “overall survival” refers to the percentage of or length of time that people in a study or treatment group are still alive following from either the date of diagnosis or the start of treatment for a disease, such as cancer. In a clinical trial, measuring the overall survival is one way to see how well a new treatment works.

As used herein, “relapse-free survival” refers to, in the case of caner, the percentage of or length of time that people in a study or treatment group survive without any signs or symptoms of that cancer after primary treatment for that cancer. In a clinical trial, measuring the relapse-free survival is one way to see how well a new treatment works. It is defined as any disease recurrence or relapse (local, regional, or distant).

The term “good survival” or “better survival” as used herein refers to an increased chance of survival as compared to patients in the “poor survival” group. For example, the biomarkers of the application can prognose or classify patients into a “good survival group”. These patients are at a lower risk of death after surgery and can also be categorized into a “low-risk group”.

The term “poor survival” or “worse survival” as used herein refers to an increased risk of disease progression or death as compared to patients in the “good survival” group. For example, biomarkers or genes of the application can prognose or classify patients into a “poor survival group”. These patients are at greater risk of death or adverse reaction from disease or surgery, treatment for the disease or other causes, and can also be categorized into a “high-risk group”.

A person skilled in the art would understand how to implement differing cut-offs for good survival vs. worse survival, depending on the clinical outcome one is predicting and the biomarkers being assayed.

In some embodiments, the at least 1 patient biomarker, is at least 2, 3 or 4 patient biomarkers.

In some embodiments, the prostate cancer is localized prostate cancer, preferably non-indolent localized prostate cancer.

In some embodiments, the method further comprises building a patient biomarker profile from the determined or measured patient biomarkers.

In some embodiments, the prostate cancer prognosis is the likelihood of disease recurrence, preferably measured by biochemical relapse.

In some embodiments, the method further comprises classifying the patient into a high risk group if the likelihood of disease recurrence is relatively high or a low risk group if the likelihood of disease recurrence is relatively low.

In some embodiments, the method further comprises treating the patient with more aggressive therapy if the patient is in the high risk group. Preferably, the more aggressive therapy comprises adjuvant therapy, preferably hormone therapy, chemotherapy or radiotherapy.

In some embodiments, the patient biomarkers further comprise CO2, CO3 and ND4L. Preferably, the at least 1 biomarker is at least 5, 6 or all 7 biomarkers. Further preferably, the at least 1 biomarker is all 7 biomarkers.

In some embodiments, the subject is classified as low risk if there exists mtSNVs in CO2, CO3, and HV1 and high risk if there exists mtSNVs in ATP8, OHR, ND4L and CSB1.

In some embodiments, the mtSNVs are the mtSNVs identified in Table 5. [NTD: Please confirm]

The present system and method may be practiced in various embodiments. A suitably configured computer device, and associated communications networks, devices, software and firmware may provide a platform for enabling one or more embodiments as described above. By way of example, FIG. 15 shows a generic computer device 100 that may include a central processing unit (“CPU”) 102 connected to a storage unit 104 and to a random access memory 106. The CPU 102 may process an operating system 101, application program 103, and data 123. The operating system 101, application program 103, and data 123 may be stored in storage unit 104 and loaded into memory 106, as may be required. Computer device 100 may further include a graphics processing unit (GPU) 122 which is operatively connected to CPU 102 and to memory 106 to offload intensive image processing calculations from CPU 102 and run these calculations in parallel with CPU 102. An operator 107 may interact with the computer device 100 using a video display 108 connected by a video interface 105, and various input/output devices such as a keyboard 115, mouse 112, and disk drive or solid state drive 114 connected by an I/O interface 109. In known manner, the mouse 112 may be configured to control movement of a cursor in the video display 108, and to operate various graphical user interface (GUI) controls appearing in the video display 108 with a mouse button. The disk drive or solid state drive 114 may be configured to accept computer readable media 116. The computer device 100 may form part of a network via a network interface 111, allowing the computer device 100 to communicate with other suitably configured data processing systems (not shown). One or more different types of sensors 135 may be used to receive input from various sources.

The present system and method may be practiced on virtually any manner of computer device including a desktop computer, laptop computer, tablet computer or wireless handheld. The present system and method may also be implemented as a computer-readable/useable medium that includes computer program code to enable one or more computer devices to implement each of the various process steps in a method in accordance with the present invention. In case of more than computer devices performing the entire operation, the computer devices are networked to distribute the various steps of the operation. It is understood that the terms computer-readable medium or computer useable medium comprises one or more of any type of physical embodiment of the program code. In particular, the computer-readable/useable medium can comprise program code embodied on one or more portable storage articles of manufacture (e.g. an optical disc, a magnetic disk, a tape, etc.), on one or more data storage portioned of a computing device, such as memory associated with a computer and/or a storage system.

In an aspect, there is provided a computer-implemented method of prognosing or predicting disease progression in a patient with prostate cancer, the method comprising: a) receiving, at at least one processor, sequencing data of mitochondrial genetic material from prostate cancer cells of the patient, the sequencing data reflecting at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); b) comparing, at the at least one processor, said sequencing data to corresponding control or reference sequences to determine mitochondrial single nucleotide variations (mtSNVs); d) determining, at the at least one processor, a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.

In some embodiments, the method further comprises displaying the prostate cancer prognosis on a user display.

In an aspect, there is provided a computer program product for use in conjunction with a general-purpose computer having a processor and a memory connected to the processor, the computer program product comprising a computer readable storage medium having a computer mechanism encoded thereon, wherein the computer program mechanism may be loaded into the memory of the computer and cause the computer to carry out the method described herein.

In an aspect, there is provided a computer readable medium having stored thereon a data structure for storing the computer program product described herein.

In an aspect, there is provided a device for prognosing or predicting disease progression in a patient with prostate cancer, the device comprising: at least one processor; and electronic memory in communication with the at one processor, the electronic memory storing processor-executable code that, when executed at the at least one processor, causes the at least one processor to: a) receive sequencing data of mitochondrial genetic material from prostate cancer cells of the patient, the sequencing data reflecting at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); b) compare said sequencing data to corresponding control or reference sequences to determine mitochondrial single nucleotide variations (mtSNVs); and c) determining, at the at least one processor, a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1. In some embodiments, the processor further displays the prostate cancer prognosis on a user display.

As used herein, “processor” may be any type of processor, such as, for example, any type of general-purpose microprocessor or microcontroller (e.g., an Intel™ x86, PowerPC™, ARM™ processor, or the like), a digital signal processing (DSP) processor, an integrated circuit, a field programmable gate array (FPGA), or any combination thereof.

As used herein “memory” may include a suitable combination of any type of computer memory that is located either internally or externally such as, for example, random-access memory (RAM), read-only memory (ROM), compact disc read-only memory (CDROM), electro-optical memory, magneto-optical memory, erasable programmable read-only memory (EPROM), and electrically-erasable programmable read-only memory (EEPROM), or the like. Portions of memory 102 may be organized using a conventional filesystem, controlled and administered by an operating system governing overall operation of a device.

As used herein, “computer readable storage medium” (also referred to as a machine-readable medium, a processor-readable medium, or a computer usable medium having a computer-readable program code embodied therein) is a medium capable of storing data in a format readable by a computer or machine. The machine-readable medium can be any suitable tangible, non-transitory medium, including magnetic, optical, or electrical storage medium including a diskette, compact disk read only memory (CD-ROM), memory device (volatile or non-volatile), or similar storage mechanism. The computer readable storage medium can contain various sets of instructions, code sequences, configuration information, or other data, which, when executed, cause a processor to perform steps in a method according to an embodiment of the disclosure. Those of ordinary skill in the art will appreciate that other instructions and operations necessary to implement the described implementations can also be stored on the computer readable storage medium. The instructions stored on the computer readable storage medium can be executed by a processor or other suitable processing device, and can interface with circuitry to perform the described tasks.

As used herein, “data structure” a particular way of organizing data in a computer so that it can be used efficiently. Data structures can implement one or more particular abstract data types (ADT), which specify the operations that can be performed on a data structure and the computational complexity of those operations. In comparison, a data structure is a concrete implementation of the specification provided by an ADT.

In an aspect, there is provided a kit for prognosing or predicting disease progression in a patient with prostate cancer, the kit comprising primer sequences that permit the sequencing of a mitochondrial genome to determine mtSNVs in ATP8, OHR, ND4L and CSB1.

In some embodiments, the primers further permit sequencing of CO2, CO3 and ND4L.

The above listed aspects and/or embodiments may be combined in various combinations as appreciated by a person of skill in the art. The advantages of the present disclosure are further illustrated by the following examples. The examples and their particular details set forth herein are presented for illustration only and should not be construed as a limitation on the claims of the present invention.

Examples

Methods/Materials

Patient Cohort

We collected 384 prostate cancer tumour samples with matched normal samples (381 blood, 3 tissue-derived). The samples had Gleason Scores ranging from 3+3 to 5+4. The 165 patients from the Canadian Prostate Cancer Genome Network (CPC-GENE) underwent either radical prostatectomy or image-guided radiotherapy as detailed in Fraser et al. (2017)⁷. In addition, 51 samples from publicly available datasets were included in the somatic mutation analysis and correlations with clinical variables, age, Gleason Score and T-category^4-6,8, three of TCGA samples had tissue-derived normal samples as opposed to blood-normals. All samples were manually macro-dissected and were assessed by an expert urological pathologist to have tumour cellularity >70%. All tumour specimens were taken from the index lesion. Publicly available tumour tissues were obtained and used following University Health Network Research Ethics Board (REB) approved study protocols (UHN 06-0822-CE, UHN 11-0024-CE, CHUQ 2012-913:H12-03-192). Local REB and ICGC guidelines were used to collect whole blood and informed consent from CPC-GENE patients at the time of clinical follow-up.

EOPC Patient Cohort and Sample Processing

We collected 168 tumour samples from EOPC patients. Informed consent and an ethical vote (institutional reviewing board) were obtained according to the current ICGC guidelines. The patients did not receive any neo-adjuvant radiotherapy, androgen deprivation therapy, or chemotherapy prior to the surgical removal of tumor tissue. Tumor samples and a normal blood control were frozen at −20° C. and subsequently stored at −80° C.

EOPC DNA Library Preparation, Sequencing and Alignment

DNA library preparation and whole-genome sequencmg was performed on Illumina sequencers with the raw length of the reads displaying a median of 101 bp. Reads were aligned to the hg19 reference genome using BWA-MEM version 0.7.8-r455 [arXiv: 1303.3997v2] and duplicates were removed using Picard (available on the World Wide Web at broadinstitute.github.io/picard). Mitochondrial reads were extracted using SAMtools³⁹.

Nuclear Mutation Calling

Recurrent nuclear genomic features were obtained from Fraser et al. (2017)⁷, which included five recurrent coding SNVs from commonly mutated genes in prostate cancer; the six most recurrent noncoding SNVs; CNAs from eight commonly mutated prostate cancer genes; the 10 GRs included the five most recurrent translocations and the four most recurrent inversions plus a recurrent inversion containing the PTEN gene; the TMPRSS-ERG fusion; presence or absence of kataegis events; chromothripsis; 3 metrics of mutation density (median dichotomized PGA estimates, number of SNVs and number of GRs); six methylation events were identified through univariate CoxPH modelling as associated with disease progression. Nuclear somatic single nucleotide variants were predicted by SomaticSniper (v1.0.2)³⁸, (n=172 samples) setting the mapping quality threshold to 1, otherwise with default parameters. Nuclear SNVs were filtered using SAMtools (v0.1.6)³⁹ and SomaticSniper (v1.0.2) provided filters, as well as a mapping quality filter and false positive filter from bam-readcount (downloaded Jan. 10, 2014). Nuclear SNVs were then annotated by ANNOVAR (v2015-06-17)⁴⁰. The nuclear mutation rate was obtained by dividing the number of SNVs after filtering by the number of callable loci. Copy number aberrations were analyzed by Affymetrix OncoScan microarrays (n=194) and methylation data was generated by Illumina Infinium Human Methylation 450k BeadChip kits (n=104). Genomic rearrangements were called using Delly (v0.5.5)⁴¹ (n=172). Chromothripsis scores (n=159) were calculated by ShatterProof (v0.14)⁴² and subsequently dichotomized with a 0.517 threshold. Sample processing, whole genome sequencing and whole genome sequencing data analysis are as described in detail by Fraser et al. (2017)⁷.

Mitochondrial SNV Calling

Reads mapped to the mitochondria during whole genome alignment were extracted using BAMQL (v1.1)⁴³ using the command:

• • bamql -l -o out_mito_reads.bam -f input_wgs.bam ‘(chr(M) & mate_chr(M))|(chr(Y) & after(59000000) & mate_chr(M))’;

The second part of the query statement collects reads where one of the pair mapped to chrM and the other unmapped which in our data was also assigned to an unresolved region in chrY.

The output files from BAMQL were used as input barn files for the mitochondrial genome analysis program MToolBox (v0.2.2)⁴⁴. The versions of the various system requirements were: Python v2.7.2; gmap v.2013-07-20⁴⁵; samtools v0.1.18³⁹; java v1.7.0_72; pi card v1.92 (available on the World Wide Web at broadinstitute.github.io/picard); muscle v3.8.3 l⁴⁶. We used default parameters for MToolBox and used the default RSRS⁴⁷ as the reference genome. The default parameters include a minimum base quality score of 25, samples that failed the MToolBox program using default parameters, but successfully completed at a lower base quality parameter setting of 20, were nonetheless removed from the analysis.

• • MToolBox_v0.2.2/MToolBox.sh -i bam -r RSRS -M -l -m ‘-D genome_index/-H hg19RSRS -M chrRSRS’ -a ‘-r genome_fasta/-F -P -C’.

The predicted mitochondrial genome for each tumour sample and the number of reads supporting each base were compared to the corresponding normal sample if available, from each patient. Positions where the absolute difference in heteroplasmy fraction (ΔHF) was greater than 0.2 were considered to be mitochondrial SNVs (mtSNVs). While this does not preclude the possibility of tissue-specific heteroplasmy being mislabeled as somatic mutations, this allowed us to identify somatic variants as well as ignore those positions that could be called population variants, reducing the number of potentially false positive variant calls.

Heteroplasmy fraction estimates were adjusted to account for tumour cellularity using cellularity values calculated by qpure⁴⁸. Tumour HF values were adjusted with the following equation:

Tumour HF_cellularity=(Tumour HF_MToolBox−(1−cellularity)*Normal HF_MToolBox)/cellularity

If there were no cellularity values available we assumed cellularity=1.0. Those values of Tumour HF_cellularity that were less than zero or greater than one were rounded to zero and one respectively.

In the mitochondrial reference genome there are three positions encoded as ‘N’ to preserve historical numbering, (523, 524 and 3107), in addition position 310 is located within a homopolymer region and is a common variant²⁸. These four positions can result in misalignments⁴⁹, therefore they were filtered out of our analyses, as in previous studies⁵⁰. We also filtered out those positions with relatively low coverage of less than 100 read depth. Positions of mitochondrial genes and subregions of the noncoding control region were obtained from the World Wide Web at mitomap.org. Pathogenicity scores from MutPred⁵¹, PolyPhen-2⁵² and SiteVar⁵³ were obtained from the MToolBox output. Mutations in tRNA genes were compared to the Mamit-tRNA database⁵⁴.

In the mitochondrial reference genome there are three positions encoded as ‘N’ to preserve historical numbering, (523, 524 and 3107), in addition position 310 is located within a homopolymer region and is a common variant²⁸. These four positions can result in misalignments⁴⁹, therefore they were filtered out of our analyses, as in previous studies⁵⁰. We also filtered out those positions with relatively low coverage of less than 100 read depth. Positions of mitochondrial genes and subregions of the noncoding control region were obtained from http://www.mitomap.org. Pathogenicity scores from MutPred⁵¹, PolyPhen-2⁵² and SiteVar⁵³ were obtained from the MToolBox output. Mutations in tRNA genes were compared to the Mamit-tRNA database⁵⁴.

We chose to a threshold of 0.2 ΔHF in order to balance removing false positives without excluding a large number of mtSNVs unnecessarily (FIG. 11c). As part of this assessment, we looked at four correlations between different nuclear and mitochondrial features using mtSNVs assessed at increasing ΔHF cutoffs from 0.1-0.6 (FIG. 11, Table 7). In each of these four cases, raising ΔHF from 0.1 to 0.2 led to increasing correlation coefficients between the two features. Three of the correlations that were not significant at 0.1 ΔHF, became significant at higher ΔHF, suggesting that some mtSNVs with lower HF values may be either false positives or low-level tissue specific heteroplasmies. Any further increases in ΔHF had differing effects on the four correlations.

mtDNA Copy Number

Mitochondrial copy number per cell (MCN) was calculated using the equation: (mitochondrial coverage/nuclear coverage)×2, using nuclear coverage data from the whole genome alignment⁷ and mitochondrial coverage data calculated by bedtools genomecov (v2.24.0)⁵⁵. The mitochondrial mutation rate per megabase DNA was calculated by dividing the number of mtSNVs by the tumour MCN multiplied by the number of callable bases, 16565, accounting for the 4 positions that were removed.

Survival and Statistical Analyses

The mtSNV data were compared to patient clinical features in the R statistical environment (v3.2.3). Binomial regression (age, PSA) and Chi-square tests (T-category, Gleason Score) were used to identify associations between the clinical variables and mtSNVs for all 384 patients. Survival analyses were performed on 165 patients due to survival data availability. Cox proportional hazards models were used to calculate HRs for mtSNVs in the different mitochondrial features such as genes or MCN, with verification of the proportional hazards assumption. The mitochondrial feature MT-ND4L was removed from this analysis as only one patient in the 165 cohort had a mtSNV in this gene. Change in 10 year percent survival was calculated using survival rates. Kaplan-Meier plots were created comparing biochemical recurrence with the presence or absence of mutations in certain mitochondrial loci, (genes or noncoding regions) or median-dichotomized tumour MCN. Nuclear genomic features were chosen based on recurrence in a previous prostate cancer study⁷. Data was visualized using the R-environment and lattice (v0.20-31), latticeExtra (v0.6-26) and circos (v0.67-4)⁵⁶. Associations between nuclear and mitochondrial genome features were calculated using Spearman's correlation.

PCR Validation

Single nucleotide variants in mitochondrial DNA were validated by Sanger re-sequencing, as previously reported⁷. Briefly, 10 ng of total genomic DNA (including mitochondrial DNA) was subjected to PCR amplification using primer pairs flanking SNVs identified from whole-genome sequencing (Table 3). Sequence data surrounding the region of interest was obtained from the World Wide Web at mitomap.org/bin/view.pl/MITOMAP/HumanMitoSeq. The amplicon sequence generated by the in silico PCR was then entered into the NCBI genome BLAST search engine to identify non-mitochondrial sequences that were similar. This was done to ensure that there were some differences between the designed primers and nuclear sequences, as well as to identify any sequence regions that could confound downstream analyses. The genome used for the BLAST search was GRCh38.p2 reference assembly top-level. These web pages were used on Aug. 20 and 21, 2015 and verified on Sep. 13, 2016. PCR reactions were purified using the QiAquick PCR purification kit (Qiagen, Toronto, Canada). Sanger re-sequencing was performed using amplicon-specific primers on an ABI 3730XL capillary electrophoresis instrument (Thermo Fisher Scientific, Burlington, Canada) at The Centre for Applied Genomics, Hospital for Sick Children, Toronto, Canada.

Single nucleotide variants in mitochondrial DNA were validated by Sanger re-sequencing, as previously reported⁷. Briefly, 10 ng of total genomic DNA (including mitochondrial DNA) was subjected to PCR amplification using primer pairs flanking SNVs identified from whole-genome sequencing (Table 3). Sequence data surrounding the region of interest was obtained from http://www.mitomap.org/bin/view.pl/MITOMAP/HumanMitoSeq. The amplicon sequence generated by the in silico PCR was then entered into the NCBI genome BLAST search engine to identify non-mitochondrial sequences that were similar. This was done to ensure that there were some differences between the designed primers and nuclear sequences, as well as to identify any sequence regions that could confound downstream analyses. The genome used for the BLAST search was GRCh38.p2 reference assembly top-level. These web pages were used on Aug. 20 and 21, 2015 and verified on Sep. 13, 2016. PCR reactions were purified using the QiAquick PCR purification kit (Qiagen, Toronto, Canada). Sanger re-sequencing was performed using amplicon-specific primers on an ABI 3730XL capillary electrophoresis instrument (Thermo Fisher Scientific, Burlington, Canada) at The Centre for Applied Genomics, Hospital for Sick Children, Toronto, Canada.

Data Availability Statement

Sequencing data is available at the European Genotype-Phenotype Archive (EGA) repository under accession EGAS00001001782.

Results

Mitochondrial Genome Sequence Analysis

We collected 384 tumours from patients with localized prostate cancer, comprising 164 EOPCs and 220 late-onset prostate cancers (LOPC; Table 4; FIG. 5). The LOPC patients represented the three NCCN risk groups: 19 low-risk, 151 intermediate-risk and 36 high-risk. The average sequencing depth of the mitochondrial genome was 13,577x, allowing extremely sensitive mutation detection. This cohort does not include any nuclear whole genome duplication events, as demonstrated by SNP microarray analysis⁷. We first evaluated the mitochondrial copy number (MCN) for each sample from the sequencing coverage of the mitochondrial and nuclear genomes. MCN ranged from 75 to 1405 (mean: 431) across the cohort, and was strongly associated with age (linear model, p=1.67×10⁻²⁶), as well with clinical indices such as T-category (ANOVA, p=6.01×10⁻³) and Gleason Score (GS; ANOVA, p=6.46×10⁻³; FIG. 6).

We next conservatively identified mitochondrial SNVs (mtSNVs) as those positions that had an absolute difference in their heteroplasmy fraction (ΔHF) between purity-adjusted tumour and paired-normal samples of at least 0.20 (FIG. 5). Because the number of identified mtSNVs is dependent on the heteroplasmy fraction threshold, we chose to balance false positives and false negatives with an intermediate value. There were 293 mtSNVs across all patients, with 47.4% of tumours (182/384) harbouring at least one and 6.8% (26/384) harbouring three or more FIG. 1a; Table 5). Proportions of patients with 0, 1, 2, 3 mtSNVs are 202/384 (52.6%), 110/384 (28.6%), 46/384 (12.0%) and 26/384 (6.8%), respectively. The number of patients with no mtSNVs was greater than expected by chance, suggesting significant variability in mtSNV burden (permutation test; p=3.4×10⁻⁵). Tumours with a larger number of mitochondria were more likely to have an mtSNV (generalized linear model (GLM) family binomial; p=8.38×10⁻⁷). mtSNVs were associated with tumour size (T-category; χ² test; p=2.47×10⁻⁴), but not other clinical prognostic indices like pre-treatment PSA and GS (FIG. 1a). PCR followed by Sanger sequencing validated 18/25 predicted mtSNVs (FIG. 7; FIG. 8; Table 1), suggesting precision of ˜75%, comparable to somatic indel detection accuracy²⁷.

Frequently Mutated Mitochondrial Loci

The noncoding control region of the mitochondria (mtDNA positions: 1-576 and 16024-16569), was the most frequently mutated region with 15.4% (59/384) of tumours harbouring mutations in that region (Table 5; FIG. 9). The control region comprises several elements, including the heavy- and light-strand promoters, as well as the origins of replication for the heavy strand (OHR), two hypervariable regions (HV1, HV2) and three conserved sequence blocks (CSB1, CSB2, CSB3). All functional locations were defined from mitmap.org²⁸. Of these regions, HV1 was the most frequently mutated (mtDNA positions: 16024-16383). Overall, mutation rates were generally consistent across regions of the mitochondrial genome (FIG. 1b).

There were 157 mtSNVs in the 13 protein coding genes, 82% (129/157) of which were nonsynonymous, including 6 premature stop codons and two mutated stop codons. The most frequently mutated protein coding gene was ND5 (30/157). We identified 21 specific positions mutated in at least two patients (FIG. 1c): ten within the control region, eight in protein-coding regions and three in rRNA subunits. Of the coding mutations, seven were non-synonymous and one introduced a premature stop codon. In the control region, position 16093—a common site of tissue specific heteroplasmy^29,30—was the most frequently mutated position (nine patients; FIG. 1c). Of protein-coding genes, ND1 was frequently mutated, with two patients having G3946A mutations (ΔHF: 0.63, 0.24), leading to a structure-disrupting E214K amino acid change, resulting in a reduction of complex assembly³¹. A second mutation, G4142A was found in two patients (ΔHF: 1.0, 0.21; R279Q) and a third mutation, G3842A, in three patients (ΔHF: 0.45, 0.21, 0.95; premature stop codon).

There were 22 mutations within mitochondrial tRNA genes, and eight of these were located within anticodon stems. In CO1 there were non-synonymous mutations at G5910A (A2T in one patient; ΔHF: 0.84) and T6664C (1254T in one patient; ΔHF: 0.46), two amino acids previously observed to be mutated in prostate cancer cells²⁰. Two patients with mutations at position 6419 were detected within the CO1 gene (ΔHF: 0.2, 0.23), although these two showed heteroplasmy within the normal samples and homoplasmy in the tumour suggesting that these mtSNVs represent either tissue-specific heteroplasmy³² or mutations that have gone to fixation in the tumour. Overall CO1 was mutated in 4.7% (18/384) of patients, markedly lower than the 11% rate previously reported²⁰.

Age Effect on the Distribution of mtSNVs in Prostate Cancer

As expected, the occurrence of mitochondrial mutations was strongly associated with patient age (GLM family binomial; p=5.88×10⁻⁹; FIG. 1a)^23-26. The mitochondrial mutation rate was significantly lower than that of the nuclear genome mutation rate (FIG. 2a; p=0.040, F-test), which may in part be explained by differential mutation detection accuracy in the two genomes. To further understand the association of mtSNVs with age, we separated patients into those 50 and under years of age (EOPC; n=164) and those over 50 (LOPC; n=220). The median ages of the EOPC and LOPC cohorts were 47 and 63.5 years old, respectively. Patients with EOPC were significantly more likely to have no mitochondrial mutations, 117/164 (71.3%), than those with LOPC (85/220, 38.6%; p=4.22×10⁻¹⁰, proportion test; FIG. 2b, c). Despite this difference in mutational load, the two groups have similar distributions of mtSNVs across the mitochondrial genome, with the highest fraction of mtSNVs within the control region (FIG. 10). EOPC patients had about 224 fewer copies of the mitochondria than LOPC patients (Mann-Whitney test; p=4.56×10⁻³⁰; FIG. 2d). This effect was inverted in the normal samples with EOPC patients having 86 more copies (Mann-Whitney; p=1.54×10⁻¹⁴; FIG. 6d), consistent with the decline in lymphocyte MCN with age³³.

Associations Between mtSNVs and Nuclear Genomic Mutations

Intriguingly, mutations in the large rRNA subunit (RNR2) were significantly correlated with mutations in the mitochondrial gene ND4 (Spearman's p=0.19; p=0.00015), suggesting to us an inter-play between different mutational types. To rigorously assess this phenomenon, we studied mutational associations between the nuclear and mitochondrial genomes. We exploited a set of 40 candidate nuclear somatic driver events recently identified through recurrence analyses, including five measures of mutation density, six methylation events, six non-coding SNVs, five coding SNVs, five measures of mutational density, ten genomic rearrangements and eight copy number aberrations (CNAs)⁷. The SNVs included recurrent coding SNVs in genes that are commonly mutated in prostate cancer, as well as the six most recurrent non-coding SNVs. To characterize per-region mtSNVs, we defined 22 mutational features representing the broad functional aspects of the mitochondria, 13 protein coding genes, 2 rRNAs, tRNAs (treated as one group), the control region and 3 subregions within the control region, along with mtSNV number and MCN. For each of the nuclear features, we evaluated their correlation to 22 mitochondrial mutational features in 194 LOPCs with nuclear mutational data (Table 6). We detected multiple nuclear-mitochondrial mutational associations (FIG. 3a). For example, SNVs in FOXA1 were significantly positively correlated with multiple mitochondrial features, as were SNVs in MED12. Nuclear-mitochondrial correlations were weakly dependent on the ΔHF threshold used to call mtSNVs (FIG. 11, Table 7).

One prominent nuclear-mitochondrial mutational interactions was co-occurrence of MYC copy number gain and mtSNVs within the OHR (FIG. 3b). Mutations within the OHR may dysregulate mtDNA replication, while MYC induces mitochondrial biogenesis by activating genes required for mitochondrial function³⁴ and influences metabolic plasticity in cancer stem cells³⁵. Risk of biochemical failure (BCR) after primary definitive treatment by radiotherapy or surgery was significantly higher for patients whose tumours harboured both MYC CNAs and OHR mtSNVs relative to those with neither or one of these two mutations, suggesting a synergistic mitochondrial-nuclear effect on disease aggression (FIG. 3c). Several other similar instances of apparent synergistic mitochondrial-nuclear effects on disease aggression were observed (FIG. 12a-e), suggesting that this is a common phenomenon in prostate cancer. While we have used the region defined as OHR (mtDNA positions: 110-441) as the mitochondrial feature, this subregion of the Control Region significantly overlaps with a region defined as HV2 (mtDNA positions: 57-372). We confirmed that HV2 mtSNVs show the same synergistic effect with MYC CNAs as mtSNVs defined as OHR (FIG. 12f). Interestingly, MYC CNAs were more common in LOPCs (14.5%; 29/200) than in EOPCs (8.4%; 10/119) making it impossible to assess if the same nuclear-mitochondrial interactions occur in both disease states. Further evaluation of changes in nuclear-mitochondrial associations across disease progression will be revealing.

Clinical Impact of mtSNVs in Prostate Cancer

The recurrence of mitochondrial mutations in specific regulatory regions and their association with prognostic nuclear mutations strongly suggested their ability to drive disease aggression. We therefore systematically evaluated the association of individual mitochondrial somatic mutational features with disease aggression in 165 patients with clinical follow-up using Cox proportional hazards modeling. Of our 22 mitochondrial mutational features (FIG. 3a), four were significantly associated with biochemical relapse rates (FIG. 4a; Table 2): mutations in CSB1, OHR, ATP8 and HV1. We should note that MT-ND4L was not included in this analysis as only one patient of the 165 had a mtSNV in this gene. To evaluate if these mutations were independent prognostic variables, we employed multivariable modeling to adjust for age, pre-treatment PSA, T-category and GS. After adjustment, mtSNVs in HV1 were associated with better patient outcome (FIG. 4b; Hazard Ratio, HR=0.28, 95% CI=0.08-0.9, p=0.032, Wald test), while mtSNVs in OHR were associated with significantly worse patient outcome (FIG. 4c; HR=2.47, 95% CI=1.13-5.38, p=0.023, Wald test).

These data suggested that mtSNVs might comprise a novel way to predict patient outcome. We therefore assessed the ability of a multi-mtSNV signature to identify patients at elevated risk for biochemical failure (who therefore might benefit from treatment intensification) and those at low risk (who might therefore be appropriate for surveillance protocols). Using leave-one-out cross-validation and univariate feature-selection, we created a three-class signature that separated patients into three distinct risk groups for biochemical failure (FIG. 13a). The signature identified both patients at elevated risk (FIG. 4d; HR=3.41, 95% CI=1.71-6.80, p=0.0005, Wald test) and patients at low-risk (HR=0.23, 95% CI=0.08-0.65, p=0.005, Wald test). These effects are independent of clinical features: when we considered only the clinically-homogeneous NCCN intermediate risk group, the same mtSNV signature again separated three groups with distinct risk profiles (FIG. 14). The cross-validation method identified seven genes (CO2, CO3, ATP8, HV1, OHR, CSB1, ND4L) as informative for classification. Patients with mtSNVs in (CO2, CO3, HV1) were classified as low-risk and patients with mtSNVs in (ATP8, OHR, ND4L, CSB1) were classified as high-risk. To show that this does not lead to over-fitting, we chose the three most frequently mutated regions of the seven (CO3, HV1, OHR) which also clearly separated patients into three groups (FIG. 13b).

Discussion

The mitochondrial mutational landscape of cancer has been relatively unexplored. Previous work has shown a large-scale mtDNA deletion has predictive value in the prostate biopsy outcomes³⁶, suggesting the feasibility of mtDNA-based molecular tests. We identify a large number of mtSNVs in localized prostate cancer. These mutations show complex interplay with nuclear mutational characteristics, and appear to work together to drive tumour aggressiveness.

Mitochondrial mutations also show associations with risk of biochemical relapse. Interestingly, mtSNVs within the control region can have conflicting outcomes, however when separated into the different noncoding subregions (HV1, OHR) we found that certain loci were associated with better outcomes and others with worse outcomes. The overlap of the OHR and HV2 within the control region and their association with MYC CNAs highlight the need for better understanding of the functions of the control region³⁷. In future, treating the control region as distinct regulatory regions may provide further insight into the roles of these regions, as well as any contribution they may make towards tumour aggression. We note that the number of pairs of nuclear-mitochondrial mutational features tested may elevate false-positive rates, and it will be key to perform validation studies in larger cohorts to verify their effect-sizes and biological significance.

The differences observed in the mitochondrial mutational profiles of EOPC and LOPC patients show a need to better understand the association between mtSNVs and aging and how this may relate to the development of prostate cancer. While the mitochondrial copy number of matched-normal samples decreases with patient age, a previously observed trend³³, tumour MCN estimates were significantly higher in older patients which could account for the higher frequency of mtSNVs in these patients. However, since the majority of the samples of each age group come from different research centres, this striking difference in tumour MCN will require further investigation to exclude any confounding effects.

Further studies will be needed to assess when different mtSNVs occur during tumour evolution, their timing relative to common nuclear mutations and the effects of these mutations on mitochondrial function. This will more clearly identify the mitochondrial mutations that are important for mitochondrial-nuclear communication and how they may interact to drive tumour formation. Localized prostate cancer remains the most diagnosed non-skin cancer in men, and identification of aggressive disease remains an urgent clinical dilemma. Addition of mtSNVs to prognostic biomarkers may be an effective way of improving prediction of patient outcome, supporting triage of patients with low-risk disease to surveillance protocols and with high-risk disease to adjuvant therapy regimens.

All documents disclosed herein, including those in the following reference list, are incorporated by reference. Although preferred embodiments of the invention have been described herein, it will be understood by those skilled in the art that that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

REFERENCES

• 1. Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128 (2012).
• 2. Barbieri, C. E. et al. The mutational landscape of prostate cancer. Eur. Urol. 64, 567-576 (2013).
• 3. Barbieri, C. E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685-689 (2012).
• 4. Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. Cell 163, 1011-1025 (2015).
• 5. Baca, S. C. et al. Punctuated evolution of prostate cancer genomes. Cell 153, 666-677 (2013).
• 6. Berger, M. F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214-220 (2011).
• 7. Fraser, M. et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature 541, 359-364 (2017).
• 8. Weischenfeldt, J. et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 23, 159-170 (2013).
• 9. Boutros, P. C. et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat. Genet. 47, 736-745 (2015).
• 10. Cooper, C. S. et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat. Genet. 47, 367-372 (2015).
• 11. Erho, N. et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PloS One 8, e66855 (2013).
• 12. Wu, C.-L. et al. Development and validation of a 32-gene prognostic index for prostate cancer progression. Proc. Natl. Acad. Sci. U.S.A 110, 6121-6126 (2013).
• 13. Lalonde, E. et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol. 15, 1521-1532 (2014).
• 14. Wallace, D. C. Mitochondria and cancer. Nat. Rev. Cancer 12, 685-698 (2012).
• 15. Kumimoto, H. et al. Frequent somatic mutations of mitochondrial DNA in esophageal squamous cell carcinoma. Int. J. Cancer 108, 228-231 (2004).
• 16. Larman, T. C. et al. Spectrum of somatic mitochondrial mutations in five cancers. Proc. Natl. Acad. Sci. U.S.A 109, 14087-14091 (2012).
• 17. McMahon, S. & LaFramboise, T. Mutational patterns in the breast cancer mitochondrial genome, with clinical correlates. Carcinogenesis 35, 1046-1054 (2014).
• 18. Chen, J. Z., Gokden, N., Greene, G. F., Mukunyadzi, P. & Kadlubar, F. F. Extensive somatic mitochondrial mutations in primary prostate cancer using laser capture microdissection. Cancer Res. 62, 6470-6474 (2002).
• 19. Gómez-Zaera, M. et al. Identification of somatic and germline mitochondrial DNA sequence variants in prostate cancer patients. Mutat. Res. 595, 42-51 (2006).
• 20. Petros, J. A. et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc. Natl. Acad. Sci. U.S.A 102, 719-724 (2005).
• 21. Kloss-Brandstätter, A. et al. Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients. Am. J. Hum. Genet. 87, 802-812 (2010).
• 22. McCrow, J. P. et al. Spectrum of mitochondrial genomic variation and associated clinical presentation of prostate cancer in South African men. Prostate 76, 349-358 (2016).
• 23. Cortopassi, G. A. & Arnheim, N. Detection of a specific mitochondrial DNA deletion in tissues of older humans. Nucleic Acids Res. 18, 6927-6933 (1990).
• 24. Corral-Debrinski, M., Shoffner, J. M., Lott, M. T. & Wallace, D. C. Association of mitochondrial DNA damage with aging and coronary atherosclerotic heart disease. Mutat. Res. 275, 169-180(1992).
• 25. Zhang, C. et al. Differential occurrence of mutations in mitochondrial DNA of human skeletal muscle during aging. Hum. Mutat. 11, 360-371 (1998).
• 26. Michikawa, Y., Mazzucchelli, F., Bresolin, N., Scarlato, G. & Attardi, G. Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. Science 286, 774-779 (1999).
• 27. Alioto, T. S. et al. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nat. Commun. 6, 10001 (2015).
• 28. Lott, M. T. et al. mtDNA Variation and Analysis Using Mitomap and Mitomaster. Curr. Protoc. Bioinforma. 44, 1.23.1-26 (2013).
• 29. Krjutškov, K. et al. Tissue-specific mitochondrial heteroplasmy at position 16,093 within the same individual. Curr. Genet. 60, 11-16 (2014).
• 30. Samuels, D. C. et al. Recurrent tissue-specific mtDNA mutations are common in humans. PLoS Genet. 9, e1003929 (2013).
• 31. Kervinen, M. et al. The MELAS mutations 3946 and 3949 perturb the critical structure in a conserved loop of the ND1 subunit of mitochondrial complex I. Hum. Mol. Genet. 15, 2543-2552 (2006).
• 32. He, Y. et al. Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature 464, 610-614 (2010).
• 33. Ding, J. et al. Assessing Mitochondrial DNA Variation and Copy Number in Lymphocytes of ˜2,000 Sardinians Using Tailored Sequencing Analysis Tools. PLoS Genet. 11, e1005306 (2015).
• 34. Li, F. et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol. Cell. Biol. 25, 6225-6234 (2005).
• 35. Sancho, P. et al. MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. Cell Metab. 22, 590-605 (2015).
• 36. Robinson, K. et al. Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay. Prostate Cancer Prostatic Dis. 13, 126-131 (2010).
• 37. Nicholls, T. J. & Minczuk, M. In D-loop: 40 years of mitochondrial 7S DNA. Exp. Gerontol. 56, 175-181 (2014).
• 38. Larson, D. E. et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics 28, 311-317 (2012).
• 39. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
• 40. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
• 41. Rausch, T. et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28, i333-i339 (2012).
• 42. Govind, S. K. et al. ShatterProof: operational detection and quantification of chromothripsis. BMC Bioinformatics 15, 78 (2014).
• 43. Masella, A. P. et al. BAMQL: a query language for extracting reads from BAM files. BMC Bioinformatics 17, 305 (2016).
• 44. Calabrese, C. et al. MToolBox: a highly automated pipeline for heteroplasmy annotation and prioritization analysis of human mitochondrial variants in high-throughput sequencing. Bioinformatics 30, 3115-3117 (2014).
• 45. Wu, T. D. & Watanabe, C. K. GMAP: a genomic mapping and alignment program for mRNA and EST sequences. Bioinformatics 21, 1859-1875 (2005).
• 46. Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792-1797 (2004).
• 47. Behar, D. M. et al. A ‘Copernican’ reassessment of the human mitochondrial DNA tree from its root. Am. J. Hum. Genet. 90, 675-684 (2012).
• 48. Song, S. et al. qpure: A Tool to Estimate Tumor Cellularity from Genome-Wide Single-Nucleotide Polymorphism Profiles. PLOS ONE 7, e45835 (2012).
• 49. Guo, Y. et al. The use of Next Generation Sequencing Technology to Study the Effect of Radiation Therapy on Mitochondrial DNA Mutation. Mutat. Res. 744, 154-160 (2012).
• 50. Ju, Y. S. et al. Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. eLife 3, (2014).
• 51. Li, B. et al. Automated inference of molecular mechanisms of disease from amino acid substitutions. Bioinformatics 25, 2744-2750 (2009).
• 52. Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting functional effect of human missense mutations using PolyPhen-2. Curr. Protoc. Hum. Genet. 7, Unit7.20 (2013).
• 53. Rubino, F. et al. HmtDB, a genomic resource for mitochondrion-based human variability studies. Nucleic Acids Res. 40, D1150-1159 (2012).
• 54. Pütz, J., Dupuis, B., Sissler, M. & Florentz, C. Mamit-tRNA, a database of mammalian mitochondrial tRNA primary and secondary structures. RNA 13, 1184-1190 (2007).
• 55. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841-842 (2010).
• 56. Krzywinski, M. I. et al. Circos: An information aesthetic for comparative genomics.

TABLE 1
Results of PCR validation of 25 mtSNVs
Sample	Posit bn	Amplicon	Validated?	HF - Tumour	HF - Normal
CPCG0196	195	1	Y	0.58T	1.0T
CPCG0242	234	1	Y	1.0G	1.0A
CPCG0189	650	2	Y	0.69C	1.0T
CPCG0248	988	3	N	0.64A	1.0G
CPCG0324	3079	5	N	1.0A	1.0G
CPCG0233	3946	6	N	0.63A	1.0G
CPCG0407	4770	7	N	0.98A	1.0G
CPCG0242	5511	9	Y	1.00	1.0T
CPCG0189	6270	10	N	0.66G	1.0G
CPCG0251	6276	10	Y	1.0A	0.55G
CPCG0331	6856	11	Y	1.0C	1.0T
CPCG0345	8391	12	N	0.59G	1.0G
CPCG0196	8433	12	Y	0.58T	1.0T
CPCG0340	10866	14	Y	1.0T	0.5C
CPCG0410	11814	15	Y	1.0C	1.0T
CPCG0352	12700	16	Y	0.87A	1.0C
CPCG0236	12763	16	Y	1.0A	1.0G
CPCG0217	13913	17	Y	1.0C	1.0T
CPCG0410	13918	17	Y	1.0C	0.97T
CPCG0340	14846	18	Y	1.0A	1.0G
CPCG0412	15045	18	N	0.51G	1.0G
CPCG0412	15708	19	Y	0.58A	1.0G
CPCG0269	15731	19	Y	0.83A	1.0G
CPCG0269	15817	19	Y	0.91G	0.83A
CPCG0356	15884	19	Y	1.0A	0.84G

TABLE 2
Results from univariate Cox proportional modeling
				p-value	p-value	10 year	number
		lower	upper	(wald	(logrank	survival	of patients
Loci	HR	95% Cl	95% Cl	test)	test)	difference	with mitoSNV
1 Control	0.79	0.429	1.45	0.447	0.446	0.01	35
Region
2 RNR1	1.48	0.671	3.28	0.329	0.326	−0.29	12
3 RNR2	1.25	0.538	2.91	0.603	0.602	−0.11	15
4 tRNAs	0.80	0.285	2.22	0.663	0.662	0.24	9
5 ND1	1.28	0.508	3.24	0.597	0.596	−0.03	10
6 ND2	1.27	0.507	3.16	0.613	0.613	0.18	12
7 ND3	1.24	0.171	9.02	0.832	0.831	0.11	3
8 ND4	1.19	0.476	2.98	0.709	0.709	0.02	12
9 ND5	1.74	0.825	3.67	0.145	0.140	−0.24	16
10 ND6	1.69	0.234	12.25	0.601	0.597	−0.06	2
11 CO1	0.66	0.239	1.82	0.422	0.419	−0.02	12
12 CO2	0.00	0.000	Inf	0.997	0.196	0.45	3
13 CO3	0.25	0.035	1.80	0.168	0.136	0.35	9
14 ATP6	0.57	0.079	4.11	0.577	0.572	0.11	4
15 ATP8	4.25	1.014	17.84	0.048	0.031	−0.23	3
16 CYB	0.44	0.132	1.47	0.181	0.172	0.24	11
17 HV1	0.26	0.080	0.82	0.022	0.013	0.32	18
18 CSB1	4.52	1.410	14.46	0.011	0.005	−0.57	3
19 OHR	2.73	1.294	5.74	0.008	0.006	−0.41	12
20 MCN	1.50	0.918	2.46	0.105	0.103	−0.15	165
21 mtSNV	0.87	0.525	1.43	0.574	0.574	−0.047	105

TABLE 3
PCR primers
Primer		Targets Region:
1F	tctatcaccctat taaccactcacg	10-385
1R	aggctggtgt tagggt tt tg
2F	aaaaat tccaccaaaccccc	287-718
2R	actggaacggggatgct tg
3F	acgggaaacagcagtgat taac	809-1103
3R	agggctaagcatagtggggt
4F	cagcaaaccctgatgaaggc	1273-1710
4R	tggtagtaaggtggagtgggt
5F	taccctagggataacagcgca	2927-3171
5R	gggaaggcgct tgtgaagt
6F	tactcctgccatcatgaccct	3828-4067
6R	gt taggggagagtgcgtc
7F	ataccccgaaaatgt tggt tatac	4434-4927
7R	ggct tacgt tagtgagggagag
8F	ctgacatccggcctgct t	4840-5171
8R	caggtgcgagatagtagtagggtc
9F	catcgccct taccacgctac	5457-5742
9R	cggcgggagaagtagat tga
10F	cataaacaacataagct	6192-6586
	tctgactct tacct
10R	ggtctcctcctccggcg
11F	tatcctaccaggct tcggaat	6642-6957
11R	acctacggtgaaaagaaagatga
12F	accacagt tcatgcccatc	8194-8482
12R	ggtgagggaggtaggtggtag
13F	caaaaaggcct tcgatacggg	9433-9876
13R	tagt tggcggatgaagcagat
14F	tgggcctagccctactagtctc	10688-10939
14R	gggtcggaggaaaaggt tgg
15F	tacgaacgcactcacagtcg	11760-11988
15R	tgtagagggagtatagggctgt
16F	atctcgaactgacactgagcc	12524-12894
16R	aaggcgaggatgaaaccgat
17F	ctaacaacat tcccccgcatc	13743-14056
17R	ggtggagat tggtgctgtg
18F	cccaccccatccaacatctc	14811-15111
18R	caagcaggaggataatgccg
19F	ggcgtcct tgccctat tact	15615-16051
19R	acccaaatctgct tcccat
20F	atggggaagcagat tgggt	16032-16298
20R	gggtgggtaggt tgt tggt

TABLE 4
Clinical and sequencing data per patient
						Normal
						mitochondrial	Normal	Tumour
						mean	mitochondrial	mitochondrial	Tumour
	Age At	Gleason	T	PSA		coverage	copy	mean	mitochondrial
Patient	Treatment	Score	category	(ng/ml)	mitoSNVs	d	num	coverage	copy nu
Baca-P03-	69	4 + 3	T2c	13.9	1	9973.43	528.32	9639.89	430.02
1426
Baca-P05-	47	3 + 4	T2b	9.3	1	5301.26	541.65	13952.8	455.87
1657
Baca-PR-05-	64	3 + 4	T2c	7.2	2	7848.46	366.84	13517.9	378.68
3595
Baca-P05-	62	4 + 3	T3a	12.5	2	9535.11	517.82	14571	483.77
3852
Baca-PR-06-	60	4 + 3	T2c	6.7	1	3687.29	518.5	22823.8	543.38
1749
Baca-PR-06-	54	4 + 3	T3a	25	1	7265.49	374.58	13011.3	320.31
3199
Baca-PR-07-	69	3 + 4	T3a	5.6	1	5986.71	206.44	6899.3	181.05
4610
Baca-P07-	57	3 + 3	T2c	4.1	1	9583.63	505.45	11448.7	231.43
4941
Baca-P07-	68	4 + 3	T3a	11	0	12286.3	703.49	12188.3	349.15
5037
Baca-PR-08-	58	3 + 4	T4	36	1	7155.13	381.71	13066.7	322.03
4154
Baca-P08-	59	3 + 4	T3a	4.1	0	13055.6	648.03	13959	466.2
716
Baca-P09-	76	3 + 4	T3b	9	1	5974.65	316.06	9801.68	388.03
37
Baca-PR-	60	3 + 3	T2c	4.5	0	808.985	48.58	17039.6	653.48
0410
Baca-PR-	62	3 + 4	T3a	6	1	2953.47	150.82	17440.3	452.67
STID000000
2872
Berger-PR-	57	3 + 4	T2c	7.8	3	2664.78	143.98	11557.9	601.49
0508
Berger-PR-	69	4 + 5	T3b	9.2	0	794.518	59.07	7999.43	460.05
0581
Berger-PR-	62	3 + 4	T3a	2.1	0	2023.96	94.9	9496.81	447.2
1701
Berger-PR-	66	4 + 4	T2c	9.8	0	1856	104.29	11199	634.19
1783
Berger-PR	66	3 + 4	T2c	6.6	0	1630.41	84.31	13476.4	682.17
2832
Berger-PR-	66	4 + 4	T3b	10.2	1	1624.68	97.23	5624.32	314.53
3027
Berger-PR-	69	3 + 4	T2c	7.2	3	1969.11	106.24	14276.4	776.69
3043
CPCG0001	69.4	3 + 4	T2b	7.7	1	2010.51	91.23	15343.8	536.19
CPCG0003	71.8	3 + 4	T2a	10	1	1592	98.23	16387.8	563.25
CPCG0004	76.5	4 + 4	T2b	14.1	0	2360.43	76.6	21736	504.1
CPCG0005	72.5	3 + 3	T2a	5.4	1	1954.36	105.73	14676.7	428.18
CPCG0006	73.5	4 + 3	T2b	8.4	0	11969.9	368.42	19269.2	631.66
CPCG0007	65.9	4 + 4	T1c	8.4	0	2622.67	107.85	19394.9	618.46
CPCG0008	74.3	3 + 4	T2a	4.7	0	8033.1	216.69	8220.56	487.07
CPCG0015	70	4 + 4	T2a	5.6	0	2445.52	123.29	11664.1	338.77
CPCG0019	71.4	4 + 5	T2a	7.3	1	1855.12	103.89	7508.09	235.48
CPCG0020	70.8	3 + 4	T1c	16	1	2152.74	102.61	15986.9	451.44
CPCG0022	70.3	3 + 3	T1c	12.6	0	6126.42	191.2	27763.9	427.62
CPCG0027	64.6	3 + 3	T1c	5	2	2309.34	124.47	18997.1	540.68
CPCG0030	73.1	4 + 4	T1c	8	2	1860.72	88.54	24737.1	435.4
CPCG0036	75.9	3 + 4	T2a	5.3	0	1546.25	83.47	21118.1	641.24
CPCG0040	71.5	3 + 4	T1c	9	3	2234.77	109.46	12738.2	385.35
CPCG0042	75.5	4 + 3	T2b	5.6	0	2661.75	127.13	12385.6	394.09
CPCG0046	79.4	4 + 3	T1c	5.1	5	1944.65	106.17	23558.9	1020.68
CPCG0047	71.9	4 + 3	T2c	13.2	0	1773.42	87.23	6868.3	181.08
CPCG0048	74.3	3 + 3	T2b	5.1	0	1965.81	100.43	18063.2	630.52
CPCG0050	75.8	3 + 3	T1c	7.7	1	2326.01	107.27	35390.2	922.94
CPCG0057	70.4	3 + 3	T2a	10	1	2814.45	142.84	7928.7	270.69
CPCG0063	68.6	4 + 3	T2a	3.8	2	2644.85	126.2	16387.6	538.02
CPCG0067	62	3 + 4	T2b	10	4	2540.37	113.15	26440.2	1255.88
CPCG0070	67.3	3 + 3	T2a	5.9	2	3288.57	130.51	23488.5	703.48
CPCG0071	74.9	4 + 3	T1c	14.7	2	2038.28	100.32	13083.5	407.14
CPCG0072	75.7	4 + 5	T2a	9.3	1	2087.05	114.92	18531.3	566.05
CPCG0073	71.6	4 + 3	T1c	10.3	2	2207.67	104.47	17129.6	500.64
CPCG0075	70.8	4 + 4	T2a	4.1	0	2219.17	110.59	11392.5	303.91
CPCG0076	76.6	3 + 3	T2a	12.7	1	1742.35	84.34	19549.5	531.43
CPCG0078	61	4 + 3	T2b	3.3	2	1105.04	49.32	14594.2	581.48
CPCG0081	75	4 + 3	T2a	17.8	2	2160.59	98.52	37008.6	1033.84
CPCG0082	70.3	4 + 3	T2a	7.8	1	1857.84	88.02	17730.5	440.85
CPCG0083	61.5	3 + 4	T2b	12.7	1	2672.43	109.97	13413.7	477.54
CPCG0084	70.8	3 + 3	T2b	7	1	2455.36	211.71	19898.8	557.13
CPCG0087	72.8	3 + 4	T1c	9.4	0	2124.21	90.43	10965.7	378.22
CPCG0089	73.9	4 + 4	T1c	4.8	1	6316.55	109.74	9884.38	579.96
CPCG0090	77.6	3 + 3	T1c	11.2	2	3146.06	107.25	26497.8	601.53
CPCG0094	77.6	4 + 3	T2b	16.41	0	1772.67	85.84	9333.85	270.47
CPCG0095	68.5	4 + 3	T2a	4	1	3226.28	116.97	9627.27	284.66
CPCG0096	71.2	3 + 3	T1c	6.1	1	2354.53	112.19	10526	336.77
CPCG0097	75.1	3 + 3	T1c	13.7	2	3186.24	114.53	15025	437.56
CPCG0098	80.7	4 + 3	T1c	7.5	4	3141.66	92.39	19866.5	675.49
CPCG0099	66.2	3 + 4	T2c	6.96	0	3088.28	123.68	20339.1	619.84
CPCG0100	55.3	4 + 5	T2c	5.56	2	1592.37	65.62	11999.8	325.79
CPCG0102	58.1	4 + 3	T3b	8.65	1	3756.32	117.24	19274.1	553.3
CPCG0103	65	3 + 4	T3b	5.2	2	3051.27	95.84	27103.1	669.18
CPCG0114	67.7	4 + 3	T2b	4.4	4	13818.6	425.97	3370.65	95.95
CPCG0117	71.3	3 + 4	T2a	10.1	1	2116.03	93.89	17318.3	1057.43
CPCG0120	73.1	4 + 5	T2a	14.79	1	4556	79.41	17038.8	1040.35
CPCG0121	63.5	3 + 4	T1c	7.2	0	1819.09	81.46	16843.6	507.7
CPCG0122	65.6	3 + 3	T1c	6.4	0	1587.25	73.44	26709.7	655.79
CPCG0123	70.7	3 + 4	T2a	8.8	1	2153.44	93.95	14680.6	408.31
CPCG0124	72	4 + 3	T2a	7.2	2	1693.03	103.91	16616.7	471.18
CPCG0126	70	3 + 3	T2a	6.1	0	2146.19	112.82	16857.3	511.86
CPCG0127	54.4	3 + 4	T2a	29.9	1	1410.98	82.03	22778.4	687.22
CPCG0128	70.2	3 + 4	T1c	30.3	2	1895.38	94.61	19629.6	527.03
CPCG0154	55.4	3 + 3	T2a	13.8	0	1661.73	94.48	12384.6	411.8
CPCG0158	70.3	3 + 4	T1c	10	1	1543.38	107.49	9261.13	444.37
CPCG0166	74	3 + 4	T2a	6.8	5	2756.4	101.74	15269.5	449.28
CPCG0182	57	4 + 3	T2c	7.64	0	2366.95	101.87	14861.1	429.06
CPCG0183	64.3	4 + 3	T3a	5.67	2	2002.32	89.43	24135.9	654.71
CPCG0184	51.8	4 + 3	T3a	5.53	0	2836.72	106.41	20155.2	504.67
CPCG0185	60	3 + 4	T3a	4.49	1	1921.47	79.18	15534.6	452.91
CPCG0187	72.4	4 + 4	T1c	13	1	2078.85	119.32	22991.9	828.01
CPCG0188	59	4 + 5	T2c	7.23	0	2202.35	89.99	25035.8	638.01
CPCG0189	57.4	3 + 4	T2b	6.52	5	2523.89	102.02	26654.4	775.6
CPCG0190	74.1	3 + 4	T3a	4.3	1	3002.16	117.98	23557.5	623.93
CPCG0191	60.7	4 + 3	T3a	11.1	0	1834.4	94.75	21490.7	646.17
CPCG0194	69.8	3 + 4	T1c	8.7	0	1901.55	196.32	7805.15	255.37
CPCG0196	52.5	4 + 3	T3b	4.88	2	3327.15	151.6	12536	343.95
CPCG0198	60.7	3 + 4	T2a	5.2	1	3099.65	146.67	29684.5	829.49
CPCG0199	74.2	4 + 3	T2a	6.3	0	2826.11	107.59	21647.3	676.99
CPCG0201	63.4	4 + 3	T1c	1.6	2	3002.98	97.47	39114.2	1120.3
CPCG0204	75.7	3 + 4	T1b	9.7	3	3464.6	105.94	10867.3	270.65
CPCG0205	65	3 + 4	T2a	20.4	1	1544.7	101.98	17086.3	532.21
CPCG0206	66.9	4 + 3	T1c	8	1	2110.22	103.11	19211.1	687.44
CPCG0208	60.4	3 + 4	T2c	5.7	0	2030.64	102.22	27846.3	833.35
CPCG0210	51.4	4 + 3	T2c	3.51	0	2301.46	125.14	13751.7	428.21
CPCG0211	75.2	3 + 4	T2a	4.5	3	1966.24	89.91	20019.9	601.45
CPCG0212	71.2	3 + 4	T1c	7	1	1851.09	99.03	9954.72	600.39
CPCG0213	67.2	3 + 4	T2a	9.3	3	2302.15	113.57	11806.2	356.88
CPCG0217	61.5	3 + 3	T3b	6.5	3	2862.32	126.84	22997.4	613.9
CPCG0232	71.6	3 + 4	T3a	8.15	1	1888.72	96.56	16843.7	497.16
CPCG0233	70.3	4 + 3	T3a	4.63	2	2754.55	124.79	31553	914.29
CPCG0234	70.1	3 + 4	T1c	5.7	2	2178.87	107.66	12593.3	446.63
CPCG0235	59.2	4 + 4	T3a	8.04	0	3220.53	123.34	37607.4	1206.8
CPCG0236	59.1	4 + 3	T3a	10.92	1	2509.78	114.9	30744.4	900.49
CPCG0237	60.4	3 + 3	T2a	10.7	1	1916.74	100.66	21603.4	479.47
CPCG0238	55.6	3 + 4	T3a	7.92	0	2171.64	86.06	14799.9	386.3
CPCG0241	66.6	3 + 4	T3a	5.64	0	1392.4	81.71	19837	522.61
CPCG0242	56	4 + 3	T3a	4	3	2229.79	104.54	21398	618.51
CPCG0243	63.7	3 + 3	T2b	13.6	0	2108.3	101.41	27303.7	705.69
CPCG0246	60.6	3 + 3	T2c	5.64	0	3078.8	106.59	21908.6	586.08
CPCG0248	54.2	3 + 4	T3a	5.1	1	2177.55	87.09	13487.4	357.01
CPCG0249	66.1	3 + 4	T3b	7.1	2	1341.68	70.87	23315.6	637.4
CPCG0250	62	3 + 3	T2c	4.23	1	2919.61	104.25	14478.6	435.33
CPCG0251	52.1	3 + 4	T2c	13.41	1	2438.75	116.04	26111.1	713.14
CPCG0255	72	3 + 3	T2c	6.9	0	1692.11	105.24	47617	1404.64
CPCG0256	63.9	3 + 4	T3a	7.32	3	2237.41	94.99	18998.2	574.56
CPCG0257	75.3	3 + 3	T2a	8	0	1875.56	96.61	30453.9	801.83
CPCG0258	49.2	3 + 3	T2c	5.13	0	2816.13	137.62	27975	645.84
CPCG0259	55.9	3 + 3	T3a	11.65	1	2343.37	112.81	25185.2	787.31
CPCG0260	65.3	4 + 3	T2b	6.59	0	2215.3	114.94	16393.6	439.11
CPCG0262	63	3 + 4	T2c	5.7	2	1748.24	96.8	22867	665.8
CPCG0263	66.4	3 + 3	T2a	13.9	1	2153.77	90.92	14025.9	376.94
CPCG0265	63.2	3 + 3	T3a	9.34	1	2865.36	125.95	24767.3	746.34
CPCG0266	66.1	3 + 4	T2c	1.74	1	1989.51	109.53	12392.6	357.7
CPCG0267	44.5	3 + 4	T2c	17.1	1	2632.29	102.84	12520.1	321.02
CPCG0268	59.3	3 + 3	T3a	12.35	1	1783.77	89.65	20844.9	632.34
CPCG0269	68.3	3 + 3	T2c	13.21	4	1862.44	75.85	20396.5	578.59
CPCG0324	64.7	3 + 4	T3a	12.1	2	1627.2	96.53	15641.5	461.67
CPCG0331	69.9	3 + 4	T3a	11.08	3	2214.28	118.64	22194.1	685.07
CPCG0334	53.7	3 + 4	T3a	7.41	0	2205.65	120.17	17649.3	526.22
CPCG0336	60.9	3 + 3	T3a	9.08	1	2531.23	122.84	22760.1	619.98
CPCG0339	57.7	3 + 4	T3a	14.29	2	2439.27	109.25	21027.2	575.8
CPCG0340	62	3 + 4	T2c	4.41	2	3925.02	145.3	28167.6	940.05
CPCG0341	56.8	4 + 3	T2c	11.3	0	1780	96.57	13179.1	450.01
CPCG0342	52.2	4 + 3	T3a	6.3	1	2051.9	102.5	42684.1	1317.94
CPCG0344	60.9	3 + 3	T2c	5.5	1	2169.22	107.1	21245.2	644.68
CPCG0345	60.4	3 + 4	T3b	6.6	1	2076.81	85.49	23445.5	669.58
CPCG0346	59.7	3 + 4	T3a	6.5	2	3160.71	122.58	17265.9	361.98
CPCG0348	57	3 + 4	T3a	4.22	0	2469.37	105.23	19175.6	627.9
CPCG0349	61.8	4 + 4	T2c	7.1	1	3936.14	141.05	29956.4	876.02
CPCG0350	53.2	4 + 3	T3b	39.47	1	3186.42	175.12	16436.5	553.25
CPCG0352	55.5	4 + 3	T2c	9.1	2	4267.8	210.29	21746	629.93
CPCG0353	65.6	3 + 4	T3b	9	0	5165.99	171.98	15483	445.09
CPCG0354	61.4	3 + 4	T2c	6.7	0	10612.5	369.9	15967.2	479.46
CPCG0355	55.5	3 + 3	T2c	6.7	2	10942.8	413.22	24203.7	722.52
CPCG0356	51.6	4 + 3	T2c	8.49	3	5522.17	183.24	24184.8	758.82
CPCG0357	59.1	3 + 4	T2c	3.11	0	2936.46	144.62	13756	432.86
CPCG0358	68.8	3 + 4	T2a	5.88	1	11783.1	558.8	19095.4	640.92
CPCG0360	66.2	3 + 4	T3b	14	0	2459.98	102.12	20880.2	626.95
CPCG0361	70.1	3 + 4	T3a	4.6	1	4085.15	171.45	23547.5	424.85
CPCG0362	57.6	3 + 4	T3b	8.77	0	5073.01	232.26	16830.4	543.17
CPCG0363	56.6	3 + 4	T2c	4.27	0	3803.3	134.64	22238.6	676.72
CPCG0364	63.2	3 + 3	T3a	8.11	0	2119.11	90.51	32021.9	585.73
CPCG0365	71.7	3 + 3	T2c	4.23	0	2595.34	108	20792.3	560.3
CPCG0366	60.5	3 + 4	T3a	15	0	2832.85	118.99	10542.6	284.93
CPCG0368	63.7	3 + 3	T2c	4.39	1	3212.27	136.26	26323.3	795.63
CPCG0369	63.7	3 + 4	T3a	7.18	0	4818.33	216.57	21784.1	636.84
CPCG0371	60.7	3 + 4	T3a	7.52	0	6744.86	304.1	15628.5	492.43
CPCG0372	60.2	3 + 4	T2c	4	1	3635.5	178.11	22791.2	726.25
CPCG0373	59.8	3 + 4	T2c	4.9	0	6165.27	290.47	15628.5	478.66
CPCG0374	63.6	3 + 3	T2c	4.7	1	5552.69	251.7	30129	839.05
CPCG0375	70.2	3 + 3	T2c	7.01	0	5556.59	228.69	30332	1023.21
CPCG0377	76.9	4 + 4	T2c	6.9	1	5674.91	238.24	24080.1	701.87
CPCG0378	69.1	3 + 4	T3b	8.7	1	6663.66	277.53	25862.6	756.27
CPCG0379	68.6	3 + 4	T3a	14.6	1	3991.82	194.66	16985.8	471.18
CPCG0380	58.1	3 + 4	T2c	6.29	1	3479.34	177.05	23339.2	716.88
CPCG0381	64.9	3 + 4	T2c	5.76	0	4173.25	180.55	18670.6	576.26
CPCG0382	71.1	4 + 4	T2c	6.8	0	3774.09	157.43	35627.8	1141.52
CPCG0387	67.1	4 + 3	T2c	4.52	2	6376.56	286.84	18213.4	529.95
CPCG0388	54.5	3 + 4	T3a	2.5	1	2485.18	106.06	22595.6	707.36
CPCG0391	60.8	3 + 3	T2c	5.3	0	6416.64	265.25	17324.3	438.19
CPCG0392	61.4	3 + 4	T3b	19.5	0	1868.71	87.57	18631.4	511.01
CPCG0401	58.1	3 + 4	T2c	3.6	0	4357.69	191.91	17145.6	532.82
CPCG0404	56.2	3 + 4	T2c	3.6	1	5948.57	243.78	40464.9	1098.8
CPCG0407	57.9	3 + 4	T2a	11.5	2	3378.68	206.76	17177.2	477.4
CPCG0408	67.9	4 + 4	T2c	3.47	0	6495.59	276.71	22309.9	641.83
CPCG0409	59.1	3 + 4	T3a	6.3	1	2922.04	173.92	28278	742.69
CPCG0410	62	3 + 4	T2c	5	3	5203.82	217.73	26133.8	741.72
CPCG0411	45.7	4 + 3	T2c	10.55	0	4019.65	163.77	14003	424.03
CPCG0412	58.7	4 + 3	T2a	3.36	3	2780.6	164.49	15645.1	479.17
CPCG0413	59.1	3 + 4	T2c	6.89	0	3915.74	186.91	21079.7	737.96
CPCG0414	43.8	4 + 3	T2c	5.4	0	3877.37	172.59	15891.4	508.01
Weischen-	46	3 + 4	T2c	6	2	3077.42	136	8577.51	368.3
feldt-
EOPC-
010
Weischen-	48	3 + 4	T2c	4.8	0	1839.24	123	4632.61	299.45
feldt-
EOPC-
011
Weischen-	51	3 + 4	T2c	23.8	0	3352.84	200.42	5115.26	370.21
feldt-
EOPC-02
Weischen-	46	5 + 4	T3a	12	1	3258.08	237.37	17967.1	528.61
feldt-
EOPC-03
Weischen-	51	4 + 3	T3b	72	2	5386.42	163.11	6291.77	427.88
feldt-
EOPC-04
Weischen-	50	3 + 4	T3a	5	1	1840.62	119.72	4111.36	258.28
feldt-
EOPC-05
Weischen-	38	3 + 4	T3b	18.2	0	2104.12	103.53	4020.19	193.78
feldt-
EOPC-06
Weischen-	49	3 + 4	T2c	5.4	4	1995.09	130.76	5886.36	375.09
feldt-
EOPC-07
Weischen-	44	3 + 4	T2c	7.8	0	3107.47	196.85	7331.15	347.3
feldt-
EOPC-08
Weischen-	48	3 + 4	T2c	5.1	0	4594.3	228.69	6755.4	408.36
feldt-
EOPC-09
ICGC_PC	45	3 + 4	T3a	30	0	2827.22	128.51	9654.26	459.73
A001
ICGC_PC	48	3 + 4	T2c	4.8	0	1901.03	126.74	4799.33	309.63
A012
ICGC_PC	45	3 + 4	T2c	NA	1	4499.82	243.23	17577.1	491.46
A013
ICGC_PC	45	3 + 4	T2a	NA	0	3804.42	234.55	11582.8	254.76
A014
ICGC_PC	48	3 + 4	T3b	NA	1	4139.76	232.51	7798.35	183.08
A015
ICGC_PC	44	3 + 4	T2a	NA	0	3967.64	227.96	7782.91	217.1
A016
ICGC_PC	48	3 + 4	T2c	13.2	0	4965.55	264.69	4464.28	233.37
A017
ICGC_PC	49	3 + 3	T2c	4.6	0	7169.97	300.19	3978.88	198.99
A018
ICGC_PC	46	3 + 4	T2c	6.74	0	4594.35	256.45	4238.89	224.99
A019
ICGC_PC	49	3 + 3	T3a	NA	0	2643.11	166.23	11609.6	317.25
A020
ICGC_PC	45	3 + 4	T2c	5.35	0	4498.3	208.64	4629.81	208.88
A021
ICGC_PC	49	3 + 4	T2c	5.88	0	5958.51	222.46	4028.03	195.82
A022
ICGC_PC	50	3 + 4	T2c	2.56	1	7928.37	330.28	10306.4	373.49
A023
ICGC_PC	43	3 + 4	T2c	11.7	0	2382.34	115.03	4937.3	219.63
A024
ICGC_PC	47	3 + 4	T2c	9.79	0	1837.06	111.03	4018.61	211.56
A025
ICGC_PC	48	3 + 3	T2c	3.8	1	2183.34	127.53	5286.37	267.53
A026
ICGC_PC	49	3 + 4	T2c	NA	0	3878.45	187.36	4240.61	224.61
A027
ICGC_PC	40	3 + 4	T2c	NA	0	4063.62	213.65	4881.5	229.56
A028
ICGC_PC	48	4 + 3	T3b	15.5	3	4670.4	178.6	5589.59	213.38
A029
ICGC_PC	48	4 + 3	T3b	62.4	0	4655.41	178.99	9524.12	361.17
A030
ICGC_PC	48	3 + 4	T2c	22.5	1	5953.36	222.93	6554.49	230.1
A031
ICGC_PC	44	3 + 4	T2a	4.23	5	3258.41	177.67	3955.93	NA
A032
ICGC_PC	43	3 + 4	T2c	5	0	2815.95	163.29	4980.66	NA
A033
ICGC_PC	46	3 + 4	T2c	5.27	0	2350.99	119.31	6313.81	278.94
A034
ICGC_PC	49	4 + 3	T3b	70.43	0	4548.29	245.85	13510.3	773.12
A035
ICGC_PC	57	3 + 4	T3a	6.52	2	4422.45	175.49	9231.92	362.04
A036
ICGC_PC	50	3 + 4	T3a	6.98	0	3709.63	NA	15562.3	884.22
A037
ICGC_PC	49	3 + 4	T2c	3.99	0	6205.3	250.06	5214.15	244.34
A038
ICGC_PC	50	3 + 3	T2	6.13	0	6296.73	263.24	5967.76	246.35
A040
ICGC_PC	48	5 + 4	T4	58	1	4421.8	231.63	3387.42	149.19
A041
ICGC_PC	47	4 + 5	NA	NA	0	2911.35	169.46	8698.75	373.5
A043
ICGC_PC	48	4 + 3	T2c	12	0	4142.43	244.97	9927.41	377.83
A044
ICGC_PC	47	3 + 4	T2c	7.65	0	4123.21	245.79	8784.67	374.29
A045
ICGC_PC	49	3 + 4	T2c	9.36	0	3982.15	229.12	6158.4	185.33
A046
ICGC_PC	50	3 + 3	T2a	8.2	1	5147.5	253.07	5545.16	212.13
A048
ICGC_PC	48	3 + 3	T2c	6.09	0	5441.71	196.27	7249.09	272.27
A049
ICGC_PC	48	3 + 4	T2c	NA	0	3497.67	145.98	6475.02	261.19
A050
ICGC_PC	41	3 + 4	T2c	NA	1	2606.4	108.46	5413.56	230.22
A051
ICGC_PC	40	3 + 4	T2c	NA	0	6947.3	264.31	5799.31	233.8
A052
ICGC_PC	48	4 + 3	T2c	9.9	0	6203.75	230.88	6614	259.63
A053
ICGC_PC	50	3 + 4	T2c	6.4	0	4053.86	213.7	5865.11	232.88
A054
ICGC_PC	48	3 + 4	T2c	6.15	0	4154.49	242.1	6373.99	292.45
A055
ICGC_PC	47	3 + 4	T2c	NA	0	4748.29	193.29	6807.71	319.99
A056
ICGC_PC	50	3 + 4	T2c	5.07	1	4296.18	220.09	6351.99	288.2
A057
ICGC_PC	47	3 + 4	T2c	5.4	0	4131.73	204.29	7484.18	298.12
A058
ICGC_PC	47	3 + 4	T2c	14.1	0	2733.23	113.62	5098.51	228.84
A059
ICGC_PC	41	3 + 3	T2c	5.74	1	7267.63	285.01	9625.05	360.89
A060
ICGC_PC	47	3 + 4	T2a	6.47	0	6088.55	256.58	5563.43	213.36
A061
ICGC_PC	45	3 + 4	T2c	8.21	0	5973.57	232.62	10047.6	405.8
A062
ICGC_PC	46	3 + 4	T2c	13	0	3077.46	177.38	8342.93	352.02
A063
ICGC_PC	47	3 + 3	T2a	5.3	0	6441.14	398.83	10255.3	420.64
A064
ICGC_PC	48	3 + 4	T2c	8.9	2	1325.05	75.46	11750	619.56
A065
ICGC_PC	50	3 + 4	T2c	12.9	1	5040.31	276.33	5742.06	236.93
A068
ICGC_PC	50	4 + 3	T3a	6.45	0	2451.17	143.26	5556.66	262.17
A069
ICGC_PC	47	3 + 4	T2c	5.2	1	3953.56	231.81	5395.4	260.33
A070
ICGC_PC	49	4 + 3	T2c	24.5	1	3776.54	223.33	6539.71	301.58
A071
ICGC_PC	49	3 + 4	T2c	11	0	4492.12	269.55	6647.67	314.24
A072
ICGC_PC	42	3 + 4	T2c	5.7	0	3321.15	251.03	5395.89	300.36
A074
ICGC_PC	40	3 + 3	T2a	5.4	2	5151.89	266.66	5965.86	338.87
A075
ICGC_PC	49	3 + 4	T2c	NA	0	3491.55	192.11	3316.82	213.37
A076
ICGC_PC	44	4 + 3	T2a	5.48	0	7752.06	405.76	8308.19	337.25
A077
ICGC_PC	47	3 + 4	T2c	16	0	4355.82	237.7	3346.03	133.55
A078
ICGC_PC	46	3 + 4	T2c	6.3	0	6685.66	343.82	2601.73	105.83
A079
ICGC_PC	50	4 + 5	T3b	13	1	2714.44	116.32	4814.68	183.35
A081
ICGC_PC	41	5 + 4	T3b	7.5	0	6940.57	290.7	5926.09	232.03
A082
ICGC_PC	45	3 + 4	T2c	16	1	11499.2	500.95	3934.47	165.31
A083
ICGC_PC	45	5 + 4	T3b	NA	0	5001.32	177.57	5497.65	205.17
A084
ICGC_PC	47	3 + 4	T2c	NA	0	3163.24	117.88	5796.65	222.73
A085
ICGC_PC	50	4 + 3	T3b	NA	1	2093.52	79.68	7527.37	284.86
A086
ICGC_PC	45	3 + 3	T2c	NA	0	4426.2	173.41	6051.99	237.24
A087
ICGC_PC	43	3 + 3	T2c	NA	0	4838.29	172.92	4928.1	189.51
A088
ICGC_PC	48	3 + 4	T2c	NA	0	3071.35	125.49	5624.6	219.75
A089
ICGC_PC	40	3 + 4	T2c	NA	0	3773.1	133.25	7026.47	285.17
A090
ICGC_PC	50	3 + 4	T2c	NA	1	7940.39	357.03	6353.35	326.23
A091
ICGC_PC	45	3 + 4	T2c	NA	0	1580.49	110.87	4981.62	249.77
A094
ICGC_PC	50	3 + 3	T2c	NA	1	2460.92	179.24	5146.51	196.13
A095
ICGC_PC	49	3 + 3	T2a	NA	0	2575.05	190.82	6107.44	232.27
A096
ICGC_PC	48	3 + 3	T2a	8.5	1	3853.91	280.28	8780.53	391.46
A097
ICGC_PC	45	4 + 5	T3a	NA	3	4548.38	376.83	6023.84	308.36
A098
ICGC_PC	48	3 + 3	T2c	NA	0	3897.72	304.27	6101.24	299.3
A102
ICGC_PC	48	3 + 3	T2c	NA	1	3976.32	300.1	7233.16	338.95
A103
ICGC_PC	44	3 + 4	T2a	NA	0	3427.5	247.03	5674.02	243.73
A104
ICGC_PC	49	3 + 4	T2c	NA	0	4097.07	175.58	7762.64	289.33
A105
ICGC_PC	43	3 + 4	T2c	NA	0	8923.14	375	5921.86	250.34
A106
ICGC_PC	47	3 + 3	T2c	NA	0	4825.85	196.81	6644.75	252.32
A107
ICGC_PC	50	3 + 4	T3a	NA	0	6116.57	213.75	8639.65	317.23
A108
ICGC_PC	48	3 + 3	T2c	NA	0	5878.11	243.55	4948.4	329.78
A110
ICGC_PC	43	3 + 4	T2c	NA	0	7863.32	459.98	7416.78	309.48
A111
ICGC_PC	47	4 + 3	T3b	NA	0	2980.66	168.21	5585.02	262.95
A112
ICGC_PC	48	4 + 5	T3b	NA	0	2915.6	229.57	4126.11	223.7
A113
ICGC_PC	46	3 + 4	T3a	NA	0	4955.88	254.74	7505.96	283.24
A116
ICGC_PC	50	3 + 3	T2c	NA	1	3994.34	192.73	8046.52	337.81
A118
ICGC_PC	44	3 + 4	T2c	NA	0	5487.62	190.05	7985.31	261.26
A121
ICGC_PC	50	4 + 3	T3b	NA	1	4089.29	139.16	16881.6	274.74
A122
ICGC_PC	46	3 + 4	T3a	NA	1	6229.33	201.83	23838.9	390.26
A123
ICGC_PC	46	3 + 4	T3a	NA	0	3088.17	103.27	18666.6	289.76
A124
ICGC_PC	44	5 + 4	T4	NA	3	6218.51	206.29	37206.4	513.19
A125
ICGC_PC	47	4 + 3	T3b	NA	0	4562.1	264.16	18594.5	589.83
A126
ICGC_PC	49	3 + 4	T2c	NA	0	3722.96	213.53	9790.9	314.37
A127
ICGC_PC	49	4 + 5	T2c	NA	0	4966.04	279.15	13371.3	395.19
A129
ICGC_PC	46	3 + 4	T3a	NA	0	1157.65	64.66	10770.6	318.28
A130
ICGC_PC	50	3 + 4	T2c	NA	0	3322.29	180.76	9669.45	304.17
A131
ICGC_PC	48	3 + 4	T3b	NA	0	2513.39	153.77	8557.46	261.06
A132
ICGC_PC	49	3 + 3	T2c	NA	0	4382.32	287.84	11193.9	325.5
A133
ICGC_PC	48	3 + 4	T2c	NA	0	3757.47	228.28	6793.07	225.09
A134
ICGC_PC	47	3 + 4	T2c	NA	0	3768.45	222.46	13255.5	269.37
A135
ICGC_PC	47	3 + 4	T2c	NA	0	2273.13	136.73	7783.32	234.65
A136
ICGC_PC	49	3 + 4	T2c	NA	0	2698.04	168.42	9615.6	308.54
A137
ICGC_PC	48	3 + 4	T2c	NA	0	2118.75	133.68	4218.26	91.54
A138
ICGC_PC	45	3 + 3	T2c	NA	1	5669.67	169.93	8477.17	179.01
A140
ICGC_PC	49	3 + 4	T2c	NA	0	3703.42	235.29	3519.06	75.73
A141
ICGC_PC	46	5 + 4	T4	NA	1	6249.11	397.65	14694.7	479.36
A142
ICGC_PC	48	3 + 4	T3a	NA	0	4739.26	144.27	10439.3	324.05
A143
ICGC_PC	46	3 + 4	T2c	NA	0	9066.31	138.77	6515.96	203.56
A144
ICGC_PC	32	3 + 3	T2a	NA	0	2457.97	155.08	6448.05	207.27
A145
ICGC_PC	46	3 + 4	T3a	NA	0	2547.86	139.34	7361.85	134.86
A148
ICGC_PC	45	4 + 3	T2c	NA	0	2529.97	148.52	7028.07	222.41
A149
ICGC_PC	40	3 + 3	T2c	NA	0	3151.92	193.85	8846	287.53
A150
ICGC_PC	49	3 + 4	T3a	NA	0	2056.8	131.17	6984.15	214.76
A151
ICGC_PC	45	3 + 4	T2c	NA	0	4032.42	251.71	9519.33	318
A152
ICGC_PC	50	3 + 4	T2c	NA	0	2467.2	149.3	9858.98	310.71
A153
ICGC_PC	48	3 + 4	T2c	NA	0	2957.33	171.59	9626.51	308.59
A154
ICGC_PC	45	3 + 4	T2a	NA	1	917.007	53.64	9799.51	306.62
A155
ICGC_PC	45	3 + 4	T2c	NA	1	4236.17	251.78	10226.1	408.15
A156
ICGC_PC	44	3 + 3	T2a	NA	0	3006.29	197.59	9086.25	313.43
A157
ICGC_PC	45	4 + 3	T3a	NA	0	4184.84	226.94	9004.93	281.4
A158
ICGC_PC	44	4 + 3	T2c	NA	0	4889.47	341.56	10928.6	327.3
A159
ICGC_PC	50	4 + 3	T2c	NA	0	2034.2	133.7	12007.2	363.41
A160
ICGC_PC	48	4 + 5	T3b	NA	2	1916.61	124.46	5272.41	182.18
A161
ICGC_PC	50	3 + 4	T2c	NA	0	3516.02	220.23	7845.21	239.88
A162
ICGC_PC	45	3 + 4	T2c	NA	1	3013.52	175.46	8769.99	268.11
A163
ICGC_PC	50	3 + 4	T3a	NA	0	4510.1	265.14	5838.26	354.37
A164
ICGC_PC	48	3 + 4	T2c	NA	0	2058.3	125.77	12277.9	379.59
A165
ICGC_PC	47	4 + 3	T2a	NA	2	2459.89	154.71	6601.8	206.31
A166
ICGC_PC	43	3 + 4	T2c	NA	0	3481.01	216.01	11925.1	357.9
A167
ICGC_PC	50	3 + 4	T2a	NA	1	4869.54	314.27	12045.6	279.19
A168
ICGC_PC	46	3 + 4	T3a	NA	2	5858.35	390.95	17049.7	470.86
A169
ICGC_PC	51	4 + 3	T2c	NA	2	3144.62	246.06	17963.1	324.48
A170
ICGC_PC	50	3 + 4	T2c	NA	1	5702.95	322.93	12983.8	353.49
A171
ICGC_PC	43	3 + 3	T2c	NA	0	6141.82	341.59	6015.86	166
A172
ICGC_PC	46	3 + 4	T2c	NA	0	6063	355.91	17240.8	463.59
A173
ICGC_PC	51	3 + 4	T3b	NA	1	4700.36	278.37	9175.36	260.85
A174
ICGC_PC	48	4 + 3	T3a	NA	0	3023.26	179.85	8788.83	257.43
A175
ICGC_PC	47	5 + 5	T4	NA	0	5185.27	302.08	4916.06	139.5
A176
ICGC_PC	46	3 + 4	T3a	NA	0	1713.44	98.87	6854.12	210.6
A177
ICGC_PC	51	3 + 3	T2a	NA	0	1792.49	105.66	8523.97	279.43
A178
ICGC_PC	45	3 + 4	T2c	NA	0	4142.21	236.83	9055.59	271.86
A179
ICGC_PC	51	3 + 4	T2c	NA	2	2446.26	139.43	12616	389.92
A180
ICGC_PC	51	3 + 4	T2c	NA	0	9884.16	557.48	7422.03	250.36
A181
ICGC_PC	51	3 + 4	T2c	NA	1	3777.99	213.81	13779.1	421.64
A182
ICGC_PC	52	3 + 4	T3a	NA	1	2994.8	167.45	5766.19	151.34
A183
ICGC_PC	51	3 + 4	T2c	NA	2	4889.25	277.56	8793.69	249.22
A184
ICGC_PC	51	3 + 3	T2c	NA	1	6046.69	350.23	10357	285.87
A185
ICGC_PC	51	3 + 4	T2c	NA	0	8935.55	150.08	16333.1	498.49
A186
ICGC_PC	46	3 + 3	T2c	NA	1	24761.9	420.19	8581.43	266.01
A187
ICGC_PC	48	3 + 4	T2c	NA	0	6424.8	115.1	3947.88	116.18
A188
ICGC_PC	51	3 + 4	T2c	NA	0	11625.9	211	9484.56	293.64
A189
ICGC_PC	51	4 + 3	T2c	NA	0	10871.4	206.33	5180.94	169.2
A190
ICGC_PC	51	3 + 4	T2c	NA	0	2626.94	150.24	7651.09	232.7
A191
ICGC_PC	52	4 + 4	T3b	NA	1	3697.6	215.29	5591.91	171.06
A192
ICGC_PC	52	5 + 4	T3b	NA	3	4695.07	262	8394.14	253.71
A193
ICGC_PC	52	3 + 4	T2c	NA	0	5640.21	314.13	16449.8	482.61
A194
ICGC_PC	47	3 + 3	T2c	NA	0	1946.43	109.94	6144.92	178.42
A195
ICGC_PC	52	4 + 5	T3b	NA	1	2681.47	146.21	4994.05	137.48
A196
ICGC_PC	50	3 + 4	T3a	NA	1	3413.79	183.69	10603.2	309.85
A197
ICGC_PC	52	4 + 5	T3b	NA	2	3070.23	172.58	10961.7	304.15
A198
ICGC_PC	51	3 + 4	T2c	NA	0	2438.98	141.68	13931.1	265.61
A199
ICGC_PC	47	3 + 4	T2c	NA	0	2912.99	178.33	25583.2	277.99
A200
TCGA-CH-	72	3 + 4	T2c	13.2	2	4645.1	256.1	8771.03	332.78
5750
TCGA-CH-	66	3 + 4	T3a	14.8	0	4837.75	275.63	9349.95	321.39
5763
TCGA-CH-	63	4 + 3	T2c	8.1	0	4387.57	267.28	6988.53	222.02
5771
TCGA-CH-	69	4 + 3	T3b	19.4	1	5554.92	288.62	21678.6	606.25
5788
TCGA-CH-	61	3 + 4	T3a	5.7	0	7282.33	418.19	8021.94	306.89
5789
TCGA-EJ-	50	5 + 3	T3a	18.4	0	5531.64	289.41	7616.2	237.24
5503
TCGA-EJ-	67	5 + 3	T3b	7.2	2	4952.82	291.73	8754.14	336.74
5506
TCGA-EJ-	67	3 + 4	T2c	4.5	0	2665.12	159.65	7271.3	244.69
7791
TCGA-G9-	57	3 + 4	NA	10.6	2	2003.55	105.24	9463.51	334.99
6336
TCGA-G9-	71	3 + 4	T4	11.6	0	2230.56	107.99	9664.85	342.25
6365
TCGA-G9-	52	3 + 4	T3b	6.4	0	2373.22	120.83	8885.26	304.54
6370
TCGA-G9-	49	3 + 4	T2c	6.8	0	1974.77	115.85	5812.83	211.12
7522
TCGA-HC-	63	3 + 3	T2a	5.1	1	2362.13	136.21	8765.79	285.05
7075
TCGA-HC-	51	3 + 4	T3a	5.5	0	2660.98	143.62	4529.49	170.1
7079
TCGA-HC-	73	4 + 3	T2a	7.7	0	2402.06	119.2	6346.51	214.41
7233
TCGA-HC-	55	3 + 4	T2c	18.1	0	3231.25	180.11	7132.52	264.64
7737
TCGA-HC-	59	3 + 4	T2c	5.9	0	2747.27	170.09	6201.89	241.73
7740
TCGA-HC-	46	4 + 3	T3b	4.4	0	3770.56	211	9518.19	327.16
7744
TCGA-HC-	56	3 + 3	T2c	4.3	0	2585.8	143.5	9352.13	272.82
8258
TCGA-HI-	55	3 + 4	T3a	2.2	0	1802.28	99.46	8035.46	278.59
7169
		mtSNVs/	MT-
		Mb	DLOOP
	Baca-P03-1426	0.14	0
	Baca-P05-1657	0.132	0
	Baca-PR-05-3595	0.319	1
	Baca-P05-3852	0.25	0
	Baca-PR-06-1749	0.111	0
	Baca-PR-06-3199	0.188	1
	Baca-PR-07-4610	0.333	1
	Baca-P07-4941	0.261	0
	Baca-P07-5037	0	0
	Baca-PR-08-4154	0.187	0
	Baca-P08-716	0	0
	Baca-P09-37	0.156	0
	Baca-PR-0410	0	0
	Baca-PR-STID0000002872	0.133	0
	Berger-PR-0508	0.301	0
	Berger-PR-0581	0	0
	Berger-PR-1701	0	0
	Berger-PR-1783	0	0
	Berger-PR-2832	0	0
	Berger-PR-3027	0.192	0
	Berger-PR-3043	0.233	0
	CPCG0001	0.113	1
	CPCG0003	0.107	0
	CPCG0004	0	0
	CPCG0005	0.141	0
	CPCG0006	0	0
	CPCG0007	0	0
	CPCG0008	0	0
	CPCG0015	0	0
	CPCG0019	0.256	0
	CPCG0020	0.134	0
	CPCG0022	0	0
	CPCG0027	0.223	0
	CPCG0030	0.277	0
	CPCG0036	0	0
	CPCG0040	0.47	1
	CPCG0042	0	0
	CPCG0046	0.296	1
	CPCG0047	0	0
	CPCG0048	0	0
	CPCG0050	0.065	0
	CPCG0057	0.223	0
	CPCG0063	0.224	0
	CPCG0067	0.192	0
	CPCG0070	0.172	1
	CPCG0071	0.297	0
	CPCG0072	0.107	0
	CPCG0073	0.241	1
	CPCG0075	0	0
	CPCG0076	0.114	0
	CPCG0078	0.208	1
	CPCG0081	0.117	1
	CPCG0082	0.137	0
	CPCG0083	0.126	0
	CPCG0084	0.108	1
	CPCG0087	0	0
	CPCG0089	0.104	0
	CPCG0090	0.201	0
	CPCG0094	0	0
	CPCG0095	0.212	0
	CPCG0096	0.179	0
	CPCG0097	0.276	1
	CPCG0098	0.357	1
	CPCG0099	0	0
	CPCG0100	0.371	1
	CPCG0102	0.109	0
	CPCG0103	0.18	0
	CPCG0114	2.517	1
	CPCG0117	0.057	0
	CPCG0120	0.058	0
	CPCG0121	0	0
	CPCG0122	0	0
	CPCG0123	0.148	0
	CPCG0124	0.256	0
	CPCG0126	0	0
	CPCG0127	0.088	0
	CPCG0128	0.229	1
	CPCG0154	0	0
	CPCG0158	0.136	1
	CPCG0166	0.672	1
	CPCG0182	0	0
	CPCG0183	0.184	1
	CPCG0184	0	0
	CPCG0185	0.133	0
	CPCG0187	0.073	1
	CPCG0188	0	0
	CPCG0189	0.389	1
	CPCG0190	0.097	0
	CPCG0191	0	0
	CPCG0194	0	0
	CPCG0196	0.351	1
	CPCG0198	0.073	1
	CPCG0199	0	0
	CPCG0201	0.108	0
	CPCG0204	0.669	1
	CPCG0205	0.113	1
	CPCG0206	0.088	1
	CPCG0208	0	0
	CPCG0210	0	0
	CPCG0211	0.301	0
	CPCG0212	0.101	0
	CPCG0213	0.507	0
	CPCG0217	0.295	0
	CPCG0232	0.121	0
	CPCG0233	0.132	0
	CPCG0234	0.27	0
	CPCG0235	0	0
	CPCG0236	0.067	0
	CPCG0237	0.126	0
	CPCG0238	0	0
	CPCG0241	0	0
	CPCG0242	0.293	1
	CPCG0243	0	0
	CPCG0246	0	0
	CPCG0248	0.169	0
	CPCG0249	0.189	0
	CPCG0250	0.139	1
	CPCG0251	0.085	0
	CPCG0255	0	0
	CPCG0256	0.315	1
	CPCG0257	0	0
	CPCG0258	0	0
	CPCG0259	0.077	1
	CPCG0260	0	0
	CPCG0262	0.181	0
	CPCG0263	0.16	1
	CPCG0265	0.081	0
	CPCG0266	0.169	0
	CPCG0267	0.188	0
	CPCG0268	0.095	0
	CPCG0269	0.417	1
	CPCG0324	0.262	0
	CPCG0331	0.264	0
	CPCG0334	0	0
	CPCG0336	0.097	0
	CPCG0339	0.21	0
	CPCG0340	0.128	0
	CPCG0341	0	0
	CPCG0342	0.046	1
	CPCG0344	0.094	1
	CPCG0345	0.09	0
	CPCG0346	0.334	0
	CPCG0348	0	0
	CPCG0349	0.069	0
	CPCG0350	0.109	0
	CPCG0352	0.192	1
	CPCG0353	0	0
	CPCG0354	0	0
	CPCG0355	0.167	1
	CPCG0356	0.239	0
	CPCG0357	0	0
	CPCG0358	0.094	0
	CPCG0360	0	0
	CPCG0361	0.142	0
	CPCG0362	0	0
	CPCG0363	0	0
	CPCG0364	0	0
	CPCG0365	0	0
	CPCG0366	0	0
	CPCG0368	0.076	1
	CPCG0369	0	0
	CPCG0371	0	0
	CPCG0372	0.083	0
	CPCG0373	0	0
	CPCG0374	0.072	0
	CPCG0375	0	0
	CPCG0377	0.086	0
	CPCG0378	0.08	0
	CPCG0379	0.128	0
	CPCG0380	0.084	0
	CPCG0381	0	0
	CPCG0382	0	0
	CPCG0387	0.228	0
	CPCG0388	0.085	0
	CPCG0391	0	0
	CPCG0392	0	0
	CPCG0401	0	0
	CPCG0404	0.055	1
	CPCG0407	0.253	0
	CPCG0408	0	0
	CPCG0409	0.081	0
	CPCG0410	0.244	0
	CPCG0411	0	0
	CPCG0412	0.378	0
	CPCG0413	0	0
	CPCG0414	0	0
	Weischenfeldt-EOPC-010	0.328	0
	Weischenfeldt-EOPC-011	0	0
	Weischenfeldt-EOPC-02	0	0
	Weischenfeldt-EOPC-03	0.114	0
	Weischenfeldt-EOPC-04	0.282	1
	Weischenfeldt-EOPC-05	0.234	1
	Weischenfeldt-EOPC-06	0	0
	Weischenfeldt-EOPC-07	0.644	0
	Weischenfeldt-EOPC-08	0	0
	Weischenfeldt-EOPC-09	0	0
	ICGC_PC	0	0
	A001
	ICGC_PC	0	0
	A012
	ICGC_PC	0.123	0
	A013
	ICGC_PC	0	0
	A014
	ICGC_PC	0.33	1
	A015
	ICGC_PC	0	0
	A016
	ICGC_PC	0	0
	A017
	ICGC_PC	0	0
	A018
	ICGC_PC	0	0
	A019
	ICGC_PC	0	0
	A020
	ICGC_PC	0	0
	A021
	ICGC_PC	0	0
	A022
	ICGC_PC	0.162	0
	A023
	ICGC_PC	0	0
	A024
	ICGC_PC	0	0
	A025
	ICGC_PC	0.226	0
	A026
	ICGC_PC	0	0
	A027
	ICGC_PC	0	0
	A028
	ICGC_PC	0.849	0
	A029
	ICGC_PC	0	0
	A030
	ICGC_PC	0.262	1
	A031
	ICGC_PC	NA	1
	A032
	ICGC_PC	NA	0
	A033
	ICGC_PC	0	0
	A034
	ICGC_PC	0	0
	A035
	ICGC_PC	0.333	0
	A036
	ICGC_PC	0	0
	A037
	ICGC_PC	0	0
	A038
	ICGC_PC	0	0
	A040
	ICGC_PC	0.405	0
	A041
	ICGC_PC	0	0
	A043
	ICGC_PC	0	0
	A044
	ICGC_PC	0	0
	A045
	ICGC_PC	0	0
	A046
	ICGC_PC	0.285	0
	A048
	ICGC_PC	0	0
	A049
	ICGC_PC	0	0
	A050
	ICGC_PC	0.262	0
	A051
	ICGC_PC	0	0
	A052
	ICGC_PC	0	0
	A053
	ICGC_PC	0	0
	A054
	ICGC_PC	0	0
	A055
	ICGC_PC	0	0
	A056
	ICGC_PC	0.209	0
	A057
	ICGC_PC	0	0
	A058
	ICGC_PC	0	0
	A059
	ICGC_PC	0.167	0
	A060
	ICGC_PC	0	0
	A061
	ICGC_PC	0	0
	A062
	ICGC_PC	0	0
	A063
	ICGC_PC	0	0
	A064
	ICGC_PC	0.195	1
	A065
	ICGC_PC	0.255	0
	A068
	ICGC_PC	0	0
	A069
	ICGC_PC	0.232	0
	A070
	ICGC_PC	0.2	1
	A071
	ICGC_PC	0	0
	A072
	ICGC_PC	0	0
	A074
	ICGC_PC	0.356	0
	A075
	ICGC_PC	0	0
	A076
	ICGC_PC	0	0
	A077
	ICGC_PC	0	0
	A078
	ICGC_PC	0	0
	A079
	ICGC_PC	0.329	0
	A081
	ICGC_PC	0	0
	A082
	ICGC_PC	0.365	0
	A083
	ICGC_PC	0	0
	A084
	ICGC_PC	0	0
	A085
	ICGC_PC	0.212	0
	A086
	ICGC_PC	0	0
	A087
	ICGC_PC	0	0
	A088
	ICGC_PC	0	0
	A089
	ICGC_PC	0	0
	A090
	ICGC_PC	0.185	0
	A091
	ICGC_PC	0	0
	A094
	ICGC_PC	0.308	0
	A095
	ICGC_PC	0	0
	A096
	ICGC_PC	0.154	1
	A097
	ICGC_PC	0.587	1
	A098
	ICGC_PC	0	0
	A102
	ICGC_PC	0.178	0
	A103
	ICGC_PC	0	0
	A104
	ICGC_PC	0	0
	A105
	ICGC_PC	0	0
	A106
	ICGC_PC	0	0
	A107
	ICGC_PC	0	0
	A108
	ICGC_PC	0	0
	A110
	ICGC_PC	0	0
	A111
	ICGC_PC	0	0
	A112
	ICGC_PC	0	0
	A113
	ICGC_PC	0	0
	A116
	ICGC_PC	0.179	1
	A118
	ICGC_PC	0	0
	A121
	ICGC_PC	0.22	0
	A122
	ICGC_PC	0.155	0
	A123
	ICGC_PC	0	0
	A124
	ICGC_PC	0.353	1
	A125
	ICGC_PC	0	0
	A126
	ICGC_PC	0	0
	A127
	ICGC_PC	0	0
	A129
	ICGC_PC	0	0
	A130
	ICGC_PC	0	0
	A131
	ICGC_PC	0	0
	A132
	ICGC_PC	0	0
	A133
	ICGC_PC	0	0
	A134
	ICGC_PC	0	0
	A135
	ICGC_PC	0	0
	A136
	ICGC_PC	0	0
	A137
	ICGC_PC	0	0
	A138
	ICGC_PC	0.337	0
	A140
	ICGC_PC	0	0
	A141
	ICGC_PC	0.126	0
	A142
	ICGC_PC	0	0
	A143
	ICGC_PC	0	0
	A144
	ICGC_PC	0	0
	A145
	ICGC_PC	0	0
	A148
	ICGC_PC	0	0
	A149
	ICGC_PC	0	0
	A150
	ICGC_PC	0	0
	A151
	ICGC_PC	0	0
	A152
	ICGC_PC	0	0
	A153
	ICGC_PC	0	0
	A154
	ICGC_PC	0.197	0
	A155
	ICGC_PC	0.148	0
	A156
	ICGC_PC	0	0
	A157
	ICGC_PC	0	0
	A158
	ICGC_PC	0	0
	A159
	ICGC_PC	0	0
	A160
	ICGC_PC	0.663	0
	A161
	ICGC_PC	0	0
	A162
	ICGC_PC	0.225	0
	A163
	ICGC_PC	0	0
	A164
	ICGC_PC	0	0
	A165
	ICGC_PC	0.585	1
	A166
	ICGC_PC	0	0
	A167
	ICGC_PC	0.216	0
	A168
	ICGC_PC	0.256	1
	A169
	ICGC_PC	0.372	1
	A170
	ICGC_PC	0.171	0
	A171
	ICGC_PC	0	0
	A172
	ICGC_PC	0	0
	A173
	ICGC_PC	0.231	0
	A174
	ICGC_PC	0	0
	A175
	ICGC_PC	0	0
	A176
	ICGC_PC	0	0
	A177
	ICGC_PC	0	0
	A178
	ICGC_PC	0	0
	A179
	ICGC_PC	0.31	0
	A180
	ICGC_PC	0	0
	A181
	ICGC_PC	0.143	0
	A182
	ICGC_PC	0.399	1
	A183
	ICGC_PC	0.484	1
	A184
	ICGC_PC	0.211	0
	A185
	ICGC_PC	0	0
	A186
	ICGC_PC	0.227	0
	A187
	ICGC_PC	0	0
	A188
	ICGC_PC	0	0
	A189
	ICGC_PC	0	0
	A190
	ICGC_PC	0	0
	A191
	ICGC_PC	0.353	0
	A192
	ICGC_PC	0.714	0
	A193
	ICGC_PC	0	0
	A194
	ICGC_PC	0	0
	A195
	ICGC_PC	0.439	0
	A196
	ICGC_PC	0.195	1
	A197
	ICGC_PC	0.397	1
	A198
	ICGC_PC	0	0
	A199
	ICGC_PC	0	0
	A200
	TCGA-CH-	0.363	0
	5750
	TCGA-CH-	0	0
	5763
	TCGA-CH-	0	0
	5771
	TCGA-CH-	0.1	1
	5788
	TCGA-CH-	0	0
	5789
	TCGA-EJ-	0	0
	5503
	TCGA-EJ-	0.359	1
	5506
	TCGA-EJ-	0	0
	7791
	TCGA-G9-	0.36	0
	6336
	TCGA-G9-	0	0
	6365
	TCGA-G9-	0	0
	6370
	TCGA-G9-	0	0
	7522
	TCGA-HC-	0.212	1
	7075
	TCGA-HC-	0	0
	7079
	TCGA-HC-	0	0
	7233
	TCGA-HC-	0	0
	7737
	TCGA-HC-	0	0
	7740
	TCGA-HC-	0	0
	7744
	TCGA-HC-	0	0
	8258
	TCGA-HI-	0	0
	7169
																				sample_size
																				(Amt_
MT-	MT-	MT-	MT-		MT-	MT-	MT-	MT-	MT-	MT-	MT-	MT-	MT-	MT-					bwa	DNA.sent.for.se-
CYB	RNR1	RNR2	ND1	MTND2	ND3	ND4	ND4L	ND5	ND6	CO1	CO2	CO3	ATP6	ATP8	OHR	CSB1	HV1	HV2	version	quencing)
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	bwa/0.5.7	NA
0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	bwa/0.5.7	NA
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa/0.5.7	356.5
0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	226.2
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	198
																			0.7.12
0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	222.32
																			0.7.12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	121.16
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	267.3
																			0.7.12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	129
																			0.7.12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	239.9
																			0.7.12
0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	399.82
																			0.7.12
0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	232.5
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	295.2
																			0.7.12
0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	259
																			0.7.12
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	bwa-mem/	232.2
																			0.7.12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	227.34
																			0.7.12
0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	bwa/0.5.7	392.06
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	391.89
																			0.7.12
0	0	0	0	1	0	1	0	1	0	0	0	0	0	0	0	0	1	0	bwa/0.5.7	228.64
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	424.02
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	512.4
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	bwa-mem/	159.8
																			0.7.12
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	310.77
0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	bwa/0.5.7	513.84
1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	500
																			0.7.15
0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	bwa-mem/	270.96
																			0.7.12
0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	308.14
																			0.7.12
0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	bwa/0.5.7	663.36
0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	bwa/0.5.7	500
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	242.19
																			0.7.12
0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	408.2
																			0.7.12
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	bwa/0.5.7	252.59
0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	bwa/0.5.7	675.13
0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	bwa-mem/	253.71
																			0.7.12
0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	299.1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa-mem/	664.9
																			0.7.12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	275.1
0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	bwa-mem/	250
																			0.7.12
0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	bwa-mem/	300
																			0.7.12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	417.15
0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	359.22
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	bwa-mem/	100
																			0.7.12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa-mem/	186.62
																			0.7.12
0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	bwa/0.5.7	250.29
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	1093.1
0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	bwa/0.5.7	318.32
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	bwa/0.5.7	642.75
0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	bwa-mem/	552.6
																			0.7.10
0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	1	bwa/0.5.7	339.15
0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	677.5
0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	205.47
																			0.7.12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	952.8
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	937.68
																			0.7.12
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	bwa/0.5.7	242.5
0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	bwa/0.5.7	980.4
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	177.25
																			0.7.12
0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	503.84
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa/0.5.7	1098.8
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	950.96
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	bwa/0.5.7	848.68
0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	1	bwa/0.5.7	150
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	501.12
0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa/0.5.7	586.8
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	774.52
0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	2064
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	bwa/0.5.7	2901.4
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	1510.3
0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	bwa/0.5.7	2036.8
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	2020.4
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	1722.2
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	522.09
																			0.7.12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	bwa/0.5.7	1513.8
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa-mem/	262.8
																			0.7.12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	259.5
0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	271.2
0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	1	bwa-mem/	991.44
																			0.7.12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	bwa/0.5.7	203.44
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	bwa/0.5.7	335.52
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	2304.5
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	1001.2
0	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	bwa/0.5.7	1000
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	1001.6
1	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	1515.8
0	0	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	bwa/0.5.7	1002.6
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	2006
0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	2015.2
0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	bwa/0.5.7	500
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	2000
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	388.8
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	bwa-mem/	635.75
																			0.7.12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	2000
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	2000
0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	1	1	0	1	bwa/0.5.7	618
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	1498
																			0.7.12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	339
0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	394.8
0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	bwa/0.5.7	563.4
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa/0.5.7	1500
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	bwa/0.5.7	1000
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	259.2
0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	bwa/0.5.7	429
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	1006.4
																			0.7.12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	1500
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa/0.5.7	279
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	1500
0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	bwa/0.5.7	253.2
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	bwa/0.5.7	85.2
0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	287.4
0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	bwa/0.5.7	306.6
0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	271.2
0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	268.4
1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	bwa/0.5.7	110.4
0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	416.5
0	0	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	bwa/0.5.7	312.2
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	318.5
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	445.9
0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	342
1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	588
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	543.9
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	310.1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	363.6
0	0	0	0	0			0	0	0	0	0	0	0	1	0	0	0	0	bwa/0.5.7	489
1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	484.2
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	246
0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	bwa/0.5.7	253
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	bwa/0.5.7	297.6
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	bwa/0.5.7	271.2
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	250.8
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	298
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa/0.5.7	256
1	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	bwa/0.5.7	277.6
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	346.2
0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	265.5
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	252.8
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	347.4
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	330.4
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	277.2
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	237.2
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	2361.7
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	1542
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa/0.5.7	309.4
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	294.6
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	355.68
0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	bwa/0.5.7	304
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	350.4
0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	309.6
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	428
0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	315
0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	bwa/0.5.7	288
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	536.2
0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	bwa/0.5.7	282.6
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	280.8
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	598
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	348
0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	673
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	374.4
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	1180
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	603
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa/0.5.7	754
0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	588
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	326
0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	399
0	0	1	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	392
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	445.2
1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	422
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	442.4
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	336
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	1	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	1	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	bwa-mem/	NA
																			0.7.8-r455
0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	bwa-mem/	NA
																			0.7.8-r455
0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa-mem/	NA
																			0.7.8-r455
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa-mem/	NA
																			0.7.8-r455
0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	bwa/0.5.7	NA
		Myc CNA	NKX3-1 CNA	Cellularity
		0	0	NA
		0	0	NA
		0	0	NA
		0	−1	NA
		0	−1	NA
		0	0	NA
		1	0	NA
		0	0	NA
		0	0	NA
		1	−1	NA
		0	0	NA
		0	0	NA
		0	0	NA
		0	0	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		0	−1	0.9
		1	−1	0.8
		0	−1	0.8
		0	0	0.8
		1	−1	0.9
		0	−1	0.7
		1	0	0.9
		0	−1	0.2
		0	0	0.3
		0	0	0.9
		0	0	0.9
		0	0	0.2
		0	−1	0.9
		0	0	NA
		1	0	0.8
		0	−1	0.9
		0	0	0.9
		0	0	0.9
		0	0	0.7
		0	0	0.9
		0	−1	0.6
		1	−1	0.2
		0	0	NA
		0	0	0.9
		0	0	0.9
		1	−1	0.8
		1	−1	0.8
		0	0	0.8
		0	0	0.9
		1	−1	0.6
		1	−1	0.4
		1	−1	0.9
		1	−1	0.6
		0	0	0.9
		0	−1	1
		0	0	0.8
		0	0	0.8
		0	0	0.5
		0	0	0.9
		0	0	0.9
		0	0	0.8
		1	−1	0.8
		0	−1	0.8
		1	−1	0.7
		0	0	NA
		0	0	NA
		0	0	0.2
		0	0	0.6
		1	−1	0.8
		0	−1	0.3
		0	0	0.8
		0	0	0.8
		0	0	0.8
		0	−1	0.9
		0	0	0.9
		0	−1	0.9
		0	0	0.8
		0	0	0.6
		0	0	0.2
		0	0	NA
		0	−1	0.7
		1	−1	0.7
		0	−1	0.6
		1	−1	0.9
		0	−1	0.8
		0	−1	0.7
		0	0	0.4
		0	−1	0.6
		0	−1	0.9
		0	0	0.9
		0	0	0.9
		0	0	0.4
		0	−1	0.8
		0	−1	0.9
		0	−1	0.3
		1	−1	0.2
		0	−1	0.8
		0	−1	0.3
		0	−1	0.5
		0	−1	0.9
		0	−1	0.2
		0	0	0.2
		0	−1	0.8
		0	−1	0.6
		0	0	0.9
		1	−1	0.8
		1	−1	0.5
		0	0	0.9
		0	0	0.6
		0	−1	1
		1	−1	0.7
		0	0	0.9
		0	0	0.2
		0	−1	0.7
		0	−1	0.6
		0	0	0.4
		0	0	0.2
		0	0	0.6
		0	−1	0.2
		0	−1	0.9
		0	−1	0.3
		0	0	0.2
		0	0	0.6
		0	−1	0.8
		0	−1	0.3
		0	−1	0.8
		0	−1	0.2
		0	0	0.3
		0	0	0.2
		0	−1	0.8
		0	−1	0.3
		0	−1	0.2
		0	−1	0.7
		0	0	0.2
		1	0	0.2
		0	−1	0.6
		0	−1	0.5
		0	0	0.3
		0	0	0.3
		1	1	0.8
		0	0	0.3
		0	−1	0.7
		0	−1	0.6
		0	−1	0.8
		0	−1	0.6
		0	0	0.5
		0	−1	0.3
		0	0	0.2
		0	−1	0.6
		0	0	0.7
		0	0	0.3
		0	−1	0.2
		0	−1	0.3
		0	0	0.4
		0	0	0.3
		0	0	0.7
		0	0	0.1
		0	−1	0.6
		0	0	0.2
		1	−1	0.7
		0	−1	0.6
		0	0	0.3
		0	0	0.3
		0	0	0.2
		0	0	0.5
		0	−1	0.3
		0	−1	0.6
		1	−1	0.8
		1	−1	0.6
		0	0	0.3
		1	1	0.7
		0	0	0.5
		0	−1	0.7
		0	0	0.2
		0	0	0.7
		0	0	0.2
		0	0	0.7
		0	−1	0.8
		0	−1	0.1
		0	−1	0.3
		0	−1	0.3
		0	0	0.1
		0	−1	0.6
		0	0	0.5
		0	0	0.2
		NA	NA	NA
		0	0	NA
		0	−1	NA
		1	−1	NA
		0	0	NA
		0	0	NA
		0	0	NA
		0	−1	NA
		0	0	NA
		0	0	NA
		0	−1	NA
		0	−1	NA
		0	0	NA
		0	0	NA
		0	−1	NA
		0	−1	NA
		0	0	NA
		0	0	NA
		0	0	NA
		NA	NA	NA
		0	0	NA
		0	0	NA
		0	0	NA
		0	0	NA
		0	−1	NA
		0	0	NA
		0	−1	NA
		0	0	NA
		0	0	NA
		1	−1	NA
		0	−1	NA
		0	1	NA
		0	0	NA
		NA	NA	NA
		0	−1	NA
		0	0	NA
		1	−1	NA
		NA	NA	NA
		NA	NA	NA
		0	−1	NA
		1	−1	NA
		0	0	NA
		0	0	NA
		NA	NA	NA
		0	−1	NA
		0	−1	NA
		0	0	NA
		0	0	NA
		NA	NA	NA
		NA	NA	NA
		0	0	NA
		0	0	NA
		0	0	NA
		NA	NA	NA
		NA	NA	NA
		0	−1	NA
		0	−1	NA
		NA	NA	NA
		0	0	NA
		NA	NA	NA
		0	−1	NA
		1	0	NA
		0	0	NA
		0	−1	NA
		0	0	NA
		0	−1	NA
		0	−1	NA
		0	0	NA
		NA	NA	NA
		NA	NA	NA
		0	−1	NA
		0	0	NA
		NA	NA	NA
		0	−1	NA
		0	0	NA
		0	−1	NA
		1	−1	NA
		0	0	NA
		0	−1	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		1	0	NA
		NA	NA	NA
		0	0	NA
		0	−1	NA
		NA	NA	NA
		0	−1	NA
		0	0	NA
		NA	NA	NA
		0	0	NA
		NA	NA	NA
		0	0	NA
		0	0	NA
		1	0	NA
		0	0	NA
		0	0	NA
		0	−1	NA
		0	0	NA
		0	0	NA
		0	−1	NA
		NA	NA	NA
		0	−1	NA
		0	−1	NA
		0	0	NA
		1	0	NA
		0	0	NA
		0	0	NA
		1	−1	NA
		0	0	NA
		NA	NA	NA
		0	−1	NA
		NA	NA	NA
		0	−1	NA
		NA	NA	NA
		0	0	NA
		NA	NA	NA
		0	0	NA
		0	0	NA
		0	0	NA
		0	−1	NA
		0	0	NA
		0	−1	NA
		NA	NA	NA
		0	−1	NA
		0	0	NA
		0	0	NA
		0	0	NA
		0	0	NA
		0	−1	NA
		NA	NA	NA
		0	−1	NA
		0	0	NA
		0	0	NA
		NA	NA	NA
		0	0	NA
		0	−1	NA
		NA	NA	NA
		0	0	NA
		0	0	NA
		0	−1	NA
		0	−1	NA
		0	−1	NA
		0	0	NA
		0	−1	NA
		0	0	NA
		NA	NA	NA
		0	0	NA
		0	−1	NA
		0	0	NA
		0	−1	NA
		0	−1	NA
		NA	NA	NA
		0	0	NA
		NA	NA	NA
		0	−1	NA
		0	0	NA
		0	0	NA
		0	0	NA
		0	−1	NA
		0	0	NA
		NA	NA	NA
		0	0	NA
		NA	NA	NA
		NA	NA	NA
		0	0	NA
		0	0	NA
		0	0	NA
		NA	NA	NA
		0	−1	NA
		0	0	NA
		NA	NA	NA
		NA	NA	NA
		0	0	NA
		NA	NA	NA
		NA	NA	NA
		NA	NA	NA
		0	0	NA
		NA	NA	NA
		NA	NA	NA
		0	−1	NA
		0	0	NA
		NA	NA	NA
		NA	NA	NA
		0	0	NA
		0	0	NA
		0	0	NA
		0	0	NA
		0	0	NA
		0	0	NA
		0	0	NA
		0	0	NA
		NA	NA	NA
		0	0	NA
		0	0	NA
		0	0	NA
		0	0	NA

TABLE 5
Table of 293 somatic mtSNVs
	Position					Tumour.H.	Normal.HF.	Normal.HF.	Normal.HF.
Patient	Reference	Tumour	Tumour.HF.	Tumour.HF	Tumour.HF	Normal	A	C	G
CPCG0187	60 T	T	0	0.22	0	0.78 T	0	0	0
CPCG0078	72 T	C	0	0.72	0	0.27 T	0	0	0
CPCG0114	72 T	T	0	0	0	1 C	0	1	0
CPCG0263	72 T	T	0	0.5	0	0.5 T	0	0	0
ICGC_PCA071	72 T	C	0	0.89	0	0.11 T	0	0	0
CPCG0166	73 G	A	0.75	0	0.25	0 A	0.99	0	0.01
CPCG0098	146 C	C	0	0.7	0	0.3 T	0	0	0
CPCG0100	146 C	T	0	0.42	0	0.58 T	0	0.01	0
ICGC_PCA169	146 C	C	0	0.69	0	0.31 T	0	0.2	0
ICGC_PCA198	146 C	T	0	0.18	0	0.82 C	0	0.83	0
CPCG0206	152 C	C	0	0.84	0	0.16 T	0	0.18	0
Baca07-4610	152 C	T	0	0.27	0	0.73 T	0	0	0
ICGC_PCA032	152 C	C	0	0.99	0	0.01 T	0	0	0
CPCG0204	183 A	G	0.49	0	0.51	0 A	1	0	0
CPCG0073	195 C	T	0	0.26	0	0.74 T	0	0	0
CPCG0196	195 C	T	0	0.37	0	0.63 T	0	0	0
ICGC_PCA118	195 C	C	0	0.56	0	0.43 T	0	0.11	0
ICGC_PCA166	199 T	C	0	0.86	0	0.14 T	0	0.15	0
ICGC_PCA015	207 G	G	0.2	0	0.8	0 A	0.71	0	0.29
CPCG0098	215 A	G	0.24	0	0.76	0 A	1	0	0
CPCG0205	227 A	A	0.82	0	0.18	0 G	0.16	0	0.84
CPCG0242	234 A	G	0.19	0	0.81	0 A	1	0	0
ICGC_PCA031	234 A	G	0.16	0	0.84	0 A	0.93	0	0.07
CPCG0070	248 A	A	0.99	0	0.01	0 A	0.74	0	0.26
CPCG0256	255 G	G	0.44	0.01	0.55	0 G	0	0	1
CPCG0158	307 C	C	0	0.64	0	0.36 C	0	1	0
CPCG0081	309 C	C	0	0.62	0	0.38 C	0	1	0
Baca06-3199	309 C	T	0	0.22	0	0.77 C	0	0.99	0
CPCG0344	499 G	G	0.21	0	0.78	0 G	0	0	1
CPCG0046	564 G	G	0.27	0.02	0.71	0 G	0	0	1
CPCG0342	564 G	A	0.88	0	0.12	0 G	0	0	1
ICGC_PCA125	574 A	A	0.83	0.17	0	0 A	0.62	0.38	0
CPCG0067	617 G	G	0.49	0	0.51	0 G	0	0	1
CPCG0189	650 T	T	0	0.5	0	0.5 T	0	0	0
CPCG0189	690 T	T	0	0.27	0	0.73 T	0	0	0
CPCG0083	709 G	A	0.56	0	0.44	0 G	0	0	1
ICGC_PCA196	709 G	A	0.61	0	0.39	0 G	0.29	0	0.71
CPCG0073	719 G	G	0.38	0	0.62	0 G	0	0	1
CPCG0019	933 G	A	0.52	0	0.48	0 G	0	0	1
CPCG0248	988 G	G	0.42	0	0.58	0 G	0	0	1
CPCG0346	988 G	G	0.38	0	0.62	0 G	0	0	1
EOPC-07	988 G	G	0.36	0	0.64	0 G	0	0	1
CPCG0204	991 G	A	0.66	0	0.34	0 G	0	0	1
CPCG0211	1079 G	G	0.26	0	0.74	0 G	0	0	0.99
ICGC_PCA057	1157 T	C	0	0.53	0	0.47 T	0	0	0
EOPC-04	1193 T	T	0	0.1	0	0.9 T	0	0.32	0
CPCG0090	1199 G	A	0.7	0	0.3	0 G	0	0	1
ICGC_PCA192	1447 G	G	0.32	0	0.68	0 G	0	0	1
ICGC_PCA032	1452 T	T	0	0	0	1 C	0	1	0
CPCG0185	1456 T	T	0	0.46	0	0.54 T	0	0	0
CPCG0412	1469 G	A	0.51	0	0.49	0 G	0	0	1
CPCG0268	1552 G	G	0.22	0	0.78	0 G	0	0	1
CPCG0097	1644 G	G	0.25	0	0.74	0 G	0	0	1
ICGC_PCA103	1659 T	T	0	0.46	0	0.54 T	0	0	0
ICGC_PCA032	1716 T	T	0	0	0	1 C	0	1	0
ICGC_PCA161	1730 T	C	0	0.73	0	0.27 T	0	0	0
ICGC_PCA075	1770 G	G	0.44	0	0.56	0 G	0	0	1
CPCG0339	1906 G	A	0.59	0	0.41	0 G	0	0	1
CPCG0098	1975 T	C	0	0.77	0	0.23 T	0	0	0
CPCG0100	2074 A	G	0.35	0	0.65	0 A	0.99	0	0
CPCG0027	2115 T	T	0	0	0	1 T	0	0.25	0
ICGC_PCA083	2269 G	A	0.6	0	0.4	0 G	0	0	1
Baca05-3852	2333 G	A	0.91	0	0.09	0 G	0.03	0	0.97
CPCG0388	2478 G	G	0.36	0	0.64	0 G	0	0	1
CPCG0183	2487 A	A	0.99	0	0	0 A	0.77	0.2	0.01
CPCG0081	2519 G	A	0.64	0	0.36	0 G	0	0	1
ICGC_PCA029	2571 G	G	0.26	0	0.74	0 G	0	0	1
CPCG0040	2607 T	T	0	0.26	0	0.74 T	0	0	0
CPCG0358	2634 T	T	0	0.41	0	0.59 T	0	0	0
CPCG0005	2697 G	G	0.48	0	0.52	0 G	0	0	1
ICGC_PCA182	2737 T	C	0	0.72	0	0.28 T	0	0	0
TCGA-CH-5750	2817 G	G	0.47	0	0.53	0 G	0	0	1
ICGC_PCA068	2844 G	G	0.5	0	0.5	0 G	0	0	1
CPCG0217	2894 T	T	0	0	0	1 T	0	0.24	0
ICGC_PCA070	2914 A	A	0.69	0	0.31	0 G	0.22	0	0.78
ICGC_PCA051	2916 G	G	0.32	0	0.68	0 G	0	0	1
ICGC_PCA163	2916 G	G	0.44	0	0.56	0 G	0	0	1
CPCG0331	2941 G	A	0.61	0	0.39	0 G	0	0	1
CPCG0410	3022 G	G	0.25	0	0.75	0 G	0	0	1
ICGC_PCA125	3063 G	A	0.69	0	0.31	0 G	0	0	1
CPCG0324	3079 G	A	0.61	0	0.39	0 G	0	0	1
CPCG0166	3174 T	T	0	0.28	0	0.72 T	0	0	0
CPCG0212	3297 T	T	0	0.23	0	0.77 T	0	0	0
CPCG0071	3492 A	A	0.75	0.24	0	0.01 A	0.97	0.03	0
CPCG0265	3496 G	G	0.4	0	0.59	0 G	0	0	1
TCGA-CH-5750	3526 G	G	0.23	0	0.77	0 G	0	0	1
CPCG0120	3697 G	G	0.35	0	0.65	0 G	0	0	1
CPCG0063	3842 G	G	0.22	0	0.77	0 G	0	0	1
ICGC_PCA122	3842 G	G	0.45	0	0.55	0 G	0	0	1
ICGC_PCA187	3842 G	G	0.21	0	0.79	0 G	0	0	1
CPCG0127	3946 G	G	0.22	0	0.78	0 G	0	0	1
CPCG0233	3946 G	G	0.4	0	0.6	0 G	0	0	1
ICGC_PCA125	3959 G	G	0.36	0	0.63	0 G	0	0	1
CPCG0213	3982 G	G	0.22	0	0.78	0 G	0	0	1
Baca05-3852	4053 A	G	0.34	0	0.65	0 A	0.96	0	0.03
CPCG0027	4142 G	A	0.59	0	0.41	0 G	0	0	1
TCGA-EJ-5506	4142 G	G	0.21	0	0.79	0 G	0	0	0.99
CPCG0003	4201 G	G	0.24	0	0.76	0 G	0	0	1
CPCG0067	4231 A	G	0.58	0	0.42	0 A	1	0	0
ICGC_PCA098	4233 T	C	0	0.53	0	0.47 T	0	0	0
CPCG0067	4407 G	A	0.63	0	0.36	0 G	0	0	1
CPCG0387	4436 C	C	0	0.56	0	0.44 C	0	1	0
CPCG0262	4482 G	G	0.27	0	0.73	0 G	0	0	1
ICGC_PCA171	4491 G	G	0.46	0	0.54	0 G	0	0	1
CPCG0204	4596 G	A	0.68	0	0.32	0 G	0	0	1
CPCG0117	4648 T	T	0	0.36	0	0.63 T	0	0	0
CPCG0407	4770 G	A	0.75	0	0.25	0 G	0	0	1
EOPC-03	4831 G	A	0.61	0	0.39	0 G	0	0	1
CPCG0409	4858 T	C	0	0.6	0	0.4 T	0	0	0
CPCG0071	4887 T	T	0	0.49	0	0.5 T	0	0	0
CPCG0339	4905 T	C	0	0.67	0	0.33 T	0	0	0
CPCG0046	4920 G	G	0.25	0	0.72	0.03 G	0	0	1
ICGC_PCA142	4958 A	A	0.96	0	0.04	0 A	0.74	0	0.26
CPCG0201	5115 T	C	0	0.9	0	0.1 T	0	0	0
CPCG0020	5195 C	C	0.05	0.95	0	0 C	0.44	0.56	0
CPCG0267	5227 G	G	0.28	0	0.72	0 G	0	0	1
ICGC_PCA185	5301 A	A	0.66	0	0.34	0 G	0.41	0	0.59
CPCG0242	5511 T	C	0	0.82	0	0.17 T	0	0	0
ICGC_PCA013	5521 G	A	0.53	0	0.47	0 G	0	0	1
ICGC_PCA140	5774 T	C	0	0.61	0	0.39 T	0	0	0
EOPC-07	5814 T	C	0	0.86	0	0.14 T	0	0	0
CPCG0350	5910 G	A	0.67	0	0.33	0 G	0	0	1
TCGA-G9-6336	5979 G	G	0.48	0	0.52	0 G	0	0	1
CPCG0356	6020 C	C	0	0.91	0	0.09 T	0	0.42	0
ICGC_PCA048	6046 T	T	0	0.28	0	0.72 T	0	0	0
CPCG0050	6054 G	G	0.21	0	0.79	0 A	0.87	0	0.13
CPCG0189	6270 G	G	0.24	0	0.76	0 G	0	0	1
CPCG0251	6276 G	A	0.87	0	0.13	0 G	0.45	0	0.55
TCGA-G9-6336	6321 G	A	0.5	0	0.5	0 G	0	0	1
CPCG0123	6419 A	A	1	0	0	0 A	0.8	0.18	0.01
CPCG0211	6419 A	A	1	0	0	0 A	0.77	0.21	0.01
CPCG0102	6496 C	T	0	0.42	0	0.58 C	0	1	0
CPCG0124	6664 T	C	0	0.8	0	0.2 T	0	0.44	0
ICGC_PCA060	6718 G	A	0.53	0	0.47	0 G	0	0	1
CPCG0096	6742 T	C	0	0.66	0	0.34 T	0	0	0
CPCG0331	6856 T	C	0	0.6	0	0.4 T	0	0	0
CPCG0090	6892 G	A	0.51	0	0.49	0 G	0	0	1
CPCG0189	6944 T	T	0	0.26	0	0.74 T	0	0	0
ICGC_PCA155	7026 G	G	0.4	0	0.6	0 G	0	0	1
EOPC-010	7293 G	G	0.25	0	0.75	0 G	0	0	1
ICGC_PCA029	7393 G	G	0.24	0	0.76	0 G	0	0	1
EOPC-010	7554 G	G	0.25	0	0.75	0 G	0	0	1
CPCG0124	7772 A	G	0.19	0	0.81	0 A	0.55	0	0.45
ICGC_PCA156	7803 T	T	0	0.37	0	0.63 T	0	0	0
CPCG0378	7919 G	G	0.26	0	0.74	0 G	0	0	1
CPCG0266	7929 G	G	0	0	0.98	0.02 G	0	0	0.75
ICGC_PCA123	7997 G	A	0.59	0	0.41	0 G	0	0	1
ICGC_PCA023	8078 G	G	0.24	0	0.76	0 G	0	0	1
ICGC_PCA174	8348 A	G	0.14	0	0.86	0 G	0.35	0	0.65
CPCG0345	8391 G	G	0.32	0	0.68	0 G	0	0	1
CPCG0103	8393 C	T	0	0.2	0	0.8 C	0	0.99	0
CPCG0196	8433 T	T	0	0.37	0	0.63 T	0	0	0
ICGC_PCA193	8547 T	C	0	0.54	0	0.46 T	0	0	0
CPCG0063	8643 C	T	0	0.1	0	0.9 C	0	0.63	0
ICGC_PCA029	8697 G	G	0.32	0	0.68	0 G	0	0	1
CPCG0082	8705 T	C	0	0.97	0	0.03 T	0	0.49	0
CPCG0217	8843 T	T	0	0	0	1 T	0	0.25	0
Berger3043	8999 T	C	0	0.9	0	0.1 T	0	0	0
CPCG0380	9182 G	A	0.62	0	0.38	0 G	0	0	1
ICGC_PCA026	9185 T	T	0	0.21	0	0.79 T	0	0	0
ICGC_PCA166	9378 T	T	0	0.41	0	0.59 T	0	0	0
CPCG0349	9380 G	A	0.8	0	0.2	0 G	0.19	0	0.81
CPCG0262	9504 G	A	0.84	0	0.16	0 G	0	0	1
CPCG0234	9516 T	T	0	0.34	0	0.66 T	0	0	0
CPCG0070	9628 G	A	0.59	0	0.41	0 G	0	0	1
CPCG0089	9673 G	G	0.12	0.09	0.79	0 G	0	0	1
CPCG0269	9786 G	G	0.28	0	0.72	0 G	0	0	1
CPCG0356	9797 T	T	0	0.22	0	0.78 C	0	0.59	0
CPCG0072	9804 G	G	0.27	0	0.73	0 A	0.8	0	0.2
CPCG0249	9840 T	C	0	0.78	0	0.22 T	0	0	0
ICGC_PCA086	9891 T	T	0	0.38	0	0.62 T	0	0	0
ICGC_PCA095	9977 T	T	0	0.4	0	0.6 T	0	0	0
ICGC_PCA193	10014 G	A	0.53	0	0.47	0 G	0	0	1
CPCG0128	10029 A	A	0.94	0	0.06	0 A	0.66	0	0.34
ICGC_PCA036	10182 G	A	0.76	0	0.24	0 G	0	0	1
CPCG0114	10277 A	A	0.97	0.03	0	0 A	0.69	0.3	0
CPCG0166	10277 A	A	0.76	0.24	0	0 A	0.99	0.01	0
CPCG0211	10277 A	A	0.99	0.01	0	0 A	0.78	0.2	0
EOPC-07	10558 T	T	0	0.4	0	0.6 T	0	0	0
CPCG0407	10586 G	A	0.77	0	0.23	0 G	0	0	1
CPCG0256	10790 T	T	0	0.4	0	0.6 T	0	0	0
CPCG0331	10800 T	T	0	0	0.26	0.74 T	0	0	0
CPCG0340	10866 T	T	0	0	0	1 C	0	0.5	0
CPCG0324	11150 G	G	0.24	0	0.76	0 G	0	0	1
CPCG0040	11343 T	C	0	0.77	0	0.23 T	0	0	0
Berger0508	11493 G	G	0.33	0	0.67	0 G	0	0	1
Berger0508	11592 G	A	0.9	0	0.1	0 G	0	0	1
CPCG0046	11651 G	A	0.85	0	0.15	0 G	0.16	0	0.84
CPCG0377	11711 G	C	0	0.72	0.28	0 G	0	0	1
ICGC_PCA041	11711 G	G	0.48	0	0.52	0 G	0	0	1
ICGC_PCA032	11788 C	T	0	0	0	1 C	0	1	0
CPCG0410	11814 T	C	0	0.54	0	0.46 T	0	0	0
CPCG0103	11852 G	G	0.22	0	0.78	0 G	0	0	1
CPCG0374	11878 T	C	0	0.57	0	0.43 T	0	0	0
ICGC_PCA081	11940 T	C	0	0.54	0	0.46 T	0	0	0
CPCG0095	11949 G	G	0.27	0	0.73	0 G	0	0	1
CPCG0076	12028 T	T	0	0.29	0	0.71 C	0	0.7	0
Berger0508	12173 T	C	0	0.86	0	0.14 T	0	0	0
CPCG0114	12276 G	G	0	0	1	0 A	0.57	0	0.43
ICGC_PCA161	12291 T	T	0	0.45	0	0.55 T	0	0.03	0
CPCG0201	12312 T	C	0	0.68	0	0.32 T	0	0	0
CPCG0361	12501 G	G	0.26	0	0.74	0 G	0	0	1
BacaSTID0000002872	12634 A	A	0.84	0	0.16	0 G	0.01	0	0.99
ICGC_PCA065	12648 A	C	0.3	0.7	0	0 A	0.65	0.35	0
CPCG0242	12651 G	G	0.21	0	0.79	0 G	0	0	1
CPCG0030	12698 T	T	0	0.24	0	0.76 T	0	0	0
CPCG0352	12700 C	A	0.55	0.45	0	0 C	0	1	0
CPCG0336	12758 T	C	0	0.54	0	0.46 T	0	0	0
CPCG0030	12758 T	T	0	0.24	0	0.76 T	0	0	0
CPCG0236	12763 G	A	0.75	0	0.25	0 G	0	0	1
Baca09-37	12769 G	A	0.76	0	0.24	0 G	0.01	0	0.99
ICGC_PCA168	12818 G	G	0.28	0	0.72	0 G	0	0	1
Berger3043	12980 G	G	0.46	0	0.54	0 G	0	0	1
CPCG0232	13121 G	A	0.58	0	0.42	0 G	0	0	1
CPCG0234	13143 T	C	0	0.61	0	0.39 T	0	0	0
Baca06-1749	13227 C	C	0	0.59	0	0.41 C	0	1	0
ICGC_PCA036	13289 G	A	0.76	0	0.24	0 G	0	0	1
CPCG0379	13368 G	A	0.86	0	0.14	0 A	0.5	0	0.5
ICGC_PCA180	13463 G	A	0.77	0	0.23	0 G	0	0	1
Baca05-3595	13466 G	A	0.55	0	0.44	0 G	0	0	1
CPCG0213	13484 T	C	0	0.54	0	0.46 T	0	0	0
CPCG0166	13507 T	T	0	0.22	0	0.78 T	0	0	0
CPCG0166	13543 T	T	0	0.2	0	0.79 T	0	0	0
CPCG0046	13568 T	T	0	0	0	1 T	0	0.35	0
ICGC_PCA075	13759 G	A	0.75	0	0.25	0 G	0.5	0	0.5
ICGC_PCA170	13888 T	T	0	0.23	0	0.77 T	0	0	0
CPCG0190	13895 T	T	0	0.46	0	0.54 T	0	0	0
CPCG0217	13913 T	T	0	0.3	0	0.7 T	0	0	0
CPCG0410	13918 T	C	0	0.79	0	0.21 T	0	0.03	0
Baca05-1657	13928 G	A	0.62	0	0.38	0 G	0	0	1
CPCG0237	14002 A	A	1	0	0	0 A	0.78	0	0.22
Berger3043	14151 T	C	0	0.88	0	0.12 T	0	0	0
CPCG0372	14172 T	T	0	0.41	0	0.59 T	0	0	0
EOPC-07	14560 G	G	0.1	0	0.9	0 A	0.7	0	0.3
CPCG0249	14638 T	C	0	0.76	0	0.24 T	0	0	0
Baca07-4941	14831 G	G	0.29	0	0.71	0 G	0	0	1
CPCG0340	14846 G	A	0.88	0	0.12	0 G	0	0	1
CPCG0387	14889 G	G	0.32	0	0.68	0 G	0	0	1
CPCG0346	14985 G	G	0.25	0	0.75	0 G	0	0	1
CPCG0078	15039 T	C	0	0.61	0	0.39 T	0	0	0
CPCG0355	15045 G	G	0.25	0	0.75	0 G	0	0	1
CPCG0412	15045 G	G	0.31	0	0.69	0 G	0	0	1
Baca08-4154	15229 T	T	0	0.07	0	0.93 C	0	0.71	0
ICGC_PCA198	15323 G	A	0.66	0	0.34	0 G	0.01	0	0.99
CPCG0067	15375 G	G	0.24	0	0.76	0 G	0	0	1
Berger3027	15446 C	T	0	0.13	0	0.87 C	0	0.52	0
Baca03-1426	15498 G	G	0.25	0	0.75	0 G	0	0	1
CPCG0057	15661 C	T	0	0.27	0	0.73 C	0	1	0
CPCG0412	15708 G	G	0.37	0	0.63	0 G	0	0	1
CPCG0269	15731 G	A	0.62	0	0.38	0 G	0	0	1
CPCG0213	15762 G	G	0.28	0	0.72	0 G	0	0	1
CPCG0269	15817 A	G	0.27	0	0.73	0 A	0.83	0	0.17
CPCG0356	15884 G	A	0.7	0	0.3	0 G	0.16	0	0.84
CPCG0098	15924 A	A	0.97	0	0.03	0 A	0.76	0	0.24
CPCG0233	15986 G	A	0.81	0	0.19	0 G	0	0	1
ICGC_PCA180	16000 G	G	0.07	0	0.93	0 G	0.34	0	0.66
ICGC_PCA091	16008 T	T	0	0.28	0	0.72 T	0	0	0
ICGC_PCA193	16012 A	G	0.39	0	0.61	0 A	1	0	0
CPCG0404	16027 T	C	0	0.84	0	0.15 T	0	0	0
CPCG0001	16035 G	G	0.23	0	0.77	0 G	0	0	1
ICGC_PCA098	16035 G	G	0.22	0	0.78	0 G	0	0	1
CPCG0269	16048 G	G	0.16	0	0.84	0 G	0.4	0	0.58
CPCG0250	16051 A	G	0.44	0	0.56	0 A	0.77	0	0.23
CPCG0040	16086 T	C	0	0.69	0	0.3 C	0	1	0
CPCG0128	16092 T	T	0	0.17	0	0.83 C	0	0.96	0
CPCG0189	16093 T	C	0	0.72	0	0.28 C	0	0.96	0
CPCG0368	16093 T	C	0	0.72	0	0.28 C	0	0.99	0
CPCG0097	16093 T	T	0	0.03	0	0.97 T	0	0.45	0
TCGA-CH-5788	16093 T	T	0	0.16	0	0.84 C	0	0.93	0
TCGA-EJ-5506	16093 T	C	0	0.69	0	0.31 C	0	0.96	0
TCGA-HC-7075	16093 T	T	0	0.03	0	0.97 C	0	0.94	0
ICGC_PCA097	16093 T	C	0	0.56	0	0.44 C	0	0.94	0
ICGC_PCA170	16093 T	T	0	0.12	0	0.88 C	0	0.9	0
ICGC_PCA184	16093 T	T	0	0.2	0	0.8 C	0	0.98	0
CPCG0183	16147 C	C	0	0.77	0	0.23 C	0	0.99	0
EOPC-04	16148 C	T	0	0.29	0	0.71 C	0	1	0
CPCG0046	16153 G	A	0.84	0	0.16	0 G	0	0	1
CPCG0355	16162 A	G	0.02	0	0.98	0 G	0.28	0	0.72
ICGC_PCA032	16169 C	C	0	1	0	0 G	0	0	0.99
Baca05-3595	16182 A	C	0.08	0.82	0.1	0 C	0.24	0.44	0.32
CPCG0256	16183 A	A	0.59	0.41	0	0 A	0.95	0.05	0
CPCG0352	16184 C	T	0	0.34	0	0.66 C	0	1	0
CPCG0084	16188 C	C	0	0.77	0	0.23 C	0	1	0
CPCG0114	16189 C	T	0	0.03	0	0.97 C	0	0.75	0
CPCG0259	16192 C	C	0	0.78	0	0.22 C	0	1	0
CPCG0198	16192 C	T	0	0.34	0	0.66 T	0	0.11	0
ICGC_PCA197	16192 C	T	0	0.42	0	0.58 T	0	0.1	0
ICGC_PCA065	16213 G	G	0.27	0	0.73	0 A	0.6	0	0.4
EOPC-05	16278 T	T	0	0.5	0	0.5 C	0	1	0
ICGC_PCA169	16304 T	T	0	0.34	0	0.66 C	0	1	0
ICGC_PCA098	16342 T	C	0	0.85	0	0.15 C	0	0.57	0
ICGC_PCA183	16390 G	A	0.86	0	0.14	0 G	0.23	0	0.76
ICGC_PCA184	16465 C	C	0	0.89	0	0.11 C	0	0.55	0
			Tumour		Locus
		Normal.HF.	Coverag	Coveragemt	Difference
	Patient	H	Normal	DNA	in H	nucleotide.variability.sco
	CPCG0187	1	7399	1019 CR	0.22	0.00186
	CPCG0078	1	6109	427 CR	0.73	0.0925
	CPCG0114	0	1191	4684 CR	1	0.0925
	CPCG0263	1	5744	867 CR	0.5	0.0925
	ICGC_PCA071	1	3206	1797 CR	0.89	0.0925
	CPCG0166	0	157	1517 CR	0.24	0.941
	CPCG0098	1	7027	1946 CR	0.7	0.661
	CPCG0100	0.99	6441	961 CR	0.41	0.661
	ICGC_PCA169	0.8	7149	3256 CR	0.49	0.661
	ICGC_PCA198	0.17	6081	1906 CR	0.66	0.661
	CPCG0206	0.82	6953	1192 CR	0.66	0.841
	Baca07-4610	1	1429	3202 CR	0.27	0.841
	ICGC_PCA032	1	2545	1947 CR	0.99	0.841
	CPCG0204	0	4619	2424 CR	0.51	0.0184
	CPCG0073	1	7698	1420 CR	0.26	0.721
	CPCG0196	1	7693	1938 CR	0.37	0.721
	ICGC_PCA118	0.89	3858	1854 CR	0.46	0.721
	ICGC_PCA166	0.85	3353	1316 CR	0.71	0.161
	ICGC_PCA015	0	3875	2173 CR	0.51	0.15
	CPCG0098	0	6941	1904 CR	0.76	0.0275
	CPCG0205	0	7020	1057 CR	0.67	0.017
	CPCG0242	0	5708	1313 CR	0.81	0.0218
	ICGC_PCA031	0	3788	3533 CR	0.77	0.0218
	CPCG0070	0	7301	1864 CR	0.24	0.00171
	CPCG0256	0	5127	836 CR	0.45	0.00081
	CPCG0158	0	3733	418 CR	0.36	0.00028
	CPCG0081	0	4648	833 CR	0.38	0.00196
	Baca06-3199	0	3321	2031 CR	0.77	0.00196
	CPCG0344	0	5510	767 CR	0.22	0.129
	CPCG0046	0	5136	1358 CR	0.29	0
	CPCG0342	0	7015	1140 CR	0.88	0
	ICGC_PCA125	0	2350	2351 CR	0.22	0.0064
	CPCG0067	0	4991	1353 TF	0.49	0
	CPCG0189	1	7069	1697 RNR1	0.5	0.00327
	CPCG0189	1	7749	1636 RNR1	0.27	0
	CPCG0083	0	7699	2079 RNR1	0.56	0.481
	ICGC_PCA196	0	4203	2359 RNR1	0.32	0.481
	CPCG0073	0	7538	1856 RNR1	0.38	0.0371
	CPCG0019	0	6070	1334 RNR1	0.52	0
	CPCG0248	0	7286	1825 RNR1	0.42	0.00217
	CPCG0346	0	7487	2850 RNR1	0.38	0.00217
	EOPC-07	0	2637	1193 RNR1	0.36	0.00217
	CPCG0204	0	6944	3211 RNR1	0.66	0
	CPCG0211	0	7251	955 RNR1	0.26	0
	ICGC_PCA057	1	5267	3788 RNR1	0.53	0
	EOPC-04	0.68	4416	5078 RNR1	0.22	0.0184
	CPCG0090	0	7220	1809 RNR1	0.7	0
	ICGC_PCA192	0	3833	3210 RNR1	0.32	0
	ICGC_PCA032	0	3591	2798 RNR1	1	0.00255
	CPCG0185	1	6988	1393 RNR1	0.45	0
	CPCG0412	0	7430	2608 RNR1	0.51	0
	CPCG0268	0	7268	1827 RNR1	0.22	0
	CPCG0097	0	7544	1857 TV	0.25	0
	ICGC_PCA103	1	5490	3077 TV	0.46	0
	ICGC_PCA032	0	3512	2843 RNR2	1	0.00071
	ICGC_PCA161	1	4449	1742 RNR2	0.73	0
	ICGC_PCA075	0	5071	4007 RNR2	0.44	0.00024
	CPCG0339	0	4152	2079 RNR2	0.59	0
	CPCG0098	1	7264	3250 RNR2	0.77	0
	CPCG0100	0	6650	1492 RNR2	0.64	0
	CPCG0027	0.75	7869	2386 RNR2	0.25	0
	ICGC_PCA083	0	3888	7545 RNR2	0.6	0
	Baca05-3852	0	5544	535 RNR2	0.88	0
	CPCG0388	0	6248	1625 RNR2	0.35	0
	CPCG0183	0.01	6505	980 RNR2	0.22	0
	CPCG0081	0	7720	2093 RNR2	0.63	0
	ICGC_PCA029	0	4628	3828 RNR2	0.26	0
	CPCG0040	1	7075	2426 RNR2	0.26	0.00021
	CPCG0358	1	7226	6151 RNR2	0.41	0
	CPCG0005	0	7295	1990 RNR2	0.48	0
	ICGC_PCA182	1	7240	3411 RNR2	0.72	0
	TCGA-CH-5750	0	7221	4353 RNR2	0.47	0
	ICGC_PCA068	0	5749	5208 RNR2	0.5	0.00027
	CPCG0217	0.76	7556	2046 RNR2	0.24	0
	ICGC_PCA070	0	5262	3922 RNR2	0.48	0
	ICGC_PCA051	0	5144	2334 RNR2	0.32	0
	ICGC_PCA163	0	6634	2865 RNR2	0.44	0
	CPCG0331	0	7516	2137 RNR2	0.61	0
	CPCG0410	0	6485	4343 RNR2	0.25	0
	ICGC_PCA125	0	7482	5738 RNR2	0.69	0
	CPCG0324	0	7139	1352 RNR2	0.61	0
	CPCG0166	1	367	1680 RNR2	0.28	0
	CPCG0212	1	5513	1785 TL1	0.23	0
	CPCG0071	0	4204	1332 ND1	0.23	0.00194
	CPCG0265	0	5814	1482 ND1	0.41	0.00248
	TCGA-CH-5750	0	6324	3582 ND1	0.23	0
	CPCG0120	0	3441	2086 ND1	0.35	0
	CPCG0063	0	6812	2780 ND1	0.23	0
	ICGC_PCA122	0	6541	3027 ND1	0.45	0
	ICGC_PCA187	0	5568	7177 ND1	0.21	0
	CPCG0127	0	6769	1093 ND1	0.22	0.00011
	CPCG0233	0	5649	2007 ND1	0.4	0.00011
	ICGC_PCA125	0	6863	4509 ND1	0.36	0
	CPCG0213	0	7271	1878 ND1	0.22	0
	Baca05-3852	0	3456	1689 ND1	0.62	0.00103
	CPCG0027	0	6519	580 ND1	0.59	0
	TCGA-EJ-5506	0	4987	2746 ND1	0.21	0
	CPCG0003	0	6785	632 ND1	0.24	0
	CPCG0067	0	2905	1230 ND1	0.42	0.00257
	ICGC_PCA098	1	3721	2957 ND1	0.53	0.00147
	CPCG0067	0	6634	1169 TM	0.64	0
	CPCG0387	0	7674	4629 TM	0.44	0
	CPCG0262	0	7254	1360 ND2	0.27	0
	ICGC_PCA171	0	7144	4922 ND2	0.46	0.0858
	CPCG0204	0	4280	1516 ND2	0.68	0.00408
	CPCG0117	1	7586	1489 ND2	0.36	0
	CPCG0407	0	7113	2902 ND2	0.75	0
	EOPC-03	0	7611	2736 ND2	0.61	0
	CPCG0409	1	7397	2673 ND2	0.6	0
	CPCG0071	1	6739	2006 ND2	0.5	0
	CPCG0339	1	7113	1937 ND2	0.67	0
	CPCG0046	0	288	1559 ND2	0.28	0
	ICGC_PCA142	0	7261	4736 ND2	0.22	0.0118
	CPCG0201	1	7055	3046 ND2	0.9	0
	CPCG0020	0	7404	1841 ND2	0.39	0.00086
	CPCG0267	0	6248	1665 ND2	0.28	0
	ICGC_PCA185	0	7102	4152 ND2	0.24	0.0256
	CPCG0242	1	7001	2241 ND2	0.83	0
	ICGC_PCA013	0	7020	3818 TW	0.53	0
	ICGC_PCA140	1	6911	4936 OLR/TC	0.61	0.0118
	EOPC-07	1	4007	1500 TC	0.86	0.0097
	CPCG0350	0	6052	1047 CO1	0.67	0.0058
	TCGA-G9-6336	0	6381	1569 CO1	0.48	0.00634
	CPCG0356	0.57	7024	4267 CO1	0.48	0.00462
	ICGC_PCA048	1	5163	4643 CO1	0.28	0
	CPCG0050	0	5512	1528 CO1	0.66	0.00066
	CPCG0189	0	7176	1576 CO1	0.24	0
	CPCG0251	0	7014	1437 CO1	0.42	0
	TCGA-G9-6336	0	7462	1839 CO1	0.5	0
	CPCG0123	0.0	6441	1175 CO1	0.2	0
	CPCG0211	0	6273	552 CO1	0.23	0
	CPCG0102	0	6397	3188 CO1	0.58	0
	CPCG0124	0.56	7058	1440 CO1	0.36	0
	ICGC_PCA060	0	7205	7567 CO1	0.53	0
	CPCG0096	1	6034	2223 CO1	0.66	0
	CPCG0331	1	7235	1771 CO1	0.6	0
	CPCG0090	0	6649	1932 CO1	0.51	0
	CPCG0189	1	7555	1925 CO1	0.25	0.00103
	ICGC_PCA155	0	6855	819 CO1	0.4	0
	EOPC-010	0	7413	2975 CO1	0.25	0
	ICGC_PCA029	0	3325	2640 CO1	0.24	0
	EOPC-010	0	4490	1572 TD	0.25	0
	CPCG0124	0	6491	1205 CO2	0.36	0.0011
	ICGC_PCA156	1	7302	3926 CO2	0.37	0
	CPCG0378	0	6772	5709 CO2	0.26	0
	CPCG0266	0.25	7012	1479 CO2	0.23	0
	ICGC_PCA123	0	7456	5877 CO2	0.58	0
	ICGC_PCA023	0	6794	6873 CO2	0.24	0.00189
	ICGC_PCA174	0	6855	3534 TK	0.2	0.00857
	CPCG0345	0	7322	1822 ATP8	0.32	0
	CPCG0103	0	6860	2618 ATP8	0.79	0.0246
	CPCG0196	1	6447	2231 ATP8	0.37	0.00559
	ICGC_PCA193	1	5751	3664 ATP8/ATP6	0.54	0.00156
	CPCG0063	0.37	6261	2790 ATP6	0.53	0
	ICGC_PCA029	0	5997	5168 ATP6	0.32	0.201
	CPCG0082	0.51	7435	1975 ATP6	0.47	0.0283
	CPCG0217	0.75	7444	2102 ATP6	0.25	0.0274
	Berger3043	1	5909	1314 ATP6	0.9	0.00083
	CPCG0380	0	7258	3467 ATP6	0.62	0.00511
	ICGC_PCA026	1	5862	2491 ATP6	0.21	0.00053
	ICGC_PCA166	1	6300	2166 CO3	0.41	0
	CPCG0349	0	7132	3251 CO3	0.61	0.0812
	CPCG0262	0	7125	1416 CO3	0.84	0
	CPCG0234	1	4614	1440 CO3	0.34	0
	CPCG0070	0	7552	3285 CO3	0.59	0
	CPCG0089	0	1850	3343 CO3	0.21	0
	CPCG0269	0	4745	1771 CO3	0.28	0
	CPCG0356	0.41	7503	4975 CO3	0.37	0.00103
	CPCG0072	0	7079	2208 CO3	0.53	0.0198
	CPCG0249	1	7215	1259 CO3	0.78	0.00141
	ICGC_PCA086	1	7088	2008 CO3	0.38	0.00197
	ICGC_PCA095	1	5302	2570 CO3	0.4	0.00221
	ICGC_PCA193	0	6772	4094 TG	0.53	0
	CPCG0128	0	7724	1809 TG	0.27	0.002
	ICGC_PCA036	0	6512	3122 ND3	0.76	0
	CPCG0114	0	2378	238 ND3	0.28	0
	CPCG0166	0	153	980 ND3	0.22	0
	CPCG0211	0.01	6462	499 ND3	0.22	0
	EOPC-07	1	5874	1890 ND4L	0.4	0
	CPCG0407	0	6878	3234 ND4L	0.77	0.0365
	CPCG0256	1	7519	2396 ND4	0.4	0.00812
	CPCG0331	1	7132	2482 ND4	0.26	0
	CPCG0340	0.5	7598	3995 ND4	0.5	0
	CPCG0324	0	7196	1616 ND4	0.24	0.0111
	CPCG0040	1	7313	2729 ND4	0.77	0
	Berger0508	0	4134	2002 ND4	0.33	0
	Berger0508	0	6491	2191 ND4	0.89	0.00028
	CPCG0046	0	6313	1618 ND4	0.69	0
	CPCG0377	0	6420	4942 ND4	0.72	0.00031
	ICGC_PCA041	0	2870	4121 ND4	0.48	0.00031
	ICGC_PCA032	0	3705	3293 ND4	1	0.00765
	CPCG0410	1	7377	4888 ND4	0.54	0
	CPCG0103	0	4684	2047 ND4	0.21	0.00133
	CPCG0374	1	7671	5544 ND4	0.57	0.00517
	ICGC_PCA081	1	4677	2560 ND4	0.54	0.00031
	CPCG0095	0	7450	2951 ND4	0.27	0
	CPCG0076	0.3	4736	1587 ND4	0.4	0.00362
	Berger0508	1	6497	2589 TH	0.86	0.00019
	CPCG0114	0	3186	5946 TL2	0.57	0
	ICGC_PCA161	0.97	4292	1590 TL2	0.43	0
	CPCG0201	1	7591	2761 TL2	0.68	0.00029
	CPCG0361	0	7551	4234 ND5	0.26	0.1
	BacaSTID0000002872	0	183	1474 ND5	0.83	0.015
	ICGC_PCA065	0	7408	1300 ND5	0.35	0.00279
	CPCG0242	0	7601	2456 ND5	0.21	0.0141
	CPCG0030	1	7622	1873 ND5	0.24	0
	CPCG0352	0	7357	4405 ND5	0.55	0
	CPCG0336	1	7419	2631 ND5	0.54	0
	CPCG0030	1	7629	1932 ND5	0.24	0
	CPCG0236	0	6877	2433 ND5	0.75	0
	Baca09-37	0	6642	6007 ND5	0.75	0
	ICGC_PCA168	0	6759	4656 ND5	0.28	0
	Berger3043	0	5006	990 ND5	0.46	0
	CPCG0232	0	6628	1541 ND5	0.58	0
	CPCG0234	1	295	1454 ND5	0.61	0.00461
	Baca06-1749	0	7251	3030 ND5	0.41	0.00031
	ICGC_PCA036	0	6801	4156 ND5	0.76	0
	CPCG0379	0	7201	3751 ND5	0.35	0.211
	ICGC_PCA180	0	6979	2001 ND5	0.77	0
	Baca05-3595	0	6961	2522 ND5	0.56	0.00236
	CPCG0213	1	7171	2098 ND5	0.54	0
	CPCG0166	1	7083	1554 ND5	0.22	0
	CPCG0166	1	398	1424 ND5	0.21	0.0003
	CPCG0046	0.65	6727	1402 ND5	0.35	0
	ICGC_PCA075	0	3756	3035 ND5	0.25	0.114
	ICGC_PCA170	1	7154	2599 ND5	0.23	0
	CPCG0190	1	7560	2513 ND5	0.46	0.00027
	CPCG0217	1	7275	1953 ND5	0.3	0
	CPCG0410	0.97	7279	4769 ND5	0.76	0
	Baca05-1657	0	6778	3786 ND5	0.62	0.186
	CPCG0237	0	7437	1036 ND5	0.22	0.0164
	Berger3043	1	6560	1893 ND6	0.88	0
	CPCG0372	1	7566	3645 ND6	0.41	0
	EOPC-07	0	4980	1721 ND6	0.6	0.0729
	CPCG0249	1	7357	1129 ND6	0.76	0
	Baca07-4941	0	3170	1959 CYB	0.29	0.0136
	CPCG0340	0	7024	3083 CYB	0.88	0
	CPCG0387	0	7477	5472 CYB	0.32	0
	CPCG0346	0	4764	2409 CYB	0.25	0
	CPCG0078	1	7038	1289 CYB	0.61	0.00033
	CPCG0355	0	6335	1368 CYB	0.24	0.00031
	CPCG0412	0	4519	2562 CYB	0.31	0.00031
	Baca08-4154	0.28	221	5590 CYB	0.64	0.0067
	ICGC_PCA198	0	7015	2528 CYB	0.65	0.0185
	CPCG0067	0	4219	1679 CYB	0.24	0
	Berger3027	0.48	4499	1352 CYB	0.39	0
	Baca03-1426	0	6803	4209 CYB	0.25	0.00271
	CPCG0057	0	7107	2735 CYB	0.73	0.003
	CPCG0412	0	7517	2739 CYB	0.37	0
	CPCG0269	0	7524	1818 CYB	0.62	0.00907
	CPCG0213	0	7336	2332 CYB	0.28	0
	CPCG0269	0	7399	1904 CYB	0.56	0.0137
	CPCG0356	0	7391	5417 CYB	0.54	0.126
	CPCG0098	0	7718	3054 TT	0.22	0.137
	CPCG0233	0	7280	2657 TP	0.81	0
	ICGC_PCA180	0	7261	2185 TP	0.28	0.00565
	ICGC_PCA091	1	5566	6514 TP	0.28	0
	ICGC_PCA193	0	5964	4106 TP	0.61	0
	CPCG0404	1	6955	5096 CR	0.85	0
	CPCG0001	0	5872	1725 CR	0.23	0
	ICGC_PCA098	0	5399	4407 CR	0.22	0
	CPCG0269	0	7225	1653 CR	0.25	0.0148
	CPCG0250	0	6934	2719 CR	0.33	0.112
	CPCG0040	0	7485	1734 CR	0.3	0.0679
	CPCG0128	0.04	7595	1451 CR	0.79	0.0481
	CPCG0189	0.04	7272	1972 CR	0.24	0.275
	CPCG0368	0.01	7180	3200 CR	0.26	0.275
	CPCG0097	0.55	6981	2403 CR	0.42	0.275
	TCGA-CH-5788	0.07	7767	4952 CR	0.77	0.275
	TCGA-EJ-5506	0.04	7178	4245 CR	0.27	0.275
	TCGA-HC-7075	0.06	7451	2210 CR	0.91	0.275
	ICGC_PCA097	0.06	7434	3754 CR	0.38	0.275
	ICGC_PCA170	0.1	7134	2704 CR	0.79	0.275
	ICGC_PCA184	0.02	7025	4272 CR	0.79	0.275
	CPCG0183	0	6878	1782 CR	0.22	0.0331
	EOPC-04	0	6318	6134 CR	0.71	0.0575
	CPCG0046	0	5392	1447 CR	0.83	0.0425
	CPCG0355	0	7034	2115 CR	0.26	0.0712
	ICGC_PCA032	0	4047	3363 CR	0.99	0.0386
	Baca05-3595	0	1937	421 CR	0.37	0.444
	CPCG0256	0	4286	982 CR	0.36	0.831
	CPCG0352	0	6912	3003 CR	0.66	0.0332
	CPCG0084	0	6562	1739 CR	0.23	0.0562
	CPCG0114	0.25	2572	6657 CR	0.72	0.756
	CPCG0259	0	7485	2143 CR	0.22	0.185
	CPCG0198	0.89	7328	3030 CR	0.23	0.185
	ICGC_PCA197	0.9	6039	2439 CR	0.32	0.185
	ICGC_PCA065	0	7620	1314 CR	0.33	0.0359
	EOPC-05	0	4040	1831 CR	0.5	0.34
	ICGC_PCA169	0	7178	3126 CR	0.66	0.264
	ICGC_PCA098	0.43	4197	3207 CR	0.28	0.0315
	ICGC_PCA183	0	3737	1891 CR	0.62	0.211
	ICGC_PCA184	0.45	4483	2172 CR	0.34	0.0153
				Tumour
	MutPred.patho-		PolyPhen.2.HumDiv.Pro	A HF
change.in.AA	genicity.sco		PolyPhen.2.HumDiv.Pred	adju
		NA
		NA
		NA
		NA
		NA		NA
		NA
		NA
		NA
		NA		NA
		NA		NA
		NA
		NA
		NA		NA
		NA
		NA
		NA
		NA		NA
		NA		NA
		NA		NA
		NA
		NA
		NA
		NA		NA
		NA
		NA
		NA
		NA
		NA
		NA
		NA
		NA
		NA		NA
		NA
		NA
		NA
		NA
		NA		NA
		NA
		NA
		NA
		NA
		NA
		NA
		NA
		NA		NA
		NA
		NA
		NA		NA
		NA		NA
		NA
		NA
		NA
		NA
		NA		NA
		NA		NA
		NA		NA
		NA		NA
		NA
		NA
		NA
		NA
		NA		NA
		NA
		NA
		NA
		NA
		NA
		NA		NA
		NA
		NA
		NA		NA
		NA
		NA		NA
		NA
		NA		NA
		NA		NA
		NA		NA
		NA
		NA
		NA		NA
		NA
		NA
		NA
		0.563		0.38 benign
		0.354		0 benign
		0.618		0.879 possibly damaging
		0.854		1 probably damaging
Premature Stop	NA
Codon
Premature Stop	NA		NA
Codon
Premature Stop	NA		NA
Codon
E214K		0.778		0.999 probably damaging
E214K		0.778		0.999 probably damaging
G218D		0.775		1 probably damaging
A226T		0.616		0.995 probably damaging
syn	NA
R279Q		0.879		0.974 probably damaging
R279Q		0.879		0.974 probably damaging
A299T		0.632		0.04 benign
I309V		0.427		0 benign
syn	NA		NA
	NA
	NA
A5T		0.194		1 probably damaging
V8I		0.439		0 benign
V43I		0.366		0.006 benign
F60S		0.796		1 probably damaging
A101T		0.717		1 probably damaging
G121D		0.809		1 probably damaging
L130P		0.737		0.999 probably damaging
S140P		0.875		0.997 probably damaging
S146P		0.635		0.925 possibly damaging
V151M		0.499		0.072 benign
syn	NA		NA
F216L		0.676		0.221 benign
syn	NA
G253D		0.851		1 probably damaging
I278V		0.311		0.005 benign
Stop Codon−>Q	NA
	NA		NA
	NA		NA
	NA
A3T		0.239		0.012 benign
A26T		0.769		0.998 probably damaging
syn	NA
L48P		0.785		0.973 probably damaging
D51N		0.715		0.998 probably damaging
Premature Stop	NA
Codon
G125S		0.926		1 probably damaging
Premature Stop	NA
Codon
K172N		0.701		1 probably damaging
K172N		0.701		1 probably damaging
S198F		0.672		1 probably damaging
I254T		0.708		0.673 possibly damaging
G272D		0.771		1 probably damaging
I280T		0.69		0.997 probably damaging
V318A		0.541		0.998 probably damaging
S330N		0.519		0.001 benign
syn	NA
A375T		0.675		1 probably damaging
A464T		0.34		0.999 probably damaging
G497E		0.356		1 probably damaging
	NA
T63A		0.523		0.017 benign
L73P		0.768		1 probably damaging
D112N		0.634		1 probably damaging
G115V		0.544		0.989 probably damaging
V138I		0.609		0.798 possibly damaging
V165I		0.616		0 benign
	NA		NA
Premature Stop	NA
Codon
P10S		0.569		0.993 probably damaging
I23T		0.735		0.005 benign
L61P		0.304		0.988 probably damaging
syn	NA
syn	NA		NA
M60T		0.202		0 benign
I106T		0.642		0.617 possibly damaging
V158A		0.704		0 benign
S219N		0.6		0.995 probably damaging
L220P		0.751		0.999 probably damaging
W58R		0.85		0.998 probably damaging
syn	NA
A100T		0.674		0.999 probably damaging
S104P		0.732		0.997 probably damaging
G141E		0.872		1 probably damaging
R156Q/R156P	0.69/		0.999/	probably damaging/
	0.731		1.0	probably damaging
G194S		0.893		1 probably damaging
syn	NA
A200T		0.708		0.006 benign
S212P		0.636		0.997 probably damaging
S229P		0.606		0.003 benign
syn	NA		NA
	NA		NA
	NA
D42N		0.742		0.999 probably damaging
L73F		0.543		1 probably damaging
L73F		0.543		1 probably damaging
L73F		0.543		1 probably damaging
L30P		0.874		1 probably damaging
syn	NA		NA	NA
syn	NA
L14R		0.752		0.999 probably damaging
I36T		0.558		0.015 benign
A131T		0.65		0.035 benign
M195T		0.684		0.949 possibly damaging
R245H		0.822		0.999 probably damaging
R278Q		0.885		0.995 probably damaging
V298M		0.605		0.85 possibly damaging
A318P		0.765		1 probably damaging
A318T		0.602		0.999 probably damaging
syn	NA		NA
L352P		0.783		0.987 probably damaging
A365T		0.57		0.004 benign
syn	NA
L394P		0.669		0.403 benign
G397E		0.87		1 probably damaging
syn	NA
	NA
NA	NA		NA	NA
	NA		NA
	NA
syn	NA
I100V		0.381		0.925 possibly damaging
syn	NA		NA
syn	NA
L121P		0.719		1 probably damaging
L122I		0.6		0.996 probably damaging
F141S		0.671		0.997 probably damaging
F141S		0.671		0.997 probably damaging
G143S		0.637		1 probably damaging
E145K		0.813		0.996 probably damaging
R161Q		0.801		0.997 probably damaging
G215D		0.769		1 probably damaging
R262H		0.77		0.999 probably damaging
syn	NA
syn	NA
G318D		0.781		1 probably damaging
syn	NA
G376D		0.82		0.994 probably damaging
S377N		0.707		0.003 benign
M383T		0.631		0.452 benign
S391P		0.793		0.997 probably damaging
Y403H		0.651		0.008 benign
I411T		0.702		0.001 benign
A475P		0.472		0.101 benign
C518R		0.501		0.003 benign
F520S		0.673		0.997 probably damaging
L526P		0.836		1 probably damaging
F528L		0.72		0.996 probably damaging
S531N		0.298		0.002 benign
T556P		0.556		0.901 possibly damaging
Stop Codon−>G	NA
I168V		0.534		0.997 probably damaging
syn	NA
syn	NA
A29T		0.391		0 benign
G34S		0.846		1 probably damaging
G48E		0.825		1 probably damaging
R80H		0.833		1 probably damaging
I98T		0.669		0.997 probably damaging
R100Q		0.824		1 probably damaging
R100Q		0.824		1 probably damaging
syn	NA
A193T		0.517		0.001 benign
G210E		0.68		1 probably damaging
L234F		0.217		1 probably damaging
G251D		0.502		0.972 probably damaging
syn	NA
S321N		0.709		0.996 probably damaging
A329T		0.323		0 benign
G339E		0.87		1 probably damaging
syn	NA
A380T		0.204		0 benign
	NA
	NA
	NA	NA
	NA	NA
	NA	NA
	NA
	NA
	NA	NA
	NA
	NA
	NA
	NA
	NA
	NA
	NA
	NA
	NA
	NA
	NA	NA
	NA	NA
	NA	NA
	NA
	NA
	NA
	NA
	NA	NA
	NA
	NA
	NA
	NA
	NA
	NA
	NA
	NA	NA
	NA	NA
	NA
	NA	NA
	NA	NA
	NA	NA
	NA	NA
						Tumour
						(Difference
		Tumour	Tumour		Tumour	in HF
		C HF	G HF		T HF	adjusted by
	change.in.AA	adju	adjusted		adju	cellularity
		0	0.247191011	0	0.752808989 T	0.247191011
		0	1	0	0 C	1
		0	0	0	1 T	1
		0	1	0	0 C	1
		0	0.89	0	0.11 C	0.89
		0	0	1	0 G	0.99
		0	0.897435897	0	0.102564103 C	0.897435897
		0	0.612941176	0	0.387058824 C	0.602941176
		0	0.69	0	0.31 C	0.49
		0	0.18	0	0.82 T	0.65
		0	1	0	0 C	0.82
		0	0.27	0	0.73 T	0.27
		0	0.99	0	0.01 C	0.99
		0.420454545	0	0.579545455	0 G	0.579545455
		0	0.346666667	0	0.653333333 T	0.346666667
		0	0.415730337	0	0.584269663 T	0.415730337
		0	0.56	0	0.43 C	0.46
		0	0.86	0	0.14 C	0.71
		0.2	0	0.8	0 G	0.51
		0.025641026	0	0.974358974	0 G	0.974358974
		1	0	0	0 A	0.84
		0	0	1	0 G	1
		0.16	0	0.84	0 G	0.77
		1	0	0	0 A	0.26
		1	0.05	0	0 A	1
		0	0.419354839	0	0.580645161 T	0.580645161
		0	0.073170732	0	0.926829268 T	0.926829268
		0	0.22	0	0.77 T	0.77
		0.75	0	0.214285714	0 A	0.785714286
		0.303370787	0.02247191	0.674157303	0 G	0.325842697
		1	0	0	0 A	1
		0.83	0.17	0	0 A	0.21
		0.49	0	0.51	0 G	0.49
		0	0.694444444	0	0.305555556 C	0.694444444
		0	0.375	0	0.625 T	0.375
		0.933333333	0	0.066666667	0 A	0.933333333
		0.61	0	0.39	0 A	0.32
		0.506666667	0	0.493333333	0 A	0.506666667
		1	0	0	0 A	1
		0.646153846	0	0.353846154	0 A	0.646153846
		1	0	0	0 A	1
		0.36	0	0.64	0 G	0.36
		0.75	0	0.25	0 A	0.75
		0.490566038	0	0.518301887	0 G	0.471698113
		0	0.53	0	0.47 C	0.53
		0	0.1	0	0.9 T	0.22
		0.875	0	0.125	0 A	0.875
		0.32	0	0.68	0 G	0.32
		0	0	0	1 T	1
		0	0.779661017	0	0.220338983 C	0.779661017
		0.80952381	0	0.19047619	0 A	0.80952381
		1	0	0	0 A	1
		0.320512821	0	0.666666667	0 G	0.333333333
		0	0.46	0	0.54 T	0.46
		0	0	0	1 T	1
		0	0.73	0	0.27 C	0.73
		0.44	0	0.56	0 G	0.44
		1	0	0	0 A	1
		0	0.987179487	0	0.012820513 C	0.987179487
		0.048823529	0	0.955882353	0 G	0.941176471
		0	0	0	1 T	0.25
				0.4	0 A	0.6
		0.91	0	0.09	0 A	0.88
		0.486486486	0	0.513513514	0 G	0.486486486
		1	0	0	0 A	0.23
		1	0	0	0 A	1
		0.26	0	0.74	0 G	0.26
		0	0.313253012	0	0.686746988 T	0.313253012
		0	1	0	0 C	1
		0.615384615	0	0.384615385	0 A	0.615384615
		0	0.72	0	0.28 C	0.72
		0.47	0	0.53	0 G	0.47
		0.5	0	0.5	0 G	0.5
		0	0	0	1 T	0.24
		0.69	0	0.31	0 A	0.47
		0.32	0	0.68	0 G	0.32
		0.44	0	0.56	0 G	0.44
		1	0	0	0 A	1
		0.925925926	0	0.074074074	0 A	0.925925926
		0.69	0	0.31	0 A	0.69
		1	0	0	0 A	1
		0	1	0	0 C	1
		0	0.270588235	0	0.729411765 T	0.270588235
		0.711176471	0.277058824	0	0.011764706 A	0.258823529
		0.526315789	0	0.460526316	0 A	0.539473684
		0.23	0	0.77	0 G	0.23
		0.443037975	0	0.556962025	0 G	0.443037975
	Premature Stop	0.916666667	0	0.041666667	0 A	0.958333333
	Codon
	Premature Stop	0.45	0	0.55	0 G	0.45
	Codon
	Premature Stop	0.21	0	0.79	0 G	0.21
	Codon
	E214K	0.239130435	0	0.760869565	0 G	0.239130435
	E214K	0.634920635	0	0.365079365	0 A	0.634920635
	G218D	0.36	0	0.63	0 G	0.37
	A226T	0.956521739	0	0.043478261	0 A	0.956521739
	syn	0.34	0	0.65	0 G	0.62
	R279Q	1	0	0	0 A	1
	R279Q	0.21	0	0.79	0 G	0.2
	A299T	0.315789474	0	0.684210526	0 G	0.315789474
	I309V	0.58	0	0.42	0 A	0.42
	syn	0	0.53	0	0.47 C	0.53
		0.63	0	0.36	0 A	0.64
		0	0.102040816	0	0.897959184	T 0.897959184
	A5T	0.333333333	0	0.666666667	0 G	0.333333333
	V8I	0.46	0	0.54	0 G	0.46
	V43I	0.772727273	0	0.227272727	0 A	0.772727273
	F60S	0	0.580645161	0	0.403225806	C 0.596774194
	A101T	0.974025974	0	0.025974026	0 A	0.974025974
	G121D	0.61	0	0.39	0 A	0.61
	L130P	0	1	0	0 C	1
	S140P	0	0.576470588	0	0.411764706	C 0.588235294
	S146P	0	1	0	0 C	1
	V151M	0.280898876	0	0.685393258	0.033707865	G 0.314606742
	syn	0.96	0	0.04	0 A	0.22
	F216L	0	1	0	0 C	1
	syn	0.001797753	0.998202247	0	0 C	0.438202247
	G253D	0.933333333	0	0.066666667	0 A	0.933333333
	I278V	0.66	0	0.34	0 A	0.25
	Stop Codon−>Q	0	1	0	0 C	1
		0.53	0	0.47	0 A	0.53
		0	0.61	0	0.39 C	0.61
		0	0.86	0	0.14 C	0.86
	A3T	0.848101266	0	0.151898734	0 A	0.848101266
	A26T	0.48	0	0.52	0 G	0.48
	syn	0	1	0	0 C	0.57
	L48P	0	0.28	0	0.72 T	0.28
	D51N	0.152608696	0	0.847391304	0 G	0.717391304
	Premature Stop	0.333333333	0	0.666666667	0 G	0.333333333
	Codon
	G125S	1	0	0	0 A	0.55
	Premature Stop	0.5	0	0.5	0 G	0.5
	Codon
	K172N	1	0	0	0 A	0.2
	K172N	1	0	0	0 A	0.23
	S198F	0	0.42	0	0.58 T	0.58
	I254T	0	0.89	0	0.11 C	0.45
	G272D	0.53	0	0.47	0 A	0.53
	I280T	0	0.76744186	0	0.23255814 C	0.76744186
	V318A	0	1	0	0 C	1
	S330N	0.6375	0	0.3625	0 A	0.6375
	syn	0	0.361111111	0	0.638888889 T	0.361111111
	A375T	0.4	0	0.6	0 G	0.4
	A464T	0.25	0	0.75	0 G	0.25
	G497E	0.24	0	0.76	0 G	0.24
		0.25	0	0.75	0 G	0.25
	T63A	0.1	0	0.9	0 G	0.45
	L73P	0	0.37	0	0.63 T	0.37
	D112N	0.412698413	0	0.587301587	0 G	0.412698413
	G115V	0	0	1	0 G	0.25
	V138I	0.59	0	0.41	0 A	0.59
	V165I	0.24	0	0.76	0 G	0.24
		0.14	0	0.86	0 G	0.21
	Premature Stop	0.41025641	0	0.58974359	0 G	0.41025641
	Codon
	P10S	0	0.2	0	0.8 T	0.79
	I23T	0	0.415730337	0	0.584269663 T	0.415730337
	L61P	0	0.54	0	0.46 C	0.54
	syn	0	0	0	1 T	0.63
	syn	0.32	0	0.68	0 G	0.32
	M60T	0	1	0	0 C	0.51
	I106T	0	0	0	1 T	0.25
	V158A	0	0.9	0	0.1 C	0.9
	S219N	1	0	0	0 A	1
	L220P	0	0.21	0	0.79 T	0.21
	W58R	0	0.41	0	0.59 T	0.41
	syn	1	0	0	0 A	0.81
	A100T	1	0	0	0 A	1
	S104P	0	0.365591398	0	0.634408602 T	0.365591398
	G141E	0.694117647	0	0.305882353	0 A	0.694117647
	R156Q/R156P	0.144578313	0.108433735	0.746987952	0 G	0.253012048
	G194S	0.373333333	0	0.626666667	0 G	0.373333333
	syn	0	0	0	1 T	0.59
	A200T	0.120512821	0	0.879487179	0 G	0.679487179
	S212P	0	1	0	0 C	1
	S229P	0	0.38	0	0.62 T	0.38
	syn	0	0.4	0	0.6 T	0.4
		0.53	0	0.47	0 A	0.53
		0.964347826	0	0.035652174	0 A	0.304347826
	D42N	0.76	0	0.24	0 A	0.76
	L73F	1	0	0	0 A	0.31
	L73F	0	1	0	0 C	0.99
	L73F	1	0	0	0 A	0.22
	L30P	0	0.4	0	0.6 T	0.4
	syn	1	0	3.60462E-17	0 A	1
	syn	0	1	0	0 C	1
	L14R	0	0	1	0 G	1
	I36T	0	0	0	1 T	0.5
	A131T	0.774193548	0	0.225806452	0 A	0.774193548
	M195T	0	0.927710843	0	0.072289157 C	0.927710843
	R245H	0.33	0	0.67	0 G	0.33
	R278Q	0.9	0	0.1	0 A	0.9
	V298M	0.935280899	0	0.064719101	0 A	0.775280899
	A318P	0	1	0	0 C	1
	A318T	0.48	0	0.52	0 G	0.48
	syn	0	0	0	1 T	1
	L352P	0	1	0	0 C	1
	A365T	0.22	0	0.78	0 G	0.22
	syn	0	1	0	0 C	1
	L394P	0	0.54	0	0.46 C	0.54
	G397E	0.3	0	0.7	0 G	0.3
	syn	0	0.217647059	0	0.782352941 T	0.482352941
		0	0.86	0	0.14 C	0.86
	NA	0	0	1	0 G	0.57
		0	0.45	0	0.55 T	0.42
		0	0.829268293	0	0.170731707 C	0.829268293
	syn	0.838709677	0	0.161290323	0 A	0.838709677
	I100V	0.84	0	0.16	0 A	0.83
	syn	0.3	0.7	0	0 C	0.35
	syn	0.304347826	0	0.695652174	0 G	0.304347826
	L121P	0	0.272727273	0	0.727272727 T	0.272727273
	L122I	0.873015873	0.126984127	0	0 A	0.873015873
	F141S	0	1	0	0 C	1
	F141S	0	0.272727273	0	0.727272727 T	0.272727273
	G143S	1	0	0	0 A	1
	E145K	0.76	0	0.24	0 A	0.75
	R161Q	0.28	0	0.72	0 G	0.28
	G215D	0.46	0	0.54	0 G	0.46
	R262H	0.734177215	0	0.265822785	0 A	0.734177215
	syn	0	0.655913978	0	0.344086022 C	0.655913978
	syn	0	0.59	0	0.41 C	0.41
	G318D	0.76	0	0.24	0 A	0.76
	syn	0.967532468	0	0.032467532	0 A	0.467532468
	G376D	0.77	0	0.23	0 A	0.77
	S377N	0.55	0	0.44	0 A	0.56
	M383T	0	1	0	0 C	1
	S391P	0	0.956521739	0	0.043478261 C	0.956521739
	Y403H	0	0.869565217	0	0.086956522 C	0.913043478
	I411T	0	0	0	1 T	0.35
	A475P	0.75	0	0.25	0 A	0.25
	C518R	0	0.23	0	0.77 T	0.23
	F520S	0	1	0	0 C	1
	L526P	0	1	0	0 C	1
	F528L	0	1	0	0 C	0.97
	S531N	0.62	0	0.38	0 A	0.62
	T556P	1	0	0	0 A	0.22
	Stop Codon−>G	0	0.88	0	0.12 C	0.88
	I168V	0	1	0	0 C	1
	syn	0.1	0	0.9	0 G	0.6
	syn	0	1	0	0 C	1
	A29T	0.29	0	0.71	0 G	0.29
	G34S	1	0	0	0 A	1
	G48E	0.653061224	0	0.346938776	0 A	0.653061224
	R80H	0.961538462	0	0.038461538	0 A	0.961538462
	I98T	0	1	0	0 C	1
	R100Q	1	0	0	0 A	1
	R100Q	0.492063492	0	0.507936508	0 G	0.492063492
	syn	0	0.07	0	0.93 T	0.64
	A193T	0.66	0	0.34	0 A	0.65
	G210E	0.24	0	0.76	0 G	0.24
	L234F	0	0.13	0	0.87 T	0.39
	G251D	0.25	0	0.75	0 G	0.25
	syn	0	0	0	1 T	1
	S321N	0.587301587	0	0.412698413	0 A	0.587301587
	A329T	0.826666667	0	0.173333333	0 A	0.826666667
	G339E	1	0	0	0 A	1
	syn	0.083333333	0	0.916666667	0 G	0.746666667
	A380T	1	0	0	0 A	0.84
		1	0	0	0 A	0.24
		1	0	0	0 A	1
		0.07	0	0.93	0 G	0.27
		0	0.28	0	0.72 T	0.28
		0.39	0	0.61	0 G	0.61
		0	1	0	0 C	1
		0.270588235	0	0.729411765	0 G	0.270588235
		0.22	0	0.78	0 G	0.22
		0.076666667	0	0.926666667	0 G	0.346666667
		0	0	1	0 G	0.77
		0	0.626506024	0	0.361445783 C	0.373493976
		0	0.101304348	0	0.898695652 T	0.858695652
		0	0.626666667	0	0.373333333 C	0.333333333
		0	0	0	1 T	0.99
		0	0	0	1 T	0.45
		0	0.16	0	0.84 T	0.77
		0	0.69	0	0.31 C	0.27
		0	0.03	0	0.97 T	0.91
		0	0.56	0	0.44 C	0.38
		0	0.12	0	0.88 T	0.78
		0	0.2	0	0.8 T	0.78
		0	0.675714286	0	0.328571429 C	0.314285714
		0	0.29	0	0.71 T	0.71
		0.943820225	0	0.056179775	0 A	0.943820225
		0	0	1	0 G	0.28
		0	1	0	0 C	0.99
		0.08	0.82	0.1	0 C	0.38
		0	1	0	0 C	0.95
		0	0	0	1 T	1
		0	0.735632184	0	0.264367816 C	0.264367816
		0	0	0	1 T	0.75
		0	0	0	1 T	1
		0	0.371363636	0	0.628636364 T	0.261363636
		0	0.42	0	0.58 T	0.32
		0.27	0	0.73	0 G	0.33
		0	0.5	0	0.5 T	0.5
		0	0.34	0	0.66 T	0.66
		0	0.85	0	0.15 C	0.28
		0.86	0	0.14	0 A	0.62
		0	0.89	0	0.11 C	0.34

TABLE 6
Mitochondrial mutation recurrence for 41 nuclear genomic features
Patient	Control
id	Region	tRNA	CYB	RNR1	RNR2	ND1	VD2	ND3	ND4	ND4L	ND5	ND6	CO1	CO2	CO3	ATP6
CPCG0001	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0003	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
CPCG0006	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0020	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
CPCG0040	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0
CPCG0046	1	0	0	0	0	0	1	0	1	0	1	0	0	0	0	0
CPCG0047	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0048	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0057	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0063	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1
CPCG0073	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0078	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0081	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
CPCG0083	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0087	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0094	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0095	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
CPCG0098	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0
CPCG0099	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0102	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
CPCG0114	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0
CPCG0117	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
CPCG0121	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0123	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
CPCG0124	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
CPCG0127	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
CPCG0128	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0154	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0158	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0166	1	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0
CPCG0182	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0183	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
CPCG0184	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0185	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0189	1	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0
CPCG0190	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
CPCG0191	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0196	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0199	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0201	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0
CPCG0205	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0206	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0208	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0210	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0211	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0
CPCG0212	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0213	0	0	1	0	0	1	0	0	0	0	1	0	0	0	0	0
CPCG0217	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	1
CPCG0232	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
CPCG0233	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0
CPCG0234	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0
CPCG0236	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
CPCG0238	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0241	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0242	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0
CPCG0246	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0248	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0249	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0
CPCG0250	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0251	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
CPCG0255	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0256	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
CPCG0258	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0259	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0260	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0262	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0
CPCG0263	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0265	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
CPCG0266	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
CPCG0267	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
CPCG0268	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0269	1	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0
CPCG0324	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0
CPCG0331	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0
CPCG0334	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0336	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
CPCG0339	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0
CPCG0340	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0
CPCG0341	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0342	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0344	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0345	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0346	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0348	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0350	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
CPCG0352	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
CPCG0353	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0354	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0355	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0356	0	0	1	0	0	0	0	0	0	0	0	0	1	0	1	0
CPCG0357	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0358	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
CPCG0360	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0361	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
CPCG0362	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0363	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0364	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0365	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0366	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0368	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0369	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0371	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0372	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
CPCG0373	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0374	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
CPCG0375	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0378	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
CPCG0379	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
CPCG0380	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
CPCG0381	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0387	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0388	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
CPCG0391	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0392	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0401	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0404	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0407	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0
CPCG0409	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
CPCG0410	0	0	0	0	1	0	0	0	1	0	1	0	0	0	0	0
CPCG0411	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0412	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0413	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0414	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0004	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0005	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
CPCG0007	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0008	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0015	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0019	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0022	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0027	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0
CPCG0030	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
CPCG0036	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0042	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0050	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
CPCG0070	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
CPCG0071	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0
CPCG0075	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0076	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
CPCG0082	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
CPCG0084	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0089	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
CPCG0090	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0
CPCG0096	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
CPCG0097	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0120	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
CPCG0122	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0126	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0194	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0198	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0204	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0
CPCG0237	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
CPCG0243	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0257	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0067	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0
CPCG0103	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
CPCG0072	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
CPCG0100	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
CPCG0187	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0188	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0235	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0349	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
CPCG0377	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
CPCG0382	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CPCG0408	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Berger0508	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Berger0581	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Berger1701	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Berger1783	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Berger2832	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Berger3027	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Berger3043	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1
EOPC-02	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EOPC-03	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
EOPC-04	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
EOPC-05	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EOPC-06	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EOPC-07	0	1	0	1	0	0	0	0	1	1	0	1	0	0	0	0
EOPC-08	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EOPC-09	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EOPC-010	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0
EOPC-011	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Baca03-1426	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Baca05-1657	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Baca05-3595	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Baca05-3852	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0
Baca06-1749	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Baca06-3199	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Baca07-4610	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Baca07-4941	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Baca07-5037	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Baca08-4154	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Baca08-716	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Baca09-37	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
BacaSTID0000000410	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BacaSTID0000002872	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
TCGA-CH-5750	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0
TCGA-CH-5763	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TCGA-CH-5771	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TCGA-CH-5788	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TCGA-CH-5789	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TCGA-EJ-5503	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TCGA-EJ-5506	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
TCGA-EJ-7791	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TCGA-G9-6336	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
TCGA-G9-6365	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TCGA-G9-6370	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TCGA-G9-7522	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TCGA-HC-7075	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TCGA-HC-7079	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TCGA-HC-7233	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TCGA-HC-7737	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TCGA-HC-7740	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TCGA-HC-7744	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TCGA-HC-8258	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TCGA-HI-7169	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
												nuclearSNV
												count
									PGA(median			(median
	Patient						mito_SNV		dichot-		chromo-	dichot-
	id	ATP8	OHR	CSB1	HV1	HV2	Count	ETS	omized)	kataegis_ind	thripsis_ind	omized)
	CPCG0001	0	0	0	1	0	1	1	1	0	0	1
	CPCG0003	0	0	0	0	0	1	0	1	0	0	1
	CPCG0006	0	0	0	0	0	0	0	1	1	0	1
	CPCG0020	0	0	0	0	0	1	0	0	0	0	1
	CPCG0040	0	0	0	1	0	3	0	1	1	0	1
	CPCG0046	0	0	0	1	0	5	0	0	0	0	0
	CPCG0047	0	0	0	0	0	0	1	1	0	0	1
	CPCG0048	0	0	0	0	0	0	1	0	0	0	0
	CPCG0057	0	0	0	0	0	1	1	1	0	0	1
	CPCG0063	0	0	0	0	0	2	0	1	0	0	1
	CPCG0073	0	1	0	0	1	2	1	1	0	0	1
	CPCG0078	0	0	0	0	1	2	0	1	0	0	1
	CPCG0081	0	1	0	0	1	2	1	1	1	0	1
	CPCG0083	0	0	0	0	0	1	1	1	0	0	1
	CPCG0087	0	0	0	0	0	0	1	1	1	0	1
	CPCG0094	0	0	0	0	0	0	1	1	1	0	1
	CPCG0095	0	0	0	0	0	1	1	1	0	0	0
	CPCG0098	0	1	1	0	1	4	0	1	1	1	1
	CPCG0099	0	0	0	0	0	0	0	1	0	0	1
	CPCG0102	0	0	0	0	0	1	0	0	0	0	0
	CPCG0114	0	0	0	1	1	4	1	0	0	0	0
	CPCG0117	0	0	0	0	0	1	0	1	0	1	0
	CPCG0121	0	0	0	0	0	0	1	1	0	0	0
	CPCG0123	0	0	0	0	0	1	1	0	0	0	1
	CPCG0124	0	0	0	0	0	2	1	0	0	0	1
	CPCG0127	0	0	0	0	0	1	0	0	0	0	0
	CPCG0128	0	0	0	1	0	2	0	0	0	1	1
	CPCG0154	0	0	0	0	0	0	1	0	0	0	0
	CPCG0158	0	1	0	0	1	1	1	1	0	0	1
	CPCG0166	0	0	0	0	1	5	0	0	0	0	0
	CPCG0182	0	0	0	0	0	0	1	0	0	0	0
	CPCG0183	0	0	0	1	0	2	0	1	0	0	1
	CPCG0184	0	0	0	0	0	0	0	1	0	0	0
	CPCG0185	0	0	0	0	0	1	1	1	0	0	1
	CPCG0189	0	0	0	1	0	5	1	1	0	1	1
	CPCG0190	0	0	0	0	0	1	0	1	0	0	0
	CPCG0191	0	0	0	0	0	0	1	1	0	1	0
	CPCG0196	1	1	0	0	1	2	1	1	0	0	0
	CPCG0199	0	0	0	0	0	0	0	0	0	0	0
	CPCG0201	0	0	0	0	0	2	1	1	1	1	1
	CPCG0205	0	1	1	0	1	1	0	0	0	0	0
	CPCG0206	0	1	0	0	1	1	0	1	0	0	0
	CPCG0208	0	0	0	0	0	0	0	0	0	1	1
	CPCG0210	0	0	0	0	0	0	0	1	0	0	0
	CPCG0211	0	0	0	0	0	3	1	1	0	0	1
	CPCG0212	0	0	0	0	0	1	0	1	0	0	1
	CPCG0213	0	0	0	0	0	3	1	1	0	0	0
	CPCG0217	0	0	0	0	0	3	0	0	0	1	0
	CPCG0232	0	0	0	0	0	1	1	1	0	1	1
	CPCG0233	0	0	0	0	0	2	0	1	1	1	1
	CPCG0234	0	0	0	0	0	2	0	0	0	0	0
	CPCG0236	0	0	0	0	0	1	0	1	1	1	1
	CPCG0238	0	0	0	0	0	0	1	1	0	1	0
	CPCG0241	0	0	0	0	0	0	1	1	0	0	1
	CPCG0242	0	1	1	0	1	3	1	1	0	0	1
	CPCG0246	0	0	0	0	0	0	0	0	0	0	0
	CPCG0248	0	0	0	0	0	1	1	1	1	0	1
	CPCG0249	0	0	0	0	0	2	0	1	1	1	1
	CPCG0250	0	0	0	1	0	1	1	0	0	0	0
	CPCG0251	0	0	0	0	0	1	0	0	1	0	0
	CPCG0255	0	0	0	0	0	0	0	1	1	1	1
	CPCG0256	0	1	0	1	1	3	1	0	1	0	0
	CPCG0258	0	0	0	0	0	0	1	0	0	0	0
	CPCG0259	0	0	0	1	0	1	0	0	0	0	1
	CPCG0260	0	0	0	0	0	0	1	1	0	1	1
	CPCG0262	0	0	0	0	0	2	1	1	1	0	1
	CPCG0263	0	0	0	0	1	1	0	1	0	1	0
	CPCG0265	0	0	0	0	0	1	1	0	1	0	1
	CPCG0266	0	0	0	0	0	1	1	1	0	0	1
	CPCG0267	0	0	0	0	0	1	0	0	0	0	0
	CPCG0268	0	0	0	0	0	1	0	1	1	1	0
	CPCG0269	0	0	0	1	0	4	0	0	0	0	1
	CPCG0324	0	0	0	0	0	2	1	1	1	1	1
	CPCG0331	0	0	0	0	0	3	1	1	0	0	1
	CPCG0334	0	0	0	0	0	0	0	1	0	0	1
	CPCG0336	0	0	0	0	0	1	1	0	1	0	0
	CPCG0339	0	0	0	0	0	2	0	0	0	0	0
	CPCG0340	0	0	0	0	0	2	1	1	1	1	1
	CPCG0341	0	0	0	0	0	0	1	1	0	0	1
	CPCG0342	0	0	0	0	0	1	1	0	0	0	1
	CPCG0344	0	0	0	0	0	1	0	1	0	0	0
	CPCG0345	1	0	0	0	0	1	0	1	0	0	1
	CPCG0346	0	0	0	0	0	2	1	1	0	0	0
	CPCG0348	0	0	0	0	0	0	0	0	0	0	0
	CPCG0350	0	0	0	0	0	1	1	1	1	1	1
	CPCG0352	0	0	0	1	0	2	1	1	0	0	0
	CPCG0353	0	0	0	0	0	0	0	0	0	0	0
	CPCG0354	0	0	0	0	0	0	1	0	1	0	1
	CPCG0355	0	0	0	1	0	2	0	0	0	0	0
	CPCG0356	0	0	0	0	0	3	1	1	1	0	0
	CPCG0357	0	0	0	0	0	0	1	1	0	0	1
	CPCG0358	0	0	0	0	0	1	1	1	0	0	0
	CPCG0360	0	0	0	0	0	0	0	1	0	0	0
	CPCG0361	0	0	0	0	0	1	1	0	0	0	0
	CPCG0362	0	0	0	0	0	0	1	0	0	0	0
	CPCG0363	0	0	0	0	0	0	0	0	0	0	0
	CPCG0364	0	0	0	0	0	0	1	0	0	1	1
	CPCG0365	0	0	0	0	0	0	0	0	0	0	0
	CPCG0366	0	0	0	0	0	0	1	1	0	0	0
	CPCG0368	0	0	0	1	0	1	0	0	0	0	0
	CPCG0369	0	0	0	0	0	0	1	1	0	0	1
	CPCG0371	0	0	0	0	0	0	1	1	1	0	1
	CPCG0372	0	0	0	0	0	1	1	1	1	0	1
	CPCG0373	0	0	0	0	0	0	0	0	0	0	0
	CPCG0374	0	0	0	0	0	1	0	1	1	0	0
	CPCG0375	0	0	0	0	0	0	0	1	0	0	1
	CPCG0378	0	0	0	0	0	1	0	1	0	0	1
	CPCG0379	0	0	0	0	0	1	1	1	0	1	1
	CPCG0380	0	0	0	0	0	1	1	1	0	0	1
	CPCG0381	0	0	0	0	0	0	0	0	0	0	0
	CPCG0387	0	0	0	0	0	2	0	0	0	0	1
	CPCG0388	0	0	0	0	0	1	0	1	0	1	1
	CPCG0391	0	0	0	0	0	0	0	0	0	0	0
	CPCG0392	0	0	0	0	0	0	1	1	0	1	1
	CPCG0401	0	0	0	0	0	0	0	0	0	0	0
	CPCG0404	0	0	0	1	0	1	0	1	1	0	1
	CPCG0407	0	0	0	0	0	2	1	1	0	0	1
	CPCG0409	0	0	0	0	0	1	1	0	0	0	1
	CPCG0410	0	0	0	0	0	3	1	1	0	1	0
	CPCG0411	0	0	0	0	0	0	0	0	0	0	0
	CPCG0412	0	0	0	0	0	3	1	1	1	0	1
	CPCG0413	0	0	0	0	0	0	0	0	0	0	0
	CPCG0414	0	0	0	0	0	0	0	0	1	0	0
	CPCG0004	0	0	0	0	0	0	NA	NA	NA	NA	NA
	CPCG0005	0	0	0	0	0	1	NA	NA	NA	NA	NA
	CPCG0007	0	0	0	0	0	0	NA	NA	NA	NA	NA
	CPCG0008	0	0	0	0	0	0	NA	NA	NA	NA	NA
	CPCG0015	0	0	0	0	0	0	NA	NA	NA	NA	NA
	CPCG0019	0	0	0	0	0	1	NA	NA	NA	NA	NA
	CPCG0022	0	0	0	0	0	0	0	0	0	0	0
	CPCG0027	0	0	0	0	0	2	0	0	0	0	0
	CPCG0030	0	0	0	0	0	2	NA	NA	NA	NA	NA
	CPCG0036	0	0	0	0	0	0	NA	NA	NA	NA	NA
	CPCG0042	0	0	0	0	0	0	NA	NA	NA	NA	NA
	CPCG0050	0	0	0	0	0	1	0	0	0	0	1
	CPCG0070	0	1	0	0	1	2	NA	NA	NA	NA	NA
	CPCG0071	0	0	0	0	0	2	NA	NA	NA	NA	NA
	CPCG0075	0	0	0	0	0	0	NA	NA	NA	NA	NA
	CPCG0076	0	0	0	0	0	1	NA	NA	NA	NA	NA
	CPCG0082	0	0	0	0	0	1	NA	NA	NA	NA	NA
	CPCG0084	0	0	0	1	0	1	NA	NA	NA	NA	NA
	CPCG0089	0	0	0	0	0	1	NA	NA	NA	NA	NA
	CPCG0090	0	0	0	0	0	2	0	0	0	0	1
	CPCG0096	0	0	0	0	0	1	NA	NA	NA	NA	NA
	CPCG0097	0	0	0	1	0	2	NA	NA	NA	NA	NA
	CPCG0120	0	0	0	0	0	1	NA	NA	NA	NA	NA
	CPCG0122	0	0	0	0	0	0	1	0	1	0	0
	CPCG0126	0	0	0	0	0	0	NA	NA	NA	NA	NA
	CPCG0194	0	0	0	0	0	0	NA	NA	NA	NA	NA
	CPCG0198	0	0	0	1	0	1	NA	NA	NA	NA	NA
	CPCG0204	0	1	0	0	1	3	NA	NA	NA	NA	NA
	CPCG0237	0	0	0	0	0	1	0	0	0	0	0
	CPCG0243	0	0	0	0	0	0	0	0	0	0	0
	CPCG0257	0	0	0	0	0	0	NA	NA	NA	NA	NA
	CPCG0067	0	0	0	0	0	4	NA	NA	NA	NA	NA
	CPCG0103	1	0	0	0	0	2	NA	NA	NA	NA	NA
	CPCG0072	0	0	0	0	0	1	NA	NA	NA	NA	NA
	CPCG0100	0	1	0	0	1	2	NA	NA	NA	NA	NA
	CPCG0187	0	0	0	0	1	1	NA	NA	NA	NA	NA
	CPCG0188	0	0	0	0	0	0	NA	NA	NA	NA	NA
	CPCG0235	0	0	0	0	0	0	NA	NA	NA	NA	NA
	CPCG0349	0	0	0	0	0	1	NA	NA	NA	NA	NA
	CPCG0377	0	0	0	0	0	1	NA	NA	NA	NA	NA
	CPCG0382	0	0	0	0	0	0	NA	NA	NA	NA	NA
	CPCG0408	0	0	0	0	0	0	NA	NA	NA	NA	NA
	Berger0508	0	0	0	0	0	3	0	NA	1	NA	0
	Berger0581	0	0	0	0	0	0	NA	NA	NA	NA	NA
	Berger1701	0	0	0	0	0	0	1	NA	0	NA	0
	Berger1783	0	0	0	0	0	0	NA	NA	NA	NA	NA
	Berger2832	0	0	0	0	0	0	1	NA	0	NA	0
	Berger3027	0	0	0	0	0	1	NA	NA	NA	NA	NA
	Berger3043	0	0	0	0	0	3	0	NA	0	NA	1
	EOPC-02	0	0	0	0	0	0	0	NA	0	NA	0
	EOPC-03	0	0	0	0	0	1	NA	NA	NA	NA	NA
	EOPC-04	0	0	0	1	0	2	0	NA	1	NA	1
	EOPC-05	0	0	0	1	0	1	0	NA	0	NA	0
	EOPC-06	0	0	0	0	0	0	0	NA	0	NA	0
	EOPC-07	0	0	0	0	0	4	0	NA	0	NA	0
	EOPC-08	0	0	0	0	0	0	0	NA	0	NA	0
	EOPC-09	0	0	0	0	0	0	0	NA	0	NA	0
	EOPC-010	0	0	0	0	0	2	0	NA	0	NA	0
	EOPC-011	0	0	0	0	0	0	0	NA	0	NA	0
	Baca03-1426	0	0	0	0	0	1	1	0	0	0	1
	Baca05-1657	0	0	0	0	0	1	1	0	0	0	0
	Baca05-3595	0	0	0	1	0	2	0	0	0	0	1
	Baca05-3852	0	0	0	0	0	2	1	0	0	0	0
	Baca06-1749	0	0	0	0	0	1	0	1	1	1	0
	Baca06-3199	0	1	0	0	1	1	1	1	1	0	1
	Baca07-4610	0	1	0	0	1	1	1	1	0	0	1
	Baca07-4941	0	0	0	0	0	1	1	0	0	0	1
	Baca07-5037	0	0	0	0	0	0	1	0	0	0	1
	Baca08-4154	0	0	0	0	0	1	0	1	1	0	1
	Baca08-716	0	0	0	0	0	0	0	0	1	0	1
	Baca09-37	0	0	0	0	0	1	1	0	0	0	1
	BacaSTID0000000410	0	0	0	0	0	0	0	0	0	0	0
	BacaSTID0000002872	0	0	0	0	0	1	1	0	1	0	0
	TCGA-CH-5750	0	0	0	0	0	2	0	0	1	0	1
	TCGA-CH-5763	0	0	0	0	0	0	NA	NA	NA	NA	NA
	TCGA-CH-5771	0	0	0	0	0	0	NA	NA	NA	NA	NA
	TCGA-CH-5788	0	0	0	1	0	1	0	1	1	1	1
	TCGA-CH-5789	0	0	0	0	0	0	0	0	0	0	0
	TCGA-EJ-5503	0	0	0	0	0	0	NA	NA	NA	NA	NA
	TCGA-EJ-5506	0	0	0	1	0	2	NA	NA	NA	NA	NA
	TCGA-EJ-7791	0	0	0	0	0	0	0	0	0	0	0
	TCGA-G9-6336	0	0	0	0	0	2	1	0	0	0	0
	TCGA-G9-6365	0	0	0	0	0	0	1	0	0	0	1
	TCGA-G9-6370	0	0	0	0	0	0	0	0	0	0	0
	TCGA-G9-7522	0	0	0	0	0	0	0	0	0	0	0
	TCGA-HC-7075	0	0	0	1	0	1	0	0	0	1	1
	TCGA-HC-7079	0	0	0	0	0	0	0	0	0	0	0
	TCGA-HC-7233	0	0	0	0	0	0	0	0	0	0	1
	TCGA-HC-7737	0	0	0	0	0	0	NA	NA	NA	NA	NA
	TCGA-HC-7740	0	0	0	0	0	0	0	0	0	0	0
	TCGA-HC-7744	0	0	0	0	0	0	1	0	1	1	1
	TCGA-HC-8258	0	0	0	0	0	0	0	0	0	0	0
	TCGA-HI-7169	0	0	0	0	0	0	0	0	0	0	1
GR
(median
dichot-									chr7:
omized)	CDH1_CNA	CDKN1B_CNA	CHD1_CNA	MYC_CNA	NKX3-1_CNA	PTEN_CNA	RB1_CNA	TP53_CNA	145019604
0	0	0	0	0	−1	0	0	0	0
0	0	0	0	1	−1	0	−1	0	0
0	−1	0	0	1	−1	0	0	0	0
0	0	0	−1	0	0	0	0	0	0
0	0	0	−1	1	0	−1	−1	1	0
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	−1	0	0	0
1	−1	0	0	0	0	0	−1	0	0
0	0	0	0	0	−1	0	−1	−1	0
0	0	0	0	1	−1	0	−1	0	0
0	0	0	0	1	−1	0	0	0	1
0	0	−1	0	1	−1	0	−1	0	0
1	−1	0	0	1	−1	0	0	−1	0
0	−1	0	0	1	−1	0	0	−1	0
1	0	0	−1	0	−1	−1	0	0	0
0	0	0	0	0	0	−1	−1	−1	0
0	0	0	0	0	0	−1	0	0	0
1	0	−1	0	1	−1	0	−1	0	1
1	0	0	−1	0	−1	−1	−1	0	0
0	0	0	0	0	0	0	0	−1	0
0	0	0	−1	0	0	−1	−1	0	0
1	0	−1	−1	0	0	0	−1	0	0
0	−1	0	0	0	−1	0	0	−1	0
0	0	0	0	0	0	0	0	1	0
1	0	0	0	0	0	−1	−1	0	0
0	0	0	0	0	0	0	0	0	0
1	0	−1	0	0	−1	0	−1	0	0
0	0	0	0	0	0	0	0	0	0
1	−1	0	−1	0	0	−1	0	−1	1
0	0	0	0	0	0	0	0	0	0
0	0	0	−1	0	0	−1	0	0	0
1	−1	0	−1	0	−1	0	0	0	0
0	1	0	−1	1	−1	−1	−1	−1	0
1	0	0	0	0	−1	−1	0	0	0
1	0	0	0	0	−1	0	−1	−1	0
1	0	0	−1	0	0	−1	0	0	0
1	0	0	0	0	−1	−1	0	0	0
1	0	1	0	0	0	0	−1	0	0
0	0	0	0	0	0	0	0	0	0
1	0	0	−1	0	−1	0	−1	0	0
0	0	0	0	0	−1	−1	0	0	0
1	0	0	0	1	−1	0	0	0	0
1	0	0	0	0	−1	0	0	0	0
1	0	0	0	0	−1	0	0	−1	0
1	0	−1	0	0	−1	−1	−1	0	0
0	0	−1	0	0	−1	0	0	1	0
0	0	0	0	0	−1	−1	0	−1	0
0	−1	−1	0	0	0	0	0	0	0
1	−1	−1	0	0	−1	−1	0	−1	0
1	0	−1	−1	0	−1	0	−1	0	0
0	0	0	0	0	0	0	0	0	0
1	0	0	−1	1	−1	0	0	0	0
1	0	0	0	0	0	−1	−1	0	0
1	0	0	0	0	−1	−1	0	0	0
1	0	0	0	1	−1	−1	0	0	0
0	0	−1	0	0	0	0	0	0	0
1	0	−1	0	0	−1	−1	0	−1	0
1	0	−1	−1	0	−1	0	−1	0	0
0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	−1	0	0
0	0	0	0	0	−1	−1	0	0	0
0	0	0	0	0	−1	0	0	0	0
0	0	0	0	0	0	0	0	0	1
1	−1	0	0	0	0	−1	0	−1	0
1	−1	0	0	0	−1	0	0	0	0
1	−1	0	0	0	−1	−1	0	0	0
0	0	−1	0	0	−1	0	0	0	0
0	0	−1	0	0	−1	−1	0	0	0
1	0	−1	0	0	0	0	0	0	0
1	0	0	−1	0	0	0	0	0	0
0	0	−1	0	0	−1	0	0	0	0
1	−1	0	0	0	−1	−1	0	−1	0
1	0	−1	0	0	−1	−1	0	0	0
1	0	−1	0	0	−1	0	−1	0	0
1	0	0	0	0	0	0	0	−1	0
1	0	0	0	1	0	0	0	0	0
1	0	−1	−1	0	−1	−1	−1	0	0
0	−1	0	0	0	−1	0	−1	0	0
1	0	0	0	0	0	−1	−1	−1	0
1	0	0	0	0	0	0	−1	0	0
0	0	1	0	1	1	0	−1	0	1
1	0	−1	0	0	0	−1	−1	0	0
0	−1	0	0	0	−1	0	−1	−1	0
1	0	−1	0	0	−1	−1	0	0	0
0	0	0	0	0	−1	−1	−1	0	0
0	0	0	0	0	0	−1	−1	0	0
1	0	−1	0	0	−1	−1	0	−1	0
1	0	0	0	0	0	0	0	−1	0
0	−1	0	0	0	−1	0	0	0	0
1	0	0	0	0	0	−1	−1	−1	0
0	−1	0	0	0	0	0	−1	−1	0
1	0	−1	−1	0	−1	0	0	0	1
0	0	0	0	0	−1	−1	0	−1	0
0	0	0	0	0	0	−1	0	−1	0
0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	−1	0	0	0	0
0	0	0	0	0	0	0	0	0	1
1	−1	−1	0	1	−1	0	0	−1	0
1	−1	−1	0	0	−1	0	0	0	0
1	0	−1	0	0	0	−1	−1	0	1
0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0
1	0	0	−1	0	0	0	0	0	0
1	−1	−1	0	0	−1	−1	0	0	0
1	−1	0	0	1	−1	0	−1	−1	0
1	0	0	0	1	−1	−1	0	0	1
0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	−1	0	0	0
1	0	−1	−1	0	−1	0	0	0	0
0	0	0	0	0	0	0	0	0	0
1	0	−1	−1	0	0	−1	−1	−1	0
0	0	−1	0	0	0	−1	0	0	0
1	0	0	−1	0	0	0	0	0	0
1	0	0	−1	0	−1	0	−1	−1	0
1	0	0	0	0	−1	−1	0	0	0
1	0	−1	0	0	−1	−1	0	−1	0
0	0	0	0	0	0	−1	0	0	0
1	−1	0	0	0	−1	−1	−1	−1	0
0	0	−1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0
NA	0	0	0	0	−1	0	0	−1	NA
NA	0	0	0	0	0	0	0	0	NA
NA	0	−1	0	0	−1	0	−1	0	NA
NA	−1	0	0	1	0	0	0	0	NA
NA	0	0	0	0	−1	−1	0	0	NA
NA	0	0	0	0	0	−1	−1	0	NA
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0
NA	0	0	0	0	−1	0	0	1	NA
NA	0	0	0	0	0	0	0	0	NA
NA	−1	0	−1	0	−1	−1	0	0	NA
0	0	0	0	0	0	0	0	0	0
NA	0	0	0	0	0	0	0	0	NA
NA	0	0	0	0	0	0	0	0	NA
NA	−1	0	0	0	0	−1	0	0	NA
NA	0	0	0	0	0	−1	0	0	NA
NA	−1	0	0	1	−1	0	0	0	NA
NA	0	0	0	0	0	0	0	1	NA
NA	0	0	0	0	0	0	0	0	NA
1	0	0	0	0	0	0	0	0	0
NA	0	0	0	0	0	−1	−1	0	NA
NA	0	0	0	0	0	0	0	0	NA
NA	−1	0	0	1	−1	0	−1	0	NA
0	0	0	0	0	0	0	0	0	0
NA	0	1	0	0	−1	0	−1	0	NA
NA	−1	0	0	0	−1	0	0	0	NA
NA	0	0	0	0	0	0	0	0	NA
NA	0	0	0	0	−1	0	0	−1	NA
0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0
NA	0	0	0	0	−1	0	0	0	NA
NA	0	0	0	0	0	0	0	0	NA
NA	0	0	0	0	0	0	0	−1	NA
NA	0	0	0	1	−1	0	0	0	NA
NA	−1	0	−1	1	−1	−1	0	−1	NA
NA	1	0	0	1	−1	0	0	−1	NA
NA	0	0	0	0	−1	0	−1	−1	NA
NA	−1	0	−1	1	−1	0	−1	0	NA
NA	0	0	−1	0	−1	0	−1	0	NA
NA	0	0	0	0	−1	0	0	0	NA
NA	−1	0	−1	1	1	0	−1	0	NA
NA	0	−1	0	0	−1	−1	0	0	NA
1	NA	NA	NA	NA	NA	NA	NA	NA	0
NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
1	NA	NA	NA	NA	NA	NA	NA	NA	0
NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
0	NA	NA	NA	NA	NA	NA	NA	NA	0
NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
1	NA	NA	NA	NA	NA	NA	NA	NA	0
0	NA	NA	NA	0	−1	NA	NA	NA	0
NA	NA	NA	1	−1	NA	NA	NA	NA	NA
0	NA	NA	NA	0	0	NA	NA	NA	0
0	NA	NA	NA	0	0	NA	NA	NA	0
0	NA	NA	NA	0	0	NA	NA	NA	0
0	NA	NA	NA	0	−1	NA	NA	NA	0
0	NA	NA	NA	0	0	NA	NA	NA	0
0	NA	NA	NA	0	0	NA	NA	NA	0
0	NA	NA	NA	NA	NA	NA	NA	NA	0
0	NA	NA	NA	0	0	NA	NA	NA	0
1	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0
1	0	0	0	0	−1	−1	0	0	0
1	0	0	0	1	−1	0	0	−1	0
1	0	0	0	0	0	0	0	0	0
1	−1	0	0	1	0	−1	0	0	0
1	0	0	0	0	0	−1	0	0	0
1	0	0	0	0	0	0	0	0	0
1	0	0	0	1	−1	−1	0	0	0
1	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0
NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
1	−1	0	−1	0	−1	1	−1	0	0
0	0	0	0	0	0	0	0	0	0
NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0
NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	−1	0	0
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0
	GR
	(median
	dichot-	chr16:	chr13:	chr2:	chr22:	chr4:
	omized)	64910033	58055742	131394079	31826396	39684557	ATM_SNV	FOXA1_SNV	MED12_SNV	SPOP_SNV	TP53_SN
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	1	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	1	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	1	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	1	0	0	0
	0	1	0	0	0	0	1	0	0	0	0
	0	0	0	0	0	1	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	1	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	1	0	0	0
	1	0	0	0	0	0	0	0	0	1	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	1	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	1	1	0	0
	0	0	0	1	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	1	0	0	0	0	1	0
	0	1	0	0	0	0	0	0	0	0	0
	1	0	1	0	0	0	0	0	0	0	0
	1	1	0	0	0	0	0	0	0	0	1
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	1
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	1	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	1	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	1	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	1	0
	0	0	0	0	0	0	0	0	0	0	1
	1	0	0	0	0	0	0	0	0	1	0
	1	0	0	0	1	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	1	0	0	0	0	0
	0	0	1	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	1	0	0	0	1	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	1	0	0	0	0	0	0	0	0
	1	0	0	0	1	0	0	0	0	0	1
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	1	0	0	0	0	0	0	0	0
	1	0	0	0	1	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	1	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	1	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	1	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	1	0	0	0	0	0	0	0	0	0
	1	0	1	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	1	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	1	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	1	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	1
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	1	0	0	0	0	0	0	0	0
	0	0	0	1	1	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	1
	1	0	0	0	0	0	0	0	0	0	0
	1	1	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	1	0	0	0	0	0	0	0
	1	0	0	0	0	1	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	1	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	1	0
	0	0	0	0	1	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	1
	0	0	0	1	0	0	0	0	0	0	0
	1	0	0	1	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	1	0
	0	0	0	0	0	0	0	0	0	0	0
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	0	0	0	0	0	0	0	0	0
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	1	0	0	0	0	0	0	0	0	0	0
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	0	0	0	0	0	0	0	0	0
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	1	0	0	0	0	0	0	0	0	1	0
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	1	0	0	0	0	0	0	0	0	0	0
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	0	0	0	0	0	0	0	0	0
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	1	0	0	0	0	0	0	0	0	1	0
	0	0	0	0	0	0	0	0	0	0	0
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	1
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	1	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	1
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	1	0	0	0	0	0	0	0	0	1	0
	0	0	0	0	0	0	0	0	0	0	0
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	0	0	0	0	0	0	0	0	0
	1	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0	0
chr3:	chr3:	chr3:	chr10:	chr21:	chr4:	chr6:	chr7:	chr17:
125 Mbp_Inv	129 Mbp_Inv	195 Mbp_Inv	89 Mbp_Inv	42 Mbp_Inv	148 Mbp_Ctx	97 Mbp_Ctx	61 Mbp_Ctx	25 Mbp_Ctx
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	1	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	1	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	1	0	0	0	0
0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	1	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	1	1	0	0
0	0	0	0	0	0	0	0	0
0	0	0	1	0	0	0	0	1
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	1	1	0	0
0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	1	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	1	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	1	0	0	0	0	1
0	0	0	0	0	0	0	0	0
0	0	0	0	0	1	1	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	1	1	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	1	1	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	1	1	0	0
0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	1	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	1	1	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	1	0	0	1	1	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	1	0
1	1	0	0	0	0	0	0	0
1	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
1	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	1	0	0	0	0
0	0	0	0	0	1	1	0	0
0	0	0	1	1	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
1	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	1	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
1	1	0	0	0	0	0	0	0
0	0	0	0	0	1	1	0	0
0	0	0	0	0	1	1	0	0
1	1	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0
1	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	1	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	1	0
0	0	0	0	0	0	0	0	0
1	1	0	0	0	0	0	0	0
0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
0	0	0	0	0	0	0	0	0
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
0	0	0	0	0	0	0	0	1
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
1	1	0	0	0	0	0	0	0
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
1	1	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	1
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
0	0	0	0	0	0	0	0	0
NA	NA	NA	NA	NA	NA	NA	NA	NA
0	0	0	1	0	0	0	0	0
NA	NA	NA	NA	NA	NA	NA	NA	NA
0	0	0	0	0	0	0	0	0
NA	NA	NA	NA	NA	NA	NA	NA	NA
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
NA	NA	NA	NA	NA	NA	NA	NA	NA
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	1	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	1	0	0
0	0	0	0	1	0	0	0	1
0	0	0	0	1	0	0	0	0
0	0	0	1	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0
0	0	1	0	0	0	0	0	0
0	0	1	0	0	0	0	0	0
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
NA	NA	NA	NA	NA	NA	NA	NA	NA
NA	NA	NA	NA	NA	NA	NA	NA	NA
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
1	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
1	1	1	0	0	0	0	0	0
NA	NA	NA	NA	NA	NA	NA	NA	NA
0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
	chr3:	chr21:	TCERG1L-	TCERG1L-				MIR129-
	125 Mbp_Inv	42 Mbp_Ctx	5'_Meth	3′_Meth	TUBA3C_Meth	SOX14_Meth	ACTL6B_Meth	2_Meth
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	0	1	0	0	1	1
	0	0	NA	NA	NA	NA	NA	NA
	0	0	0	1	0	0	1	1
	0	0	0	0	0	0	1	1
	0	0	1	1	0	0	1	0
	0	0	NA	NA	NA	NA	NA	NA
	0	1	0	0	1	1	1	0
	0	0	1	1	0	1	1	1
	0	1	NA	NA	NA	NA	NA	NA
	0	0	0	1	0	0	1	1
	0	1	0	1	0	1	1	1
	0	0	0	1	0	0	1	1
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	0	1	0	0	1	1
	0	0	0	1	0	1	0	1
	0	0	1	0	1	0	0	1
	0	0	0	1	0	0	1	0
	0	1	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	1	0	0	0	0	0
	0	0	NA	NA	NA	NA	NA	NA
	0	0	1	0	1	1	0	1
	0	0	1	0	0	0	1	1
	0	0	NA	NA	NA	NA	NA	NA
	0	0	1	0	1	1	0	0
	0	0	1	0	0	0	0	1
	0	0	0	1	0	0	1	1
	0	0	0	1	1	1	0	1
	0	0	1	0	1	1	1	0
	0	0	0	1	0	0	1	1
	0	0	0	1	0	0	1	1
	0	0	0	1	0	1	1	1
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	1	0	0	1	1	1
	0	0	0	1	0	0	0	1
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	0	0	1	1	1	0
	0	0	1	0	1	1	0	0
	0	0	1	1	0	1	0	0
	0	0	0	1	0	0	0	0
	0	0	NA	NA	NA	NA	NA	NA
	0	0	1	1	0	0	1	1
	0	0	0	1	0	0	1	1
	0	0	0	1	0	0	1	1
	0	0	0	0	0	0	1	1
	0	0	0	1	1	0	0	1
	0	1	1	0	1	1	1	1
	0	0	0	1	0	0	1	0
	0	0	1	0	1	1	1	0
	0	1	1	0	1	0	1	0
	0	0	0	1	1	1	1	1
	0	1	0	1	0	1	0	1
	0	0	0	0	1	1	0	0
	0	0	0	0	0	0	0	0
	0	0	1	0	1	1	1	0
	0	1	0	1	1	0	0	0
	0	1	1	0	1	1	1	1
	0	1	1	0	1	1	1	1
	0	0	0	0	1	1	0	0
	0	0	1	1	1	1	1	0
	0	0	0	1	0	0	1	1
	0	0	1	0	0	1	0	1
	1	0	0	0	0	1	1	1
	1	0	1	0	1	0	0	1
	0	0	0	1	1	1	1	0
	0	0	1	0	0	1	0	0
	0	0	1	0	1	1	1	0
	0	0	0	1	0	1	0	0
	0	0	0	0	0	1	0	0
	0	0	1	1	0	1	0	0
	1	0	0	0	1	0	1	0
	0	0	0	1	0	1	1	1
	0	1	0	1	1	0	0	0
	0	1	1	0	1	0	1	1
	0	0	0	1	0	1	0	0
	0	0	1	0	0	0	0	1
	0	0	0	1	0	0	1	0
	1	0	0	1	1	0	0	1
	0	0	1	0	0	1	0	0
	0	0	0	1	0	1	0	0
	0	0	1	0	1	0	1	0
	0	0	0	0	1	0	0	0
	0	0	0	1	0	1	1	1
	1	0	0	0	1	0	1	0
	0	0	1	0	0	1	1	1
	0	0	1	0	1	0	0	0
	1	1	0	0	0	0	0	0
	0	0	1	0	1	1	1	1
	1	0	0	0	1	1	0	0
	0	0	1	0	1	0	0	0
	0	0	1	1	0	1	0	0
	0	1	1	1	1	0	1	1
	0	0	1	0	0	1	0	1
	0	0	1	0	0	1	0	0
	0	0	1	1	1	1	0	0
	0	0	0	1	0	0	0	1
	0	0	0	1	0	1	1	1
	0	0	0	1	0	0	1	1
	0	0	0	1	0	1	0	1
	0	0	1	0	0	0	0	0
	0	0	0	1	0	0	0	0
	0	0	0	1	0	1	1	1
	0	0	1	0	1	0	0	0
	0	0	0	0	1	1	1	1
	0	0	0	1	0	1	1	0
	1	0	0	1	1	1	0	1
	0	0	0	1	1	1	0	0
	0	0	0	0	0	0	0	1
	0	1	1	1	1	0	0	0
	0	0	0	0	0	0	1	0
	0	0	0	0	1	1	0	0
	0	0	0	1	0	1	0	1
	0	0	1	0	1	1	1	0
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	0	1	0	0	1	1
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	1	0	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	1	0	NA	NA	NA	NA	NA	NA
	0	0	1	1	1	1	1	1
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	1	NA	NA	NA	NA	NA	NA
	0	1	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	1	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	1	0	NA	NA	NA	NA	NA	NA
	NA	NA	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA
	0	0	NA	NA	NA	NA	NA	NA

7: Table of mtSNVs with LHF values between 0.1 and 0.2
		Ref-								Tu-	Nor-		Locus
		erence	Tu-	Tu-	Tu-	Tumour	Normal	Normal	Normal	mour	mal		Dif-
		Tu-	mour	mour	mour	HF-T	Tumour	TUmour	Tumour	Cov-	Cov-	Coverage	ference
Patient	Position	mour	HF-A	HF-C	HF-G	Normal	HF-A	HF-C	HF-T	erage	erage	mtDNA	in HF
CPCG0120	61 C	C	0	0.88	0.04	0.08 C	0	1	0	0	2414	1066 CR	0.12
ICGC_PCA087	72 T	T	0	0.13	0	0.87 T	0	0	0	1	1733	1357 CR	0.13
ICGC_PCA161	146 C	T	0	0.01	0	0.99 T	0	0.17	0	0.83	2239	839 CR	0.16
ICGC_PCA053	152 C	T	0	0.13	0	0.87 T	0	0	0	1	3817	3423 CR	0.13
ICGC_PCA130	203 G	G	0.14	0	0.86	0 G	0	0	1	0	5419	597 CR	0.14
CPCG0211	204 T	C	0	0.99	0	0.01 C	0	0.85	0	0.15	6273	732 CR	0.14
CPCG0128	249 A	A	1	0	0	0 A	0.89	0	0.11	0	6347	859 CR	0.11
CPCG0126	291 A	A	0.88	0	0	0.12 A	1	0	0	0	6805	1010 CR	0.12
CPCG0126	294 T	T	0	0.13	0	0.87 T	0	0	0	1	6536	916 CR	0.13
CPCG0126	296 C	C	0	0.88	0.12	0 C	0	1	0	0	6269	678 CR	0.12
CPCG0126	297 A	G	0	0.15	0.85	0 G	0	0	1	0	5914	543 CR	0.15
CPCG0126	299 C	C	0.11	0.89	0	0 C	0	1	0	0	7035	1001 CR	0.11
CPCG0267	302 A	A	0.99	0.01	0	0 A	0.86	0.14	0	0	2788	429 CR	0.13
CPCG0371	302 A	A	0.99	0.01	0	0 A	0.89	0.11	0	0	3650	1316 CR	0.1
CPCG0071	302 A	A	0.87	0.12	0.01	0 A	0.98	0.02	0	0	2725	1059 CR	0.1
CPCG0126	302 A	A	0.84	0.16	0	0 A	0.98	0.01	0	0	5384	584 CR	0.15
Baca05-3595	303 C	C	0.02	0.97	0	0 C	0.2	0.8	0	0	4713	210 CR	0.17
Baca05-3595	309 C	T	0	0.24	0	0.76 T	0	0.12	0	0.88	3340	1188 CR	0.13
Baca05-3595	460 T	T	0.11	0	0	0.88 T	0.27	0	0	0.73	6244	2829 CR	0.15
CPCG0204	529 G	G	0	0	1	0 G	0.11	0	0.89	0	6579	2313 CR	0.11
CPCG0089	545 G	G	0.12	0.01	0.87	0 G	0	0	1	0	1106	2018 CR	0.13
ICGC_PCA184	586 G	G	0.19	0	0.81	0 G	0	0	1	0	6197	3270 TF	0.19
CPCG0096	653 G	G	0	0	1	0 G	0.11	0	0.89	0	7418	1911 RNR1	0.1
CPCG0036	709 G	G	0.19	0	0.81	0 G	0	0	1	0	7241	777 RNR1	0.19
ICGC_PCA053	827 A	A	0.88	0	0.12	0 A	1	0	0	0	5176	5170 RNR1	0.12
ICGC_PCA094	953 T	T	0	0.14	0	0.86 T	0	0	0	1	4544	1383 RNR1	0.14
CPCG0084	1072 G	G	0.19	0	0.81	0 G	0	0	1	0	5886	1888 RNR1	0.19
ICGC_PCA064	1252 G	G	0.19	0	0.81	0 G	0	0	1	0	7649	6466 RNR1	0.19
CPCG0070	1324 T	T	0	0	0	1 T	0	0.16	0	0.84	7774	3376 RNR1	0.16
ICGC_PCA124	1454 G	G	0.16	0	0.84	0 G	0	0	1	0	7325	2704 RNR1	0.16
ICGC_PCA132	1485 G	G	0.13	0	0.87	0 G	0	0	1	0	6697	2019 RNR1	0.13
CPCG0005	1826 G	G	0.15	0	0.85	0 G	0	0	1	0	7673	1994 RNR2	0.15
CPCG0089	1906 G	G	0.07	0.04	0.88	0 G	0	0	1	0	2144	3082 RNR2	0.11
CPCG0067	2203 G	G	0.04	0.01	0.9	0.06 G	0	0	1	0	213	1286 RNR2	0.1
CPCG0368	2233 T	T	0	0	0	1 T	0	0.16	0	0.84	7765	3094 RNR2	0.15
ICGC_PCA197	2296 T	T	0	0.19	0	0.81 T	0	0	0	1	7371	2948 RNR2	0.19
CPCG0413	2321 A	G	0.04	0	0.96	0 G	0.2	0	0.8	0	7059	3641 RNR2	0.15
CPCG0408	2345 G	G	0.14	0	0.86	0 G	0	0	1	0	7306	6130 RNR2	0.14
CPCG0114	2487 A	A	0.99	0.01	0	0 A	0.84	0.15	0	0	1953	252 RNR2	0.15
CPCG0123	2487 A	A	1	0	0	0 A	0.85	0.12	0.01	0.01	6361	1104 RNR2	0.14
CPCG0166	2487 A	A	0.86	0.13	0.01	0 A	1	0	0	0	126	1065 RNR2	0.13
CPCG0211	2487 A	A	1	0	0	0 A	0.81	0.17	0.01	0.01	6421	605 RNR2	0.19
Berger3027	2487 A	A	0.95	0.05	0	0 A	0.8	0.2	0	0	2734	790 RNR2	0.15
CPCG0067	2536 G	G	0.11	0	0.89	0 G	0	0	1	0	5891	2001 RNR2	0.11
Baca06-3199	2553 G	G	0.12	0	0.88	0 G	0	0	1	0	6914	6249 RNR2	0.12
CPCG0361	2587 G	G	0.15	0	0.85	0 G	0	0	1	0	7215	3708 RNR2	0.15
ICGC_PCA172	2609 T	T	0	0.18	0	0.82 T	0	0	0	1	5372	5848 RNR2	0.18
Baca06-1749	2698 G	G	0.15	0	0.85	0 G	0	0	1	0	6547	2793 RNR2	0.15
ICGC_PCA165	2698 G	G	0.12	0	0.88	0 G	0	0	1	0	7239	1912 RNR2	0.12
CPCG0046	2700 G	G	0.01	0	0.88	0.11 G	0	0	1	0	379	1626 RNR2	0.12
CPCG0201	2702 G	G	0.13	0	0.87	0 G	0	0	1	0	7436	2468 RNR2	0.13
ICGC_PCA059	2916 G	G	0.16	0	0.84	0 G	0	0	1	0	4442	2547 RNR2	0.16
TCGA-CH-5789	3243 A	A	0.89	0	0.11	0 A	1	0	0	0	7105	6797 TL1	0.1
ICGC_PCA034	3358 G	G	0.13	0	0.87	0 G	0	0	1	0	5359	2244 ND1	0.13
CPCG0094	3447 A	A	0.88	0.1	0.01	0.01 A	1	0	0	0	4366	939 ND1	0.12
CPCG0123	3447 A	A	1	0	0	0 A	0.84	0.12	0.02	0.02	5662	1018 ND1	0.16
CPCG0183	3447 A	A	1	0	0	0 A	0.85	0.11	0.02	0.02	6238	951 ND1	0.15
CPCG0211	3447 A	A	1	0	0	0 A	0.88	0.1	0.02	0	6535	637 ND1	0.12
CPCG0071	3447 A	A	0.85	0.14	0.01	0.01 A	0.95	0.05	0	0	4372	1535 ND1	0.11
BacaSTID0000002872	3447 A	A	1	0	0	0 A	0.88	0.1	0.01	0.01	4415	1634 ND1	0.12
Berger3043	3452 T	T	0	0.19	0	0.81 T	0	0	0	1	4071	795 ND1	0.19
ICGC_PCA023	3457 G	G	0.13	0	0.87	0 G	0	0	1	0	5304	5385 ND1	0.13
CPCG0089	3464 T	T	0.07	0.06	0	0.87 T	0	0	0	1	4676	3687 ND1	0.13
CPCG0123	3468 A	A	1	0	0	0 A	0.85	0.12	0.01	0.02	5725	954 ND1	0.14
CPCG0183	3468 A	A	0.99	0.01	0	0 A	0.87	0.09	0.01	0.02	6470	924 ND1	0.12
CPCG0071	3468 A	A	0.86	0.12	0	0.01 A	0.96	0.04	0	0	4425	1497 ND1	0.1
CPCG0123	3475 A	A	1	0	0	0 A	0.88	0.11	0	0.01	5599	907 ND1	0.12
ICGC_PCA173	3483 G	G	0	0	1	0 G	0.12	0	0.88	0	7586	4617 ND1	0.12
CPCG0089	3488 T	T	0.06	0.07	0.01	0.87 T	0	0	0	1	3368	3131 ND1	0.13
CPCG0123	3492 A	A	0.97	0.02	0	0 A	0.82	0.16	0.01	0	5220	813 ND1	0.15
CPCG0183	3492 A	A	1	0	0	0 A	0.81	0.18	0.01	0	5640	720 ND1	0.19
CPCG0211	3492 A	A	0.99	0.01	0	0 A	0.81	0.18	0	0	6252	475 ND1	0.18
CPCG0067	3531 G	G	0.08	0.02	0.89	0 G	0	0	1	0	2461	766 ND1	0.1
Baca09-37	3567 C	C	0	0.82	0	0.17 C	0	1	0	0	6043	4943 ND1	0.17
CPCG0127	3592 G	G	0.1	0	0.9	0 G	0	0	1	0	6787	1064 ND1	0.1
CPCG0210	3614 T	T	0	0.11	0	0.89 T	0	0	0	1	7477	1319 ND1	0.11
ICGC_PCA184	3715 G	G	0.12	0	0.88	0 G	0	0	1	0	6406	3722 ND1	0.12
CPCG0189	3834 G	G	0.2	0	0.8	0 G	0	0	1	0	7677	1734 ND1	0.2
ICGC_PCA048	4142 G	G	0.2	0	0.8	0 G	0	0	1	0	3163	2816 ND1	0.2
CPCG0346	4153 G	G	0.16	0	0.84	0 G	0	0	1	0	5516	1739 ND1	0.16
CPCG0267	4226 T	T	0	0.04	0	0.96 T	0	0.17	0	0.83	6856	1733 ND1	0.13
ICGC_PCA192	4408 G	G	0.1	0	0.9	0 G	0	0	1	0	3913	2915 TM	0.1
ICGC_PCA132	4412 G	G	0.11	0	0.89	0 G	0	0	1	0	6704	2125 TM	0.11
CPCG0378	4428 G	G	0.18	0	0.82	0 G	0	0	1	0	7468	4250 TM	0.18
Baca07-5037	4762 T	T	0	0.17	0	0.83 T	0	0	0	1	7290	7502 ND2	0.17
CPCG0022	4848 G	G	0	0	0.87	0.13 G	0	0	0.98	0.02	1236	3356 ND2	0.11
CPCG0126	4969 G	G	0.19	0	0.81	0 G	0	0	1	0	7426	1891 ND2	0.19
CPCG0236	5177 G	G	0.14	0	0.86	0 G	0	0	1	0	7524	2322 ND2	0.13
CPCG0123	5208 A	A	1	0	0	0 A	0.88	0.09	0.01	0.02	5545	1037 ND2	0.12
CPCG0183	5208 A	A	1	0	0	0 A	0.88	0.09	0.01	0.02	6415	831 ND2	0.12
CPCG0211	5208 A	A	1	0	0	0 A	0.89	0.08	0.02	0	6277	413 ND2	0.11
CPCG0122	5208 A	A	1	0	0	0 A	0.89	0.09	0.01	0.01	6710	621 ND2	0.11
ICGC_PCA184	5476 T	T	0	0.19	0	0.81 T	0	0	0	1	7121	4051 ND2	0.19
CPCG0234	5511 T	T	0.02	0.08	0	0.9 T	0	0	0	1	106	1613 ND2	0.1
CPCG0344	5511 T	T	0	0.19	0	0.81 T	0	0	0	1	7434	2172 ND2	0.19
ICGC_PCA103	5521 G	G	0.14	0	0.86	0 G	0	0	1	0	6905	3724 TW	0.14
CPCG0071	5734 T	T	0	0.11	0	0.88 T	0	0	0	1	4363	1110 OLR	0.12
CPCG0346	5801 T	T	0	0.12	0	0.88 T	0	0	0	1	7580	3087 TC	0.12
CPCG0089	6054 G	G	0.08	0.03	0.88	0 G	0	0	1	0	3712	3366 CO1	0.12
ICGC_PCA131	6128 C	C	0	0.6	0	0.4 T	0	0.4	0	0.6	7042	2821 CO1	0.2
ICGC_PCA069	6164 C	C	0.13	0.87	0	0 C	0	1	0	0	5295	2424 CO1	0.13
ICGC_PCA001	6221 T	C	0	1	0	0 C	0	0.89	0	0.11	4346	1283 CO1	0.11
ICGC_PCA017	6366 G	G	0.13	0	0.87	0 G	0	0	1	0	3616	4404 CO1	0.13
CPCG0048	6419 A	A	1	0	0	0 A	0.88	0.11	0	0	6135	1051 CO1	0.11
CPCG0005	6419 A	A	0.99	0.01	0	0 A	0.86	0.14	0	0	6158	1041 CO1	0.13
CPCG0084	6419 A	A	0.99	0.01	0	0 A	0.84	0.15	0	0	6190	1189 CO1	0.15
CPCG0100	6419 A	A	0.98	0.01	0	0 A	0.88	0.11	0	0	5818	896 CO1	0.1
CPCG0089	6430 T	T	0.06	0.04	0.01	0.9 T	0	0	0	1	3642	5059 CO1	0.1
CPCG0089	6438 T	T	0.05	0.05	0	0.9 T	0	0	0	1	3156	4906 CO1	0.1
CPCG0166	6480 G	G	0.24	0	0.76	0 G	0.43	0	0.57	0	6847	1518 CO1	0.19
CPCG0362	6532 T	T	0	0.11	0	0.89 T	0	0	0	1	7341	3512 CO1	0.11
CPCG0122	6555 A	A	1	0	0	0 A	0.9	0.07	0.03	0.01	7189	686 CO1	0.1
ICGC_PCA070	6627 G	G	0.17	0	0.83	0 G	0	0	1	0	5014	3745 CO1	0.17
CPCG0183	6819 A	A	1	0	0	0 A	0.89	0.08	0.01	0.01	6151	618 CO1	0.11
CPCG0122	6819 A	A	1	0	0	0 A	0.87	0.1	0.02	0	5544	369 CO1	0.13
Berger1701	6819 A	A	1	0	0	0 A	0.81	0.16	0.01	0.01	1949	371 CO1	0.18
Berger2832	6819 A	A	0.87	0.12	0.01	0 A	0.99	0.01	0	0	2556	356 CO1	0.11
TCGA-CH-5763	6819 A	A	1	0	0	0 A	0.88	0.1	0.01	0.01	2450	1031 CO1	0.12
ICGC_PCA189	6991 T	T	0	0.12	0	0.88 T	0	0	0	1	7055	7399 CO1	0.12
CPCG0020	7020 G	G	0.15	0	0.85	0 G	0	0	1	0	4448	711 CO1	0.15
CPCG0042	7102 T	T	0	0	0	1 T	0	0.1	0	0.9	6816	1647 CO1	0.1
CPCG0211	7236 G	G	0	0	1	0 G	0.12	0	0.88	0	6411	889 CO1	0.12
ICGC_PCA152	7391 T	T	0	0.11	0	0.89 T	0	0	0	1	6554	3031 CO1	0.1
TCGA-EJ-5506	7566 G	G	0.2	0	0.8	0 G	0	0	0.99	0	7401	4137 TD	0.19
ICGC_PCA129	7859 G	G	0.04	0	0.96	0 G	0.22	0	0.78	0	7117	4475 CO2	0.18
ICGC_PCA132	7923 A	A	0.88	0	0.12	0 A	1	0	0	0	6656	2270 CO2	0.12
CPCG0166	8088 T	T	0	0.1	0	0.9 T	0	0	0	1	108	1604 CO2	0.1
CPCG0117	8403 T	T	0	0.18	0	0.82 T	0	0	0	1	7413	1495 ATP8	0.18
CPCG0183	8577 A	A	1	0	0	0 A	0.89	0.09	0.01	0.01	6412	1054 ATP6	0.11
ICGC_PCA145	8752 A	A	0.87	0	0.13	0 A	1	0	0	0	5177	1819 ATP6	0.13
CPCG0089	8959 G	G	0.07	0.03	0.89	0.01 G	0	0	1	0	3013	2740 ATP6	0.1
CPCG0243	8995 G	G	0	0	1	0 G	0.12	0	0.88	0	7381	1823 ATP6	0.12
CPCG0081	9035 T	T	0	0	0	1 T	0	0.16	0	0.84	7716	1845 ATP6	0.16
ICGC_PCA172	9165 T	T	0	0.14	0	0.86 T	0	0	0	1	5046	5174 ATP6	0.14
CPCG0050	9276 G	G	0.16	0	0.84	0 G	0	0	1	0	7018	1577 CO3	0.16
ICGC_PCA034	9552 T	T	0	0.12	0	0.88 T	0	0	0	1	5171	2128 CO3	0.12
CPCG0123	9726 A	A	1	0	0	0 A	0.88	0.08	0.01	0.02	6869	1607 CO3	0.12
CPCG0067	9744 G	G	0.11	0	0.89	0 G	0	0	1	0	6386	2243 CO3	0.11
TCGA-HC-7740	9746 G	G	0.46	0	0.54	0 G	0.27	0	0.73	0	6363	2884 CO3	0.19
ICGC_PCA174	9931 G	G	0.17	0	0.83	0 G	0	0	1	0	7355	4095 CO3	0.17
ICGC_PCA170	9942 G	G	0.1	0	0.9	0 G	0	0	1	0	7249	2955 CO3	0.1
CPCG0126	10197 G	G	0.15	0	0.85	0 G	0	0	1	0	5271	1260 ND3	0.14
Baca05-3595	10203 G	G	0	0	1	0 G	0.2	0	0.8	0	2812	112 ND3	0.19
CPCG0324	10237 T	T	0	0	0	1 T	0	0.18	0	0.82	7346	1476 ND3	0.18
CPCG0123	10277 A	A	1	0	0	0 A	0.88	0.11	0	0	6675	1499 ND3	0.12
CPCG0183	10277 A	A	0.99	0	0	0 A	0.86	0.12	0.01	0.01	7016	1350 ND3	0.13
CPCG0184	10277 A	A	1	0	0	0 A	0.9	0.09	0	0	6598	1654 ND3	0.1
CPCG0234	10277 A	A	0.8	0.18	0.02	0 A	0.99	0.01	0	0	138	921 ND3	0.19
CPCG0097	10277 A	A	0.87	0.12	0	0 A	0.99	0.01	0	0	583	1107 ND3	0.12
CPCG0100	10277 A	A	0.99	0.01	0	0 A	0.89	0.1	0	0	6041	1016 ND3	0.1
CPCG0183	10283 A	A	1	0	0	0 A	0.88	0.1	0.01	0.01	6903	1395 ND3	0.12
CPCG0211	10283 A	A	1	0	0	0 A	0.89	0.1	0.01	0	6495	540 ND3	0.11
CPCG0048	10306 A	A	0.99	0.01	0	0 A	0.86	0.13	0	0	6152	1091 ND3	0.13
CPCG0081	10306 A	A	1	0	0	0 A	0.89	0.1	0	0	7641	1378 ND3	0.11
CPCG0123	10306 A	A	1	0	0	0 A	0.83	0.16	0	0.01	6752	1535 ND3	0.17
CPCG0183	10306 A	A	1	0	0	0 A	0.86	0.12	0.01	0	7275	1419 ND3	0.14
CPCG0211	10306 A	A	0.99	0.01	0	0 A	0.87	0.12	0	0	6406	556 ND3	0.12
CPCG0015	10306 A	A	0.99	0.01	0	0 A	0.88	0.12	0	0	5306	1884 ND3	0.11
Baca08-4154	10306 A	A	0.84	0.16	0	0 A	0.95	0.05	0	0	249	3705 ND3	0.11
BacaSTID0000002872	10306 A	A	1	0	0	0 A	0.86	0.13	0	0	4051	1542 ND3	0.13
CPCG0194	10326 T	T	0	0	0	1 T	0	0.2	0	0.8	5883	1053 ND3	0.19
ICGC_PCA138	10373 G	A	0.94	0	0.06	0 A	0.77	0	0.23	0	3764	1249 ND3	0.17
CPCG0212	10453 A	A	0.84	0	0.16	0 A	1	0	0	0	6070	1936 TR	0.16
CPCG0234	10454 T	T	0	0.16	0	0.84 T	0	0	0	1	148	1705 TR	0.16
CPCG0408	10591 T	T	0	0	0	1 T	0	0.14	0	0.86	7721	6744 ND4L	0.14
EOPC-04	10603 C	C	0.15	0.85	0	0 C	0	0.99	0	0	3530	5885 ND4L	0.14
CPCG0361	10677 G	G	0.1	0	0.89	0 G	0	0	1	0	5789	3685 ND4L	0.11
CPCG0391	10686 G	G	0.12	0	0.88	0 G	0	0	1	0	7276	6103 ND4L	0.12
ICGC_PCA053	10731 G	G	0.11	0	0.89	0 G	0	0	1	0	6919	6480 ND4L	0.11
ICGC_PCA102	10768 A	A	0.74	0	0.26	0 A	0.61	0	0.39	0	4758	2928 ND4	0.14
CPCG0089	10934 G	G	0.07	0.03	0.89	0 G	0	0	1	0	2594	2217 ND4	0.11
CPCG0089	11031 G	G	0.08	0.03	0.89	0 G	0	0	1	0	2913	3705 ND4	0.11
CPCG0257	11124 T	T	0	0.18	0	0.82 T	0	0	0	1	7628	1926 ND4	0.18
ICGC_PCA192	11126 G	G	0.12	0	0.88	0 G	0	0	1	0	3845	2760 ND4	0.12
ICGC_PCA040	11166 G	G	0.03	0	0.97	0 G	0.14	0	0.86	0	5903	5831 ND4	0.1
CPCG0346	11223 T	T	0	0.13	0	0.87 T	0	0	0	1	7478	2780 ND4	0.12
CPCG0067	11225 G	G	0.11	0	0.89	0 G	0	0	1	0	6154	1591 ND4	0.11
CPCG0340	11250 T	T	0	0.19	0	0.81 T	0	0	0	1	7525	3514 ND4	0.19
CPCG0078	11557 A	A	0.94	0	0.06	0 A	0.82	0	0.18	0	7451	1000 ND4	0.12
CPCG0072	11914 A	G	0.11	0	0.89	0 G	0	0	1	0	4976	1962 ND4	0.11
CPCG0046	12125 G	G	0	0	0.88	0.11 G	0	0	1	0	389	1921 ND4	0.11
CPCG0392	12134 T	T	0	0	0	1 T	0	0.14	0	0.86	7599	1948 ND4	0.14
CPCG0241	12235 T	T	0	0.15	0	0.85 T	0	0	0	1	7385	1447 TS2	0.15
CPCG0084	12457 G	G	0.13	0	0.87	0 G	0.01	0	0.99	0	3270	1337 ND5	0.12
CPCG0166	12471 T	T	0	0.2	0	0.8 T	0	0	0	1	193	1606 ND5	0.2
CPCG0388	12541 G	G	0.13	0	0.87	0 G	0	0	1	0	7537	2422 ND5	0.13
Baca05-3852	12631 T	T	0	0.15	0	0.85 T	0	0	0	1	6577	1992 ND5	0.15
CPCG0187	12772 G	G	0	0	1	0 G	0.17	0	0.83	0	7180	891 ND5	0.17
Berger1701	12775 G	G	0.16	0	0.84	0 G	0	0	0.99	0	2788	841 ND5	0.15
ICGC_PCA156	12977 T	T	0	0.18	0	0.82 T	0	0	0	1	6751	3729 ND5	0.18
ICGC_PCA127	13042 G	G	0.17	0	0.83	0 G	0	0	1	0	6856	3318 ND5	0.17
CPCG0122	13094 T	T	0	0.12	0	0.88 T	0	0	0	0.99	7441	983 ND5	0.11
ICGC_PCA172	13105 G	G	0.09	0	0.91	0 G	0.23	0	0.77	0	5389	5714 ND5	0.14
TCGA-EJ-7791	13376 T	T	0	0	0	0.99 T	0	0.14	0	0.86	6535	2460 ND5	0.13
Baca06-1749	13424 T	T	0	0.16	0	0.84 T	0	0	0	1	7371	3119 ND5	0.15
ICGC_PCA031	13466 G	G	0	0	1	0 G	0.17	0	0.83	0	5931	5521 ND5	0.17
CPCG0020	13590 G	G	0.16	0	0.84	0 G	0	0	1	0	7611	1841 ND5	0.16
CPCG0089	13674 T	T	0.05	0.07	0.01	0.87 T	0	0	0	1	3237	4163 ND5	0.13
CPCG0353	13708 G	G	0.1	0	0.9	0 G	0	0	1	0	6663	3432 ND5	0.1
CPCG0046	13940 G	G	0.06	0	0.89	0.05 G	0	0	1	0	318	1344 ND5	0.11
CPCG0123	14102 T	T	0	0.19	0	0.81 T	0	0	0	0.99	7411	2392 ND5	0.18
ICGC_PCA024	14311 T	T	0	0.14	0	0.86 T	0	0	0	1	4940	2480 ND6	0.14
CPCG0030	14423 G	G	0.15	0	0.84	0 G	0.02	0	0.98	0	7206	1664 ND6	0.14
CPCG0072	14470 T	T	0	0.12	0	0.88 T	0	0	0	1	6689	2084 ND6	0.12
CPCG0234	14560 G	G	0	0	0.89	0.1 G	0	0	1	0	997	1290 ND6	0.11
CPCG0234	14698 G	G	0	0	0.9	0.1 G	0	0	1	0	1360	1364 TE	0.1
ICGC_PCA143	14798 T	C	0	0.85	0	0.15 C	0	0.7	0	0.3	7083	4223 CYB	0.15
CPCG0236	14859 G	G	0.18	0	0.82	0 G	0	0	1	0	7208	2114 CYB	0.18
ICGC_PCA055	14985 G	G	0.12	0	0.88	0 G	0	0	1	0	7069	4679 CYB	0.12
CPCG0046	15200 G	G	0.01	0	0.9	0.09 G	0	0	1	0	424	1479 CYB	0.1
EOPC-07	15211 C	T	0	0.01	0	0.99 T	0	0.11	0	0.89	5386	1718 CYB	0.11
CPCG0363	15216 G	G	0.11	0	0.89	0.01 G	0	0	1	0	6276	3366 CYB	0.11
ICGC_PCA022	15228 T	T	0	0.18	0	0.82 T	0	0	0	1	4273	6156 CYB	0.18
ICGC_PCA137	15255 T	T	0	0.11	0	0.89 T	0	0	0	1	6969	2363 CYB	0.11
ICGC_PCA035	15356 G	G	0.15	0	0.84	0 G	0	0	1	0	7076	4723 CYB	0.15
EOPC-02	15458 T	C	0	0.71	0	0.28 C	0	0.91	0	0.09	4983	3285 CYB	0.19
CPCG0183	15536 A	A	1	0	0	0 A	0.89	0.07	0.01	0.02	7009	1083 CYB	0.11
CPCG0211	15536 A	A	1	0	0	0 A	0.89	0.08	0.02	0.01	6942	570 CYB	0.11
ICGC_PCA118	15614 G	G	0.15	0	0.85	0 G	0	0	1	0	7135	3573 CYB	0.15
ICGC_PCA172	15825 C	T	0	0.1	0	0.9 T	0	0.25	0	0.75	5181	5498 CYB	0.15
ICGC_PCA078	15900 T	T	0	0.14	0	0.86 T	0	0	0	1	3010	3847 TT	0.14
CPCG0046	15927 G	G	0.1	0	0.85	0.05 G	0	0	1	0	419	1717 TT	0.15
CPCG0235	15976 T	T	0	0.2	0	0.8 T	0	0	0	1	7757	2096 TP	0.2
CPCG0048	16092 T	C	0	0.85	0	0.15 C	0	0.96	0	0.04	7162	1622 CR	0.11
CPCG0057	16093 T	C	0	0.87	0	0.13 C	0	0.97	0	0.03	7070	2406 CR	0.11
CPCG0199	16093 T	C	0	0.8	0	0.2 C	0	0.94	0	0.06	7365	2534 CR	0.13
CPCG0250	16093 T	C	0	0.84	0	0.16 C	0	0.96	0	0.04	7176	2788 CR	0.13
CPCG0259	16093 T	C	0	0.85	0	0.15 C	0	0.97	0	0.03	7063	2312 CR	0.12
CPCG0354	16093 T	C	0	0.87	0	0.13 C	0	0.98	0	0.02	7123	4981 CR	0.11
Baca08-4154	16093 T	C	0	0.92	0	0.08 C	0	0.73	0	0.27	104	6163 CR	0.19
ICGC_PCA053	16093 T	C	0	0.79	0	0.21 C	0	0.98	0	0.02	6911	7080 CR	0.19
ICGC_PCA095	16093 T	C	0	0.81	0	0.19 C	0	0.97	0	0.03	4785	2264 CR	0.16
ICGC_PCA151	16093 T	C	0	0.88	0	0.12 C	0	0.98	0	0.01	5414	1639 CR	0.11
CPCG0378	16117 T	T	0	0.16	0	0.84 T	0	0	0	1	7660	7058 CR	0.16
CPCG0194	16129 A	G	0	0	1	0 G	0.14	0	0.85	0	3933	498 CR	0.14
CPCG0346	16145 G	G	0.12	0	0.88	0 G	0	0	1	0	7495	3317 CR	0.12
ICGC_PCA153	16147 C	C	0	0.87	0	0.13 C	0	1	0	0	6929	2343 CR	0.13
CPCG0122	16175 A	A	1	0	0	0 A	0.9	0.1	0.01	0	5458	475 CR	0.1
CPCG0194	16183 A	C	0.17	0.83	0	0 C	0.27	0.73	0	0	1329	490 CR	0.1
ICGC_PCA127	16184 C	C	0	0.89	0	0.11 C	0	1	0	0	6185	3060 CR	0.11
CPCG0007	16187 T	T	0	0.02	0	0.98 T	0	0.14	0	0.86	6350	1529 CR	0.11
Baca05-3852	16187 T	C	0	0.98	0	0.02 C	0	0.86	0	0.14	6536	1173 CR	0.12
CPCG0070	16189 C	T	0	0.03	0	0.97 T	0.01	0.14	0	0.86	7212	2311 CR	0.11
CPCG0194	16189 C	C	0	0.98	0	0.01 C	0	0.87	0	0.12	1847	550 CR	0.11
EOPC-02	16189 C	T	0	0.16	0	0.84 T	0.01	0.03	0	0.96	2314	1217 CR	0.12
BacaSTID0000000410	16189 C	T	0	0.28	0	0.72 T	0	0.12	0	0.87	6024	402 CR	0.16
BacaSTID0000002872	16189 C	C	0	0.86	0	0.14 C	0	1	0	0	3393	2188 CR	0.13
CPCG0194	16223 T	T	0	0.01	0	0.99 T	0	0.14	0	0.86	3820	597 CR	0.13
ICGC_PCA001	16223 T	T	0	0	0	1 T	0	0.12	0	0.88	5297	1828 CR	0.12
EOPC-02	16231 T	C	0	0.86	0	0.14 C	0	1	0	0	2802	1558 CR	0.14
ICGC_PCA171	16247 A	A	0.96	0	0.04	0 A	0.86	0	0.14	0	4771	2537 CR	0.1
ICGC_PCA026	16258 A	A	0.81	0	0.19	0 A	1	0	0	0	4236	1740 CR	0.19
EOPC-02	16261 C	T	0	0.13	0	0.87 T	0	0.01	0	0.99	3465	2005 CR	0.12
EOPC-02	16265 A	C	0.11	0.89	0	0 C	0	1	0	0	3807	2232 CR	0.1
CPCG0363	16266 C	C	0	0.9	0	0.1 C	0	1	0	0	6878	2983 CR	0.1
CPCG0194	16266 C	T	0	0.01	0	0.99 T	0	0.13	0	0.87	4844	875 CR	0.12
CPCG0194	16274 G	A	1	0	0	0 A	0.89	0	0.11	0	5382	956 CR	0.1
CPCG0260	16278 T	C	0	0.88	0	0.11 C	0	1	0	0	6258	1496 CR	0.11
CPCG0349	16296 C	T	0	0.01	0	0.99 T	0	0.18	0	0.82	7025	3138 CR	0.16
TCGA-HC-7233	16311 C	T	0	0.01	0	0.99 T	0	0.13	0	0.87	3246	1622 CR	0.12
CPCG0183	16318 A	A	1	0	0	0 A	0.86	0	0.14	0	7392	1684 CR	0.14
CPCG0194	16390 G	A	1	0	0	0 A	0.89	0	0.11	0	5047	1010 CR	0.1
CPCG0382	16519 C	C	0	1	0	0 C	0	0.9	0	0.1	4052	1521 CR	0.1
CPCG0089	16522 T	T	0.06	0.05	0	0.89 T	0	0	0	1	2521	2119 CR	0.11
CPCG0256	16527 C	T	0	0.16	0	0.84 T	0	0.06	0	0.94	2232	692 CR	0.1

Claims

1. A method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells;b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1);c) comparing the sequence of said patient biomarkers to control or reference biomarkers, preferably from the subject's own matched normal tissue or blood, to determine mitochondrial single nucleotide variations (mtSNVs); andd) determining the a prostate cancer prognosis;wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.

2. The method according to claim 1, wherein the at least 1 patient biomarker, is at least 2, 3 or 4 patient biomarkers.

3. The method according to claim 1, wherein the prostate cancer is localized prostate cancer, preferably non-indolent localized prostate cancer.

4. The method according to claim 1, further comprising building a patient biomarker profile from the determined or measured patient biomarkers.

5. The method according to claim 1, wherein the prostate cancer prognosis is the likelihood of disease recurrence, preferably measured by biochemical relapse.

6. The method of claim 5, further comprising classifying the patient into a high risk group if the likelihood of disease recurrence is relatively high or a low risk group if the likelihood of disease recurrence is relatively low.

7. The method of claim 6, further comprising treating the patient with more aggressive therapy if the patient is in the high risk group.

8. The method of claim 7, wherein the more aggressive therapy comprises adjuvant therapy, preferably hormone therapy, chemotherapy or radiotherapy.

9. The method according to claim 1, wherein the patient biomarkers further comprises CO2, CO3 and ND4L.

10. The method of claim 9, wherein the at least 1 biomarker is at least 5, 6 or all 7 biomarkers.

11. The method of claim 10, wherein the at least 1 biomarker is all 7 biomarkers.

12. The method of claim 11, wherein the subject is classified as low risk if there exists mtSNVs in CO2, CO3, and HV1 and high risk if there exists mtSNVs in ATP8, OHR, ND4L and CSB1.

13. The method according to claim 1, wherein the mtSNVs are the mtSNVs identified in Table 5.

13.-14. (canceled)

15. A computer program product for use in conjunction with a general-purpose computer having a processor and a memory connected to the processor, the computer program product comprising a computer readable storage medium having a computer mechanism encoded thereon, wherein the computer program mechanism may be loaded into the memory of the computer and cause the computer to carry out the method of claim 1.

16. A computer readable medium having stored thereon a data structure for storing the computer program product according to claim 15.

17. A device for prognosing or predicting disease progression in a patient with prostate cancer, the device comprising: at least one processor; andelectronic memory in communication with the at one processor, the electronic memory storing processor-executable code that, when executed at the at least one processor, causes the at least one processor to:a) receive sequencing data of mitochondrial genetic material from prostate cancer cells of the patient, the sequencing data reflecting at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1);b) compare said sequencing data to corresponding control or reference sequences, preferably from the subject's own matched normal tissue or blood, to determine mitochondrial single nucleotide variations (mtSNVs); andc) determining, at the at least one processor, a prostate cancer prognosis;wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.

18. The device according to claim 17, wherein the processor further displays the prostate cancer prognosis on a user display.

19. A kit for prognosing or predicting disease progression in a patient with prostate cancer, the kit comprising primer sequences that permit the sequencing of a mitochondrial genome to determine mtSNVs in ATP8, OHR, ND4L and CSB1.

20. The kit of claim 19, wherein the primers further permit sequencing of CO2, CO3 and ND4L.